Text 1

Baskar, P.
10/724972

FILE 'CAPLUS' ENTERED AT 11:32:06 ON 07 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 7 Sep 2005 VOL 143 ISS 11
FILE LAST UPDATED: 6 Sep 2005 (20050906/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

-key terms

L12 2638 SEA FILE=CAPLUS ABB=ON PLU=ON (STAPHYLOCOCC? OR S)(W)EPIDERMID? AND (TREAT? OR THERAP? OR PREVENT? OR DIAGNOS? OR DETERM? OR DETECT? OR DET## OR SCREEN?)
L13 107 SEA FILE=CAPLUS ABB=ON PLU=ON L12 AND (ADJUVANT OR IMMUNOADJUVANT OR IMMUNOACTIVAT? OR IMMUNOSTIMUL? OR IMMUN?(W)(ACTIVAT? OR STIMUL?) OR VACCIN? OR IMMUNIS? OR IMMUNIZ?)
L16 69 SEA FILE=CAPLUS ABB=ON PLU=ON L13 AND INFECTION
L17 16 SEA FILE=CAPLUS ABB=ON PLU=ON L16 AND CARRIER

L17 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 01 Jul 2005
ACCESSION NUMBER: 2005:570914 CAPLUS
DOCUMENT NUMBER: 143:95811
TITLE: Immunogenic peptide-**carrier** conjugates for **treating** neurodegenerative disease, cancer and **infection**
INVENTOR(S): Arumugham, Rasappa G.; Prasad, A. Krishna
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: PCT Int. Appl., 155 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058940	A2	20050630	WO 2004-US42701	20041217

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,

VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-530480P P 20031217

AB The present invention is directed to methods of producing conjugates of peptide immunogens with protein/polypeptide **carrier** mols., which are useful as immunogens, wherein peptide immunogens are conjugated to protein **carriers** via activated functional groups on amino acid residues of the **carrier** or of the optionally attached linker mol., and wherein any unconjugated reactive functional groups on amino acid residues are inactivated via capping, thus retaining the immunol. functionality of the **carrier** mol., but reducing the propensity for undesirable reactions that could render the conjugate less safe or effective. Furthermore, the invention also relates to such immunogenic products and immunogenic compns. containing such immunogenic products made by such methods.

L17 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 28 May 2004
ACCESSION NUMBER: 2004:433723 CAPLUS
DOCUMENT NUMBER: 141:2300
TITLE: Bioinformatic method for identifying LPXTG-anchored surface proteins from Gram-positive bacteria, proteins obtained thereby and antibodies thereof
INVENTOR(S): Hook, Magnus; Xu, Yi; Sillanpaa, Jouko V.; Sthanam, Narayana; Ponnuraj, Karthe; Patti, Joseph M.; Hutchins, Jeff T.; Hall, Andrea; Bowden, Maria G.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 120 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004101919	A1	20040527	US 2003-661809	20030915

PRIORITY APPLN. INFO.: US 2002-410303P P 20020913

AB A bioinformatic method is provided for identifying and isolating proteins with MSCRAMM-like characteristics from Gram pos. bacteria, such as Enterococcus, Staphylococcus, Streptococcus and Bacillus bacteria, which can then be utilized in methods to **prevent** and **treat infections** caused by Gram-pos. bacteria. The method involves identifying from sequence information those proteins with a putative C-terminal LPXTG cell wall sorting signal and other structural similarities to MSCRAMM proteins having the LPXTG-anchored cell wall proteins. The MSCRAMM proteins and immunogenic regions therein that are identified and isolated using the present invention may be used to generate antibodies useful in the **diagnosis, treatment** or **prevention** of Gram pos. bacterial **infections**.

L17 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 27 May 2004
ACCESSION NUMBER: 2004:430722 CAPLUS
DOCUMENT NUMBER: 141:2334
TITLE: Polysaccharide over-producing Staphylococcii with modified icaR gene and ica regulatory element, and methods for **treating** staphylococcal **infections**
INVENTOR(S): Pier, Gerald B.; Jefferson, Kimberly
PATENT ASSIGNEE(S): The Brigham and Women's Hospital, Inc., USA
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043407	A2	20040527	WO 2003-US36371	20031112
WO 2004043407	A3	20050811		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004175731	A1	20040909	US 2003-712391	20031112
PRIORITY APPLN. INFO.:			US 2002-425569P P	20021112

AB The invention relates to nucleic acid sequences and related compns. for producing over-expression of the polysaccharide PNAG (poly-N-acetyl glucosamine), a polysaccharide antigen present on the surface of virulent strains of Staphylococci. PNAG may be isolated and formulated into **vaccines** or used to generate antibodies. Binding agents of the nucleic acids are also described. The invention also relates to **diagnostic** and **therapeutic** methods using the compns. It has been discovered that modifications to the intercellular adhesion (ica) locus result in altered production of PNAG. The invention relates to the discovery of transcriptional control mechanisms of the ica locus. The invention is premised in part on the identification of a 5 nucleotide motif within the ica promoter region which has a functional role in transcriptional regulation of the ica locus. This motif may function independently of IcaR protein. The invention is further premised in part on the observation that IcaR protein binds to the promoter region of the ica locus and that disruption of the icaR coding region results in over-production of polysaccharide as well as resultant biofilm.

L17 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 22 Feb 2004
ACCESSION NUMBER: 2004:142988 CAPLUS
DOCUMENT NUMBER: 140:198065

TITLE: **Vaccine** compositions comprising Neisserial adhesin, autotransporter, toxin, iron acquisition protein and membrane-associated protein against Neisserial **infection**

INVENTOR(S): Berthet, Francois-xavier Jacques; Biemans, Ralph; Denoel, Philippe; Feron, Christiane; Goraj, Karine; Poolman, Jan; Weynants, Vincent

PATENT ASSIGNEE(S): Glaxosmithkline Biologicals S.A., Belg.

SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014418	A2	20040219	WO 2003-EP8571	20030731
WO 2004014418	A3	20040722		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493092	AA	20040219	CA 2003-2493092	20030731
EP 1524993	A2	20050427	EP 2003-784153	20030731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:		
GB 2002-18035	A	20020802
GB 2002-18036	A	20020802
GB 2002-18037	A	20020802
GB 2002-18051	A	20020802
GB 2002-20197	A	20020830
GB 2002-20199	A	20020830
GB 2002-25524	A	20021101
GB 2002-25531	A	20021101
GB 2002-30164	A	20021224
GB 2002-30168	A	20021224
GB 2002-30170	A	20021224
GB 2003-5028	A	20030305

WO 2003-EP8571 W 20030731

AB The present invention relates to immunogenic compns. and **vaccines** for the **treatment** and **prevention** of Neisserial disease caused by e.g. Neisseria meningitidis or Neisseria gonorrhoeae. Immunogenic compns. of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response.

L17 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 14 Feb 2003
ACCESSION NUMBER: 2003:117857 CAPLUS
DOCUMENT NUMBER: 138:168811
TITLE: Identification of opsonic antigens expressed by pathogenic microbes during **infection** for use as **vaccines** and to generate **therapeutic** antibodies
INVENTOR(S): Foster, Simon; Mond, James; Clarke, Simon; McDowell, Philip; Brummel, Kirsty
PATENT ASSIGNEE(S): University of Sheffield, UK; Biosynexus Incorporated
SOURCE: PCT Int. Appl., 189 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003011899	A2	20030213	WO 2002-GB3606	20020802
WO 2003011899	A3	20040226		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2453937	AA	20030213	CA 2002-2453937	20020802
EP 1412379	A2	20040428	EP 2002-751380	20020802
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2004536885	T2	20041209	JP 2003-517090	20020802
PRIORITY APPLN. INFO.:			GB 2001-18825	A 20010802
			GB 2002-349	A 20020109
			WO 2002-GB3606	W 20020802

AB The invention relates to a method, i.e. SEREX or serol. identification of antigens by recombinant expression cloning, for the identification

of antigenic polypeptides, typically opsonic antigens, expressed by pathogenic microbes. The identified antigens are useful as **vaccines**, and for generating **therapeutic** and/or **diagnostic** antibodies. Thus, partial gene sequences and encoded proteins (e.g. Hex A and 29 kDa peptides) of Staphylococcus aureus and **S. epidermidis** were identified by the disclosed method.

L17 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 29 Dec 2002
ACCESSION NUMBER: 2002:977842 CAPLUS
DOCUMENT NUMBER: 138:71914
TITLE: Monoclonal and polyclonal antibodies recognizing surface proteins of both coagulase-negative Staphylococci and Staphylococcus aureus
INVENTOR(S): Foster, Timothy J.; Roche, Fiona; Patti, Joseph M.; Hutchins, Jeff T.; Hall, Andrea; Domanski, Paul; Patel, Pratisksha; Syribeys, Peter; Speziale, Pietro
PATENT ASSIGNEE(S): Inhibitex, Inc., USA; The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin; Universita' Degli Studi Di Pavia
SOURCE: PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002102829	A2	20021227	WO 2002-US19220	20020617
WO 2002102829	A3	20040325		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2450939	AA	20021227	CA 2002-2450939	20020617
US 2003185833	A1	20031002	US 2002-172502	20020617
US 6841154	B2	20050111		
EP 1423701	A2	20040602	EP 2002-756219	20020617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1543569	A	20041103	CN 2002-816001	20020617
JP 2004534080	T2	20041111	JP 2003-506301	20020617
US 2005106648	A1	20050519	US 2004-20509	20041227

PRIORITY APPLN. INFO.:			
US 2001-298098P	P	20010615	
US 2002-172502	A3	20020617	
WO 2002-US19220	W	20020617	

AB Polyclonal and monoclonal antibodies cross-reactive to both coagulase-neg. (e.g. S. hemolyticus) and coagulase-pos. Staphylococcus (e.g. S. aureus), are provided. These antibodies are specific to surface proteins from both coagulase-pos. and coagulase neg. staph bacteria. The antibodies may be generated from surface proteins that have been isolated on the basis of characteristics that may be common between S. aureus and coagulase-neg. staphylococci, and these recombinant surface proteins are used to generate the antibodies of the invention. There is also provided **vaccines** and methods which utilize these proteins and antibodies for the **treatment** or protection against a wide variety of staphylococcal **infections**.

L17 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 30 Aug 2002
ACCESSION NUMBER: 2002:658589 CAPLUS
DOCUMENT NUMBER: 137:184456
TITLE: Polysaccharide/adhesin for use as **vaccine** and anti-PS/A antibodies for passive immunotherapy of staphylococcal **infections**
INVENTOR(S): Pier, Gerald; Wang, Ying; McKenney, David
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 30 pp., Cont.-in-part of U.S. Ser. No. 399,904, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2002119166	A1	20020829	US 2001-771003		20010126
PRIORITY APPLN. INFO.:			US 1998-93117P	P	19980715
			US 1999-354408	B2	19990715
			US 1999-399904	B2	19990921

AB The invention relates to compns. of the capsular polysaccharide/adhesin (PS/A) of staphylococci. The PS/A may be isolated or synthesized and includes various modifications to the structure of native PS/A based on the chemical characterization of PS/A. The invention also relates to the use of the PS/A as a **vaccine** for inducing active immunity to **infections** caused by Staphylococcus aureus, **S. epidermidis**, other related coagulase-neg. staphylococci and organisms carrying the ica (intracellular adhesin) locus, and to the use of antibodies directed to PS/A for inducing passive immunity to the same class of **infections**.

L17 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 02 Aug 2002
ACCESSION NUMBER: 2002:575103 CAPLUS
DOCUMENT NUMBER: 137:168250
TITLE: Hyperimmune serum-reactive antigens derived from expression libraries for **treating** or **preventing** pathogen **infection**, cancer, allergy, and autoimmune disease

INVENTOR(S): Meinke, Andreas; Nagy, Eszter; Von Ahsen, Uwe; Klade, Christoph; Henics, Tamas; Zauner, Wolfgang; Minh, Duc Bui; Vytvytska, Oresta; Etz, Hildegard; Dryla, Agnieszka; Weichhart, Thomas; Hafner, Martin; Tempelmaier, Brigitte
PATENT ASSIGNEE(S): Cistem Biotechnologies Gmbh, Austria; Intercell AG
SOURCE: PCT Int. Appl., 252 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059148	A2	20020801	WO 2002-EP546	20020121
WO 2002059148	C2	20021031		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AT 200100130	A5	20021215	AT 2001-130	20010126
AT 410798	B	20030725		
CA 2436057	AA	20020801	CA 2002-2436057	20020121
EP 1355930	A2	20031029	EP 2002-716669	20020121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002007067	A	20040615	BR 2002-7067	20020121
JP 2004531476	T2	20041014	JP 2002-559450	20020121
NO 2003003364	A	20030924	NO 2003-3364	20030725
ZA 2003005764	A	20040726	ZA 2003-5764	20030725
US 2005037444	A1	20050217	US 2004-470048	20040206
PRIORITY APPLN. INFO.:			AT 2001-130 A	20010126
			WO 2002-EP546 W	20020121

AB Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity that are suited for use as **vaccines** for **treating** related diseases in animals or humans. The method is characterized by providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity; providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity; **screening** said at least one expression library with said antibody preparation; identifying antigens which bind in said **screening** to antibodies in said antibody preparation; **screening** the identified antigens with individual antibody prepns. from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity; identifying the hyperimmune serum-reactive antigen

portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody prepns. from said individual sera; and optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.

L17 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 03 May 2002
ACCESSION NUMBER: 2002:332582 CAPLUS
DOCUMENT NUMBER: 136:339489
TITLE: **Vaccines** comprising lipoteichoic acid and **adjuvant** for **preventing** and **treating infection** by gram-positive microorganism
INVENTOR(S): Drabick, Joseph J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002051793	A1	20020502	US 2001-948553	20010910
WO 2002045742	A2	20020613	WO 2001-US28217	20010910
WO 2002045742	A3	20021212		
WO 2002045742	C1	20030306		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001088961	A5	20020618	AU 2001-88961	20010910
US 2003157133	A1	20030821	US 2003-370596	20030224

PRIORITY APPLN. INFO.:		
US 2000-231959P	P	20000912
US 2001-948553	A1	20010910
WO 2001-US28217	W	20010910

AB Compns., **vaccines**, methods, and kits for **treating**, **preventing**, or inhibiting an **infection** or disease caused by a gram-pos. organism are disclosed. The compns. comprise lipoteichoic acid from at least one gram-pos. organism such as Streptococcus, Micrococcus, Lactobacillus, Staphylococcus, Bacillus or Listeria, Staphylococcus aureus, **Staphylococcus epidermidis**, Staphylococcus pyogenes, Listeria monocytogenes, Bacillus cereus. Also disclosed are antibodies which specifically bind to lipoteichoic acid.

L17 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 28 Dec 2001
ACCESSION NUMBER: 2001:935789 CAPLUS
DOCUMENT NUMBER: 136:65197
TITLE: Sequences of antigenic polypeptides of staphylococcus aureus and their uses in against bacterial **infection**
INVENTOR(S): Foster, Simon; McDowell, Philip; Brummell, Kirsty; Clarke, Simon
PATENT ASSIGNEE(S): University of Sheffield, UK; Biosynexus Inc.
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098499	A1	20011227	WO 2001-GB2685	20010620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2412504	AA	20011227	CA 2001-2412504	20010620
EP 1292681	A1	20030319	EP 2001-940746	20010620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011823	A	20030610	BR 2001-11823	20010620
JP 2004500883	T2	20040115	JP 2002-504647	20010620
NO 2002005838	A	20030218	NO 2002-5838	20021205
US 2003186275	A1	20031002	US 2003-311879	20030318
PRIORITY APPLN. INFO.:			GB 2000-14907 A	20000620
			WO 2001-GB2685 W	20010620

AB The invention discloses methods for the identification of antigenic proteins expressed by pathogenic microbes, **vaccines** comprising the proteins, recombinant methods to manufacture the proteins and **therapeutic** antibodies directed to the proteins. In particular, the invention discloses amino acid sequences of staphylococcus aureus antigenic proteins, the DNA sequences encoding polypeptides and genomic DNA library of staphylococcus aureus. The invention also provides expression vectors encoding antigenic peptides, methods for the production of the proteins, antibodies to the proteins as well as methods of preparing the antibodies. The invention further provides **vaccine** comprising the antigenic proteins, pharmaceutical **carrier**, and **adjuvant** as well as methods of **immunizing** animals or humans.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 24 Aug 2001
ACCESSION NUMBER: 2001:618030 CAPLUS
DOCUMENT NUMBER: 135:179709
TITLE: A 52-kilodalton protein from coagulase-negative staphylococci and its fragments with immunogenic activity and applications
INVENTOR(S): Ljungh, Asa; Li, Dai-Qing; Lundberg, Fredrik
PATENT ASSIGNEE(S): Biostapro AB, Swed.
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060852	A1	20010823	WO 2001-SE340	20010216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1261631	A1	20021204	EP 2001-906475	20010216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003523191	T2	20030805	JP 2001-560235	20010216
US 2003082200	A1	20030501	US 2002-203613	20020816
PRIORITY APPLN. INFO.:			SE 2000-514 A	20000217
			WO 2001-SE340 W	20010216

AB A protein isolated from **Staphylococcus epidermidis** having a mol. weight of .apprx.52 kD **determined** by SDS-PAGE and an N-terminal amino acid sequence of Thr-Ala-Asp-Pro-Pro-Ala-Asp-Lys-Thr-Ser, and antigenic **determinant**-containing fragments of the protein, optionally coupled to an inert **carrier** or matrix, are disclosed. Also disclosed are a recombinant DNA mol. coding for the protein or the protein fragments, a vector comprising the DNA mol. or the corresponding RNA mol., and antibodies or antigen-binding peptides recognizing and specifically binding to the protein or protein fragment. The protein or protein fragment, or the vector, may be used for the production of **vaccines** against Staphylococcal **infections**, and the antibodies or antigen-binding peptides may be used for the production of a medicament for passive **immunization**; a **vaccine** against Staphylococcal **infections**.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 04 May 2001
ACCESSION NUMBER: 2001:319756 CAPLUS

DOCUMENT NUMBER: 134:352262
TITLE: **Vaccine** compositions
INVENTOR(S): Murphy, John R.; O'Lear, Edward; Harrison, Robert J.
PATENT ASSIGNEE(S): Advanced Microbial Solutions Corp., USA
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001030384	A1	20010503	WO 2000-US29231		20001023
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
US 2005031645	A1	20050210	US 2004-822953		20040412
PRIORITY APPLN. INFO.:			US 1999-161193P	P	19991022
			US 1999-161292P	P	19991025
			WO 2000-US29231	W	20001023
			US 2001-868753	B1	20010621

AB Disclosed are virulent or opportunistic prokaryotes in which metal ion-dependent gene regulation confers a growth or an infectious advantage. The prokaryote contains a DNA mol. containing a sequence encoding a dominant, metal ion-independent repressor protein or a partially metal ion independent repressor protein. The prokaryotes are formulated into **vaccine** compns. and administered to a human or other animal to enhance protective immunity against infectious and diseases caused by prokaryotes in which metal ion-dependant gene regulation confers a growth or an infectious advantage.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 29 Sep 2000
ACCESSION NUMBER: 2000:688110 CAPLUS
DOCUMENT NUMBER: 133:265638
TITLE: Staphylococcus antigen and **vaccine**
INVENTOR(S): Pavliak, Viliam; Fattom, Ali Ibrahim
PATENT ASSIGNEE(S): Nabi, USA
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000056357	A2	20000928	WO 2000-US6922	20000317
WO 2000056357	A3	20010201		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6936258	B1	20050830	US 1999-272359	19990319
CA 2366433	AA	20000928	CA 2000-2366433	20000317
EP 1162997	A2	20011219	EP 2000-916405	20000317
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009157	A	20020416	BR 2000-9157	20000317
JP 2002539272	T2	20021119	JP 2000-606261	20000317
NZ 514455	A	20031128	NZ 2000-514455	20000317
AU 773226	B2	20040520	AU 2000-37513	20000317
AU 2000037513	A5	20001009		
US 2005118190	A1	20050602	US 2004-14997	20041220
PRIORITY APPLN. INFO.:			US 1999-272359 A2	19990319
			WO 2000-US6922 W	20000317

AB A neg.-charged Staphylococcus antigen contains amino acids and a N-acetylated hexosamine as a major carbohydrate component. The antigen is common to many coagulase-neg. strains of Staphylococcus, including **S. epidermidis**, S. hemolyticus and S. hominis. Staphylococcus strains that carry the antigen include many clin. significant strains of Staphylococcus. The antigen and antibodies to the antigen are useful in kits and assays for **diagnosing** Staphylococcus **infection**. **Vaccines** of the antigen and of whole cells that carry the antigen are also disclosed.

L17 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 10 Mar 2000
ACCESSION NUMBER: 2000:161169 CAPLUS
DOCUMENT NUMBER: 132:212703
TITLE: Multicomponent **vaccines** for **prevention** of staphylococcal **infections**
INVENTOR(S): Patti, Joseph M.; Foster, Timothy J.; Hook, Magnus
PATENT ASSIGNEE(S): Inhibitex, Inc., USA; The Texas A & M University System; The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin
SOURCE: PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2000012131	A1	20000309	WO 1999-US19727		19990831
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2340304	AA	20000309	CA 1999-2340304		19990831
AU 9955889	A1	20000321	AU 1999-55889		19990831
AU 771426	B2	20040318			
EP 1109577	A1	20010627	EP 1999-942533		19990831
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
BR 9913340	A	20011106	BR 1999-13340		19990831
JP 2002523473	T2	20020730	JP 2000-567242		19990831
US 6703025	B1	20040309	US 1999-386959		19990831
PRIORITY APPLN. INFO.:			US 1998-98439P	P	19980831
			WO 1999-US19727	W	19990831

AB Multicomponent **vaccines** are provided which aid in the **prevention** and **treatment** of staphylococcal **infections** and which include certain selected combinations of bacterial binding proteins or fragments thereof, or antibodies to those proteins or fragments. By careful selection of the proteins, fragments, or antibodies, a **vaccine** is provided that imparts protection against a broad spectrum of Staphylococcus bacterial strains and against proteins that are expressed at different stages of the logarithmic growth curve. In one embodiment of the invention, a composition is provided that includes at least a collagen-binding protein or peptide (or an appropriate site directed mutated sequence thereof) such as CNA, or a protein or fragment with sufficiently high homol. thereto, in combination with a fibrinogen binding protein, preferably Clumping factor A ("ClfA") or Clumping factor B ("ClfB"), or a useful fragment thereof or a protein or fragment with sufficiently high homol. thereto. The **vaccines** and products of the present invention are advantageous in that they respond to the urgent need of the medical community for a substitute for small mol. antibiotics, which are rapidly losing effectiveness and provide effective combinations of the large number of known bacterial surface adhesins which can impart effective protection against a broad spectrum of bacterial **infections**.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 28 Jan 2000
ACCESSION NUMBER: 2000:68367 CAPLUS
DOCUMENT NUMBER: 132:121461
TITLE: Polysaccharide **vaccine** for staphylococcal **infections**

INVENTOR(S): Pier, Gerald B.; McKenney, David; Wang, Ying
PATENT ASSIGNEE(S): Brigham and Women's Hospital, Inc., USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000003745	A2	20000127	WO 1999-US16129	19990715
WO 2000003745	A3	20000420		
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2333931	AA	20000127	CA 1999-2333931	19990715
AU 9950001	A1	20000207	AU 1999-50001	19990715
AU 771563	B2	20040325		
EP 1096952	A2	20010509	EP 1999-934091	19990715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: US 1998-93117P P 19980715
WO 1999-US16129 W 19990715

AB The invention relates to compns. of the capsular polysaccharide/adhesin (PS/A) of Staphylococci. The PS/A may be isolated or synthesized and includes various modifications to the structure of native PS/A based on the chemical characterization of PS/A. The invention also relates to the use of the PS/A as a **vaccine** for inducing active immunity to **infections** caused by Staphylococcus aureus, **S. epidermidis** , other related coagulase-neg. staphylococci and organisms carrying the ica (intracellular adhesin) locus, and to the use of antibodies directed to PS/A for inducing passive immunity to the same class of **infections**. The invention also describes use of ica gene-expressing and coagulase-neg. Staphylococcus for preparation and purification of PS/A, as well as primers for **detecting** ica gene in isolated of S. aureus.

L17 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 20 Jun 1996
ACCESSION NUMBER: 1996:357167 CAPLUS
DOCUMENT NUMBER: 125:31923
TITLE: Broadly reactive opsonic antibodies reactive with common staphylococcal antigens
INVENTOR(S): Fisher, Gerald W.
PATENT ASSIGNEE(S): United States Dept. of the Army, USA
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9609321	A1	19960328	WO 1995-US11992	19950921

W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

CA 2200691	AA	19960328	CA 1995-2200691	19950921
AU 9536371	A1	19960409	AU 1995-36371	19950921
AU 707298	B2	19990708		
EP 783520	A1	19970716	EP 1995-933880	19950921
EP 783520	B1	20011128		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 2000509961	T2	20000808	JP 1996-511066	19950921
AT 209659	E	20011215	AT 1995-933880	19950921
PT 783520	T	20020531	PT 1995-933880	19950921
ES 2169153	T3	20020701	ES 1995-933880	19950921
PRIORITY APPLN. INFO.:			US 1994-308495 A	19940921
			WO 1995-US11992 W	19950921

AB The invention describes the identification, making, and isolation of Ig and antigen useful for **preventing, diagnosing,** and **treating** staphylococcal **infections.** The invention further describes an in vivo animal model useful for testing the efficacy of pharmaceutical compns., including pharmaceutical compns. of Ig and isolated antigen. The antigen is a 45,000.apprx.50,000 daltons surface protein of a coagulase-neg. **Staphylococcus epidermidis,** and can be used as **vaccine** with or without conjugated to a second compound, e.g. capsular polysaccharide antigen of Staphylococcus aureus. The isolated broadly reactive and opsonic Ig. comprises monoclonal or polyclonal antibody.

FILE 'MEDLINE' ENTERED AT 11:32:09 ON 07 SEP 2005

FILE 'BIOSIS' ENTERED AT 11:32:09 ON 07 SEP 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 11:32:09 ON 07 SEP 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 11:32:09 ON 07 SEP 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'CONFSCI' ENTERED AT 11:32:09 ON 07 SEP 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'SCISEARCH' ENTERED AT 11:32:09 ON 07 SEP 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'JICST-EPLUS' ENTERED AT 11:32:09 ON 07 SEP 2005
COPYRIGHT (C) 2005 Japan Science and Technology Agency (JST)

FILE 'JAPIO' ENTERED AT 11:32:09 ON 07 SEP 2005
COPYRIGHT (C) 2005 Japanese Patent Office (JPO)- JAPIO

L18 40 S L17

L19 37 DUP REM L18 (3 DUPLICATES REMOVED)

L19 ANSWER 1 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2005-180418 [19] WPIDS
CROSS REFERENCE: 2005-011161 [01]
DOC. NO. CPI: C2005-057783
TITLE: New substituted benzimidazole compounds, useful for **treating, preventing** or lessening severity of bacterial **infection** e.g. urinary tract **infection,** pneumonia, prostatitis and bloodstream **infection,** are gyrase and topoisomerase IV inhibitors.
DERWENT CLASS: B02
INVENTOR(S): CHARIFSON, P S; DEININGER, D D; DRUMM, J; GRILLOT, A; LETIRAN, A; LIAO, Y; PEROLA, E; RONKIN, S M; STAMOS, D; WANG, T
PATENT ASSIGNEE(S): (CHAR-I) CHARIFSON P S; (DEIN-I) DEININGER D D; (DRUM-I) DRUMM J; (GRIL-I) GRILLOT A; (LETI-I) LETIRAN A; (LIAO-I) LIAO Y; (PERO-I) PEROLA E; (RONK-I) RONKIN S M; (STAM-I) STAMOS D; (WANG-I) WANG T
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2005038247	A1	20050217	(200519)*		202

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
US 2005038247	A1	Provisional	US 2003-443917P	20030131
		CIP of	US 2004-767638	20040129
			US 2004-901928	20040729

PRIORITY APPLN. INFO: WO 2004-US2541 20040129
AN 2005-180418 [19] WPIDS
CR 2005-011161 [01]
AB US2005038247 A UPAB: 20050321
NOVELTY - 207 Benzimidazole compounds (I) e.g. 1-ethyl-3-(7-(3-fluoropyridin-2-yl)-5-(6-methylaminopyridin-3-yl)-1H-benzoimidazol-2-yl)urea (Ia) and (7-(3-fluoropyridin-2-yl)-5-(2-(4-methyl-3-oxopiperazin-1-ylmethyl)-pyrimidin-5-yl)-1H-benzoimidazol-2-yl)carbamic acid ethyl ester (Ib) are new.

DETAILED DESCRIPTION - 207 Benzimidazole compounds (I) e.g. 1-ethyl-3-(7-(3-fluoropyridin-2-yl)-5-(6-methylaminopyridin-3-yl)-1H-benzoimidazol-2-yl)urea of formula (Ia) and (7-(3-fluoropyridin-2-yl)-5-(2-(4-methyl-3-oxopiperazin-1-ylmethyl)-pyrimidin-5-yl)-1H-benzoimidazol-2-yl)carbamic acid ethyl ester of formula (Ib) are new.

INDEPENDENT CLAIMS are also included for:

(1) a composition (A) comprising (I) and a **carrier, adjuvant** or vehicle; and

(2) a method of inhibiting gyrase and topoisomerase IV activity in a biological sample or in a patient comprising contacting the biological sample with (A) or (I).

ACTIVITY - Antibacterial; Uropathic; Respiratory-Gen.; Antiinflammatory; Dermatological.

MECHANISM OF ACTION - Gyrase inhibitor; Topoisomerase IV inhibitor.

The ability of (I) to inhibit DNA gyrase was tested using gyrase ATPase assay. The results showed that the inhibition constant of (I) was 50 nM.

USE - (I) are useful for decreasing bacterial quantity, **treating**, **preventing** or lessening the severity of a bacterial **infection** , where the bacterial **infection** is characterized by the presence of Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium, Klebsiella pneumoniae, Enterobacter sp., Proteus sp., Pseudomonas aeruginosa, E. coli, Serratia marcesens, Staphylococcus aureus, Coag. Neg. Staph, Haemophilus influenzae, Bacillus anthracis, Mycoplasma pneumoniae, Moraxella catarralis, Chlamydia pneumoniae, Legionella pneumophila, **Staphylococcus epidermidis**, Mycobacterium tuberculosis or Helicobacter pylori and the **infection** is a urinary tract **infection**, respiratory **infection**, pneumonia, prostatitis, skin or soft tissue **infection**, intra-abdominal **infection**, bloodstream **infection** or **infection** of febrile neutropenic patients (all claimed). (I) are useful to **treat** noscomial **infections** in hospitals.

ADVANTAGE - (I) are more potent in **treating** drug-resistant bacterial **infections** than existing compounds.

Dwg.0/0

L19 ANSWER 2 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

ACCESSION NUMBER: 2004-813793 [80] WPIDS

DOC. NO. CPI: C2004-283112

TITLE: Reduction or **prevention** of transmission of a nosocomial pathogen e.g. gram-positive bacterium involves administration of an antibiotic to **prevent** colonization or **infection** by the pathogen, to a population of individuals.

DERWENT CLASS: B05 D22

INVENTOR(S): JABES, D; LEACH, T S; MOSCONI, G; MUSCONI, G

PATENT ASSIGNEE(S): (JABE-I) JABES D; (LEAC-I) LEACH T S; (MOSC-I) MOSCONI G; (OSCI-N) OSCIENT PHARM CORP; (VICU-N) VICURON PHARM INC

COUNTRY COUNT: 108

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2004096143	A2	20041111	(200480)*	EN	47
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NA NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW					
US 2005043223	A1	20050224	(200515)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE

WO 2004096143	A2	WO 2004-US12856	20040426
US 2005043223	A1 Provisional	US 2003-465757P	20030425
		US 2004-832965	20040426

PRIORITY APPLN. INFO: US 2003-465757P 20030425; US 2004-832965 20040426

AN 2004-813793 [80] WPIDS

AB WO2004096143 A UPAB: 20041213

NOVELTY - Reduction or **prevention** of transmission of a nosocomial pathogen involves: identifying a **carrier** who is colonized with a nosocomial pathogen or fomite that is contaminated with nosocomial pathogen and administering an antibiotic for a sufficient duration to **prevent** colonization or **infection** by the pathogen, to a population of individuals at risk of being colonized or infected by the pathogen from the **carrier** or fomite.

ACTIVITY - Antibacterial; **Immunostimulant**; Anti-HIV; Virucide; Cytostatic; Antiinflammatory; Gastrointestinal-Gen.

MECHANISM OF ACTION - Growth inhibitor; Bacterial growth inhibitor. Mice was colonized with a clinical isolate VanA strain of E. faecium vancomycin-resistant Enterococcus (VRE) isolated from a septicemia patient. A single inoculation of 5 multiply 108 cfu VRE by oral gavage (day 0) was followed by **treatment** with vancomycin in the drinking water to maintain colonization. On day 22, each group received the same vancomycin-containing drinking water. One group also received ramoplanin (100 mu g/ml) in its drinking water (test group). The dose of ramoplanin per day was estimated to be 15 mg/kg on a standard water consumption of 150 ml/kg/day. **Treatment** with ramoplanin was discontinued on day 20, and vancomycin **treatment** was discontinued on day 36. The control group consisted of five mice, while the ramoplanin group consisted of four mice. **Treatment** with ramoplanin significantly reduced the fecal density and carriage of VRE in mice. After one week of **treatment**, the VRE concentration per gram of feces fell from 9.7 log units to an undetectable level (less then 3.1 log units) in all animals. Seven days after **treatment** with ramoplanin, the VRE concentration per gram of feces was similar to the pre-**treatment** levels. The test group had showed that the % mice with VRE was found to be 0% at day 29. Also when ramoplanin was tested against gram-positive bacteria (such as Bacillus spp.) in an in vitro assay and the MIC90 value was found to be 0.25 mu g/ml.

USE - For the reduction or **prevention** of the transmission of a nosocomial pathogen e.g. gram-positive bacterium in a **carrier** having a bacteremia (i.e. antibiotic-resistant) (e.g. Enterococcus (such as E. faecium, E. faecalis, E. raffinosus, E. avium, E. hirae, E. gallinarum, E. casseliflavus, E. durans, E. malodoratus, E. mundtii, E. solitarius or E. pseudoavium), Staphylococcus (such as S. aureus, **S. epidermidis**, S. hominis, S. saprophyticus, S. hemolyticus, S. capitis, S. auricularis, S. lugdenis, S. warneri, S. saccharolyticus, S. caprae, S. pasteurii, S. schleiferi, S. xylosus, S. cohnii or S. simulans), Streptococcus (such as S. pyogenes, S. agalactiae, S. pneumoniae, S. bovis or S. viridans), Clostridium difficile, Clostridium perfringens) or a member of the population e.g. patient, employee, visitor in a health care facility, doctor, nurse, orderly, medical student, physical **therapist**, health care administrator, visiting nurse, food service personnel, janitor, works in an intensive care unit, surgical unit or geriatric ward; or a fomite e.g. fomite bedding

or bandages, environmental surface. The **carrier** or a member of population has received broad-spectrum antibiotic **therapy** for at least one week within the previous month; is receiving concurrent broad-spectrum antibiotic **therapy**; is immunocompromised; having neutropenia, HIV **infection**, AIDS, or is within 14 days of receiving chemotherapy or radiation **therapy** in preparation for autologous or allogeneic hematopoietic stem cell transplant, bone marrow transplant or solid organ transplant, as part of antineoplastic **therapy**; has receiving immunosuppressive **therapy** (such as steroid **therapy**) for at least seven days; has or is at risk for enteritis, colitis, typhlitis, or mucositis of the gastro-intestinal tract (all claimed), Crohn's disease.

ADVANTAGE - The method controls the transmission of nosocomial pathogens in health care facilities; reduces or **prevents** the transmission of pathogens to uncolonized individuals; reduces the endemic rates of nosocomial **infections** and **prevents** epidemics of these **infections** in healthcare facilities (e.g. hospitals, nursing homes, clinics, hospices, infirmaries, rehabilitation centers, and assisted living facilities).

Dwg.0/1

L19 ANSWER 3 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2004-775921 [76] WPIDS
DOC. NO. CPI: C2004-271719
TITLE: New isolated C3 binding region from the Staphylococcus aureus Efb protein having the ability to inhibit complement activation, for use in **treating** hemolytic anemia, lupus, **infections** and arthritis.
DERWENT CLASS: B04 D16
INVENTOR(S): BROWN, E; HOOK, M; LEE, L
PATENT ASSIGNEE(S): (TEXA) UNIV TEXAS A & M SYSTEM
COUNTRY COUNT: 108
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2004094600	A2	20041104	(200476)*	EN	62

RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2004094600	A2	WO 2004-US11949	20040416

PRIORITY APPLN. INFO: US 2003-463028P 20030416
AN 2004-775921 [76] WPIDS
AB WO2004094600 A UPAB: 20041125
NOVELTY - An isolated C3 binding region from the Staphylococcus aureus

Efb protein having the ability to inhibit complement activation, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a pharmaceutical composition comprising the C3 binding region and a vehicle, **carrier** or excipient;

(2) an isolated antibody that recognizes the C3 binding region;

(3) isolated antisera containing the antibody of (2);

(4) a **diagnostic** kit comprising an antibody of (2) and means for **detecting** binding by that antibody;

(5) a **diagnostic** kit comprising C3 binding region means for **detecting** binding to the protein fragment;

(6) a method of **diagnosing** an **infection** of S. aureus, comprising adding an antibody of (2) to a sample suspected of being infected with S. aureus, and **determining** if antibodies have bound to the sample;

(7) a pharmaceutical composition comprising the antibody of (2) and a vehicle, **carrier** or excipient;

(8) a method of inducing an immunological response, comprising administering to a human or animal an immunogenic amount of an isolated C3 binding region;

(9) an isolated nucleic acid coding for the C3 binding region;

(10) a **vaccine** comprising the C3 binding region to elicit an immune response, and a vehicle, **carrier** or excipient;

(11) inhibiting complement activity in a human or animal patient, comprising administering to the patient the C3 binding region to inhibit complement activity;

(12) a method of inhibiting complement activation in a human or animal patient in need of the inhibition, comprising administering to the patient the Efb protein of S. aureus or the C3 binding region of the Efb protein of S. aureus to inhibit complement activity;

(13) a pharmaceutical composition comprising the S. aureus Efb protein or the C3 binding region of the S. aureus Efb protein to inhibit complement activation, and a vehicle, **carrier** or excipient;

(14) a method of **treating** or **preventing** hemolytic anemia in a human or animal patient in need of the **treatment**, comprising administering to the patient the Efb protein of S. aureus or the C3-binding region of the Efb protein of S. aureus to inhibit complement activation;

(15) a method of reducing the induction of complement activation by a biological or prosthetic tissue or organ implant, comprising coating the implant with an Efb protein or the C3 binding region of the Efb protein to inhibit complement activation when the implant is implanted into a human or animal patient; and

(16) a method of inducing an immunological response, comprising administering to a patient the C3 binding region of the **Staphylococcus epidermidis** Efb protein.

ACTIVITY - Antianemic; Immunosuppressive; Nephrotropic; Dermatological; Antiinflammatory; Antiarthritic; Antibacterial. No biological data given.

MECHANISM OF ACTION - C3-Antagonist; **Vaccine**.

USE - The methods and compositions of the present invention are useful in **therapeutics** where the inhibition of complement is desirable, such as in hemolytic anemia, systemic lupus erythematosus, Staphylococcal **infections** and autoimmune arthritis, **prevention** of graft or implant rejection, and to alleviate complement activation that is associated with kidney dialysis methods

such as hemodialysis.
Dwg.0/10

L19 ANSWER 4 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2004-677375 [66] WPIDS
DOC. NO. CPI: C2004-241419
TITLE: Immunogenic polysaccharide-protein conjugate useful for **treating** nosocomial **infections** by bacteria e.g., Staphylococcus aureus, comprises staphylococcal surface adhesin **carrier** protein and polysaccharide antigen of nosocomial pathogen.
DERWENT CLASS: B04 D16
INVENTOR(S): BAKER, S M; PAVLIAK, V; PILLAI, S P
PATENT ASSIGNEE(S): (AMHP) WYETH HOLDINGS CORP
COUNTRY COUNT: 108
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2004080490	A2	20040923	(200466)*	EN	81

RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2004080490	A2	WO 2004-US6661	20040304

PRIORITY APPLN. INFO: US 2003-452728P 20030307
AN 2004-677375 [66] WPIDS
AB WO2004080490 A UPAB: 20041015
NOVELTY - An immunogenic polysaccharide-protein conjugate (I) comprises one or more staphylococcal surface adhesin **carrier** proteins (II), and one or more polysaccharide antigens derived from a nosocomial pathogen or an oligosaccharide fragment representing one or more antigenic epitopes of one or more polysaccharide antigens derived from nosocomial pathogen, where (I) generates specific antibodies to both polysaccharide antigen and (II).

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) an immunogenic composition (C1) comprising (I) in a **carrier** or diluent; and

(2) a hyperimmune globulin (III) containing antibodies directed against the polysaccharide antigen and (II) of (I).

ACTIVITY - Antibacterial.

MECHANISM OF ACTION - **Immunostimulator; Vaccine**. In vivo analysis of the polysaccharide-protein conjugate immunogenic compositions to induce IgG responses against capsular polysaccharide (CP) of Staphylococcus aureus Type 5 and the surface adhesin protein **carrier** was carried out as follows. Swiss-Webster mice were

immunized subcutaneously (SC) three times in two-week intervals with the conjugate immunogenic compositions (1 micro g). The immune response to S.aureus CP5 and surface adhesin protein was assayed one week after injection by standard antigen enzyme linked immunosorbent assay (ELISA). The results showed that covalent attachment of CPs to surface adhesin proteins results in the induction of a capsular polysaccharide (CP)-specific IgG response, and the conjugated surface adhesin proteins induced similar titers of surface adhesin protein-specific antibodies compared with the unconjugated surface adhesin proteins.

USE - (I) is useful in the preparation of a composition for the **treatment** or **prevention** of a nosocomial **infection**. (I) or C1 is useful for inducing active immunity against nosocomial **infections** in a mammal subject to such **infections**, which involves administering C1 to the mammal. C1 is useful for preparing an immunotherapeutic agent against nosocomial **infections**, which involves **immunizing** a mammal with C1, collecting plasma from the **immunized** mammal, and harvesting from the collected plasma a hyperimmune globulin that contains anti-polysaccharide antibodies and anti-staphylococcal surface adhesin **carrier** protein antibodies. (III) is useful for inducing passive immunity to nosocomial **infections** in a mammal subject to such **infections**, which involves administering (II) to the mammal. (III) is useful in the preparation of a composition for inducing passive immunity to a nosocomial **infection** (all claimed). (I), (III) or C1 is useful for **immunizing** against surface adhesin **carrier** protein and diseases caused by nosocomial pathogens such as Staphylococcus aureus, coagulase-negative staphylococci (CoNS), Enterococcus sp., Candida albicans, Enterobacter sp., Haemophilus influenzae, Klebsiella pneumoniae, Escherichia coli and Pseudomonas aeruginosa.

ADVANTAGE - (I) or C1 generates specific antibodies to both polysaccharide antigen and surface adhesin **carrier** protein (claimed). (I) **prevents** bacterial adherence to mammalian host cells, induces anti-polysaccharide IgG responses, and the protein in conjugate elicits responses against protective epitopes. (I) enables **treatment** against broad spectrum of bacterial **infections** e.g., S.aureus and E.coli.

DESCRIPTION OF DRAWING(S) - The figure shows the graph representing the immune response to Staphylococcus aureus CP8 conjugated to fibrinogen-binding protein of **S. epidermidis**.

Dwg.15A/20

L19 ANSWER 5 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

ACCESSION NUMBER:	2004-411631 [38] WPIDS
DOC. NO. CPI:	C2004-154555
TITLE:	Generating a Staphylococcus that overproduces a polysaccharide useful as a **vaccine** against staphylococcal **infection** comprises introducing into a bacterium an intercellular adhesion (ica) nucleic acid linked to an ica regulatory nucleic acid.
DERWENT CLASS:	B04 D16
INVENTOR(S):	JEFFERSON, K; PIER, G B
PATENT ASSIGNEE(S):	(BGHM) BRIGHAM & WOMENS HOSPITAL INC
COUNTRY COUNT:	106
PATENT INFORMATION:	

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2004043407	A2	20040527	(200438)*	EN	98
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZW					
US 2004175731	A1	20040909	(200459)		
AU 2003290867	A1	20040603	(200470)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2004043407	A2	WO 2003-US36371	20031112
US 2004175731	A1 Provisional	US 2002-425569P	20021112
		US 2003-712391	20031112
AU 2003290867	A1	AU 2003-290867	20031112

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2003290867	A1 Based on	WO 2004043407

PRIORITY APPLN. INFO: US 2002-425569P 20021112; US 2003-712391 20031112

AN 2004-411631 [38] WPIDS

AB WO2004043407 A UPAB: 20040616

NOVELTY - Generating (M1) a (Staphylococcus) bacterium that overproduces polysaccharide by introducing into a bacterium an intercellular adhesion (ica) nucleic acid operably linked to an ica regulatory nucleic acid, is new.

DETAILED DESCRIPTION - Generating (M1) a (Staphylococcus) bacterium that overproduces polysaccharide comprises:

(a) introducing into a bacterium, an intercellular adhesion (ica) nucleic acid operably linked to an ica regulatory nucleic acid (II), where the (II) comprises nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule having a fully defined sequence of 60 base pairs (S1) as given in the specification, having an addition, deletion or substitution in a region between and including nucleotides 9 and 43 of (S1), and that enhance production of a polysaccharide from an ica locus, and their complements,

(b) introducing into a bacterium an ica nucleic acid operably linked to (II), where (II) comprises a mutant icaR nucleic acid, and measuring polysaccharide production from the bacterium, where a high level of polysaccharide production is indicative of (I)

(c) recombinantly down-regulating wild-type IcaR protein production, and selecting (I); or

(d) recombinantly altering the TATTT nucleotide sequence in the ica promoter region.

INDEPENDENT CLAIMS are also included for:

(1) a recombinant bacterium which overproduces polysaccharide and comprises an ica nucleic acid operably linked (II), where the bacterium is not MN8 mucoid (MN8m), or a mutant icaR nucleic acid;

(2) producing (M2) an antibody to a bacterial polysaccharide, by

isolating a bacterial polysaccharide from (I), administering the isolated bacterial polysaccharide to a subject to produce an antibody, and harvesting antibody from the subject;

(3) an isolated nucleic acid molecule (N1), comprising nucleic acid molecules as mentioned in (II) of (M1) and chosen from the fragment of a nucleic acid molecule having (S2), and its complements, where the fragment spans a MN8m mutation and enhances production of a polysaccharide from an ica locus when operably linked to an ica nucleic acid;

(4) an expression vector (III) comprising (N1) operably linked to an ica nucleic acid;

(5) a host cell transformed or transfected with (III);

(6) identifying (M3) an isolated binding agent, by contacting a first nucleic acid molecule having (S1) or its functionally equivalent fragment with a candidate molecule and **determining** whether the candidate molecule binds to the first nucleic acid molecule, and contacting a second nucleic acid having (S2) or its functionally equivalent fragment with the candidate molecule and **determining** whether the candidate molecule binds to the second nucleic acid molecule, where a candidate molecule that binds to either the first or the second nucleic acid molecule but not both is indicative of an isolated binding agent;

(7) identifying (M4) an ica promoter sequence associated with polysaccharide overproduction, involves **detecting** a nucleic acid molecule having a sequence alteration from wild-type in a region between and including 9 and 43 of (S1);

(8) identifying (M5) an ica regulatory nucleic acid molecule that enhances polysaccharide production, by altering a nucleic acid molecule having (S1), and **determining** a level of reporter production by a bacterium that comprises the altered nucleic acid molecule operably linked to reporter nucleic acid, where a higher than wild-type level of reporter protein production is indicative of (II) that enhances polysaccharide production;

(9) a composition (C1) comprising an isolated binding agent that binds to a nucleic acid having (S2) or (S1) with greater affinity than to (S1) or (S2);

(10) over-producing (M6) a protein in a bacterium, by introducing a nucleic acid operably linked to (II) into a bacterium, where the nucleic acid encodes a protein to be over-produced, and (II) comprises a mutant icaR nucleic acid.

ACTIVITY - Antibacterial.

No supporting data is given.

MECHANISM OF ACTION - **Vaccine**; Anti-poly-N-acetyl glucosamine antibodies.

USE - (M1) is useful for generating a polysaccharide over-producing bacterium, such as Staphylococcus, which is chosen from **S. epidermidis**, S. aureus, S. capitis, S. caprae, S. hemolyticus, S. auricularis, S. intermedius, S. lugdunensis, S. pasteuri and S. piscifermentans, where the recombinant bacterium is useful for producing a bacterial polysaccharide, which involves culturing the bacterium in a growth medium, and harvesting the bacterial polysaccharide from the culture. The bacterial polysaccharide is composed of beta 1-6 linked glucosamine units, where 0-100% of the units are acetate substituted, or less than 50% of the units are acetate substituted, and the polysaccharide is useful in producing antibody in a non-human subject such as rabbit or mouse. The method further involves formulating the bacterial polysaccharide as a **vaccine** (claimed). The polysaccharide produced using (I), is useful for **immunizing** humans and animals against

infection by Staphylococcus bacteria. The isolated binding agent of (M3) is useful for **treating** an **infection** in a subject, which involves administering the binding agent that selectively binds to a nucleic acid having (S2), to a subject who is in need of the **treatment**, where the **infection** is **S. epidermidis** or S. aureus **infection**. The polysaccharides of (M1) are useful for inducing immunity to bacterial **infection**, for producing antibodies for **diagnostic** and **therapeutic** purposes, and also in research applications. The anti-PNAG antibodies are useful for inducing passive **immunization** in a subject by **preventing** the development of **infection** in those subjects at risk of exposure to or infected with infectious agents.

ADVANTAGE - (M1) enables generation of bacterium capable of over-producing polysaccharide such as poly-N-acetyl glucosamine (claimed).

Dwg.0/12

L19 ANSWER 6 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

ACCESSION NUMBER: 2004-431602 [40] WPIDS
DOC. NO. CPI: C2004-161597
TITLE: Compositions comprising isolated bacterial polysaccharides comprising beta-1,6-glucosamine polymers with less than half the glucosamine amino groups being substituted with acetate, useful for **treating** or **preventing** Staphylococcal **infections**.
DERWENT CLASS: A11 A96 B04 C03 D16
INVENTOR(S): MAIRA-LITRAN, T; PIER, G B
PATENT ASSIGNEE(S): (BGHM) BRIGHAM & WOMENS HOSPITAL INC
COUNTRY COUNT: 106
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2004043405	A2	20040527	(200440)*	EN	68
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW					
W: AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW					
AU 2003295520	A1	20040603	(200470)		
US 2005118198	A1	20050602	(200537)		
EP 1565478	A2	20050824	(200556)	EN	
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2004043405	A2	WO 2003-US36358	20031112
AU 2003295520	A1	AU 2003-295520	20031112
US 2005118198	A1 Provisional	US 2002-425425P	20021112
		US 2003-713790	20031112
EP 1565478	A2	EP 2003-786713	20031112
		WO 2003-US36358	20031112

Searcher : Shears 571-272-2528

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2003295520	A1 Based on	WO 2004043405
EP 1565478	A2 Based on	WO 2004043405

PRIORITY APPLN. INFO: US 2002-425425P 20021112; US 2003-713790 20031112

AN 2004-431602 [40] WPIDS

AB WO2004043405 A UPAB: 20040624

NOVELTY - A new composition (C1) comprises an isolated bacterial polysaccharide comprising:

(a) a beta -1,6-glucosamine polymer of at least four monomeric units in which less than 50% of glucosamine amino groups are substituted with acetate; or

(b) a beta -1,6-glucosamine polymer of at least two monomeric units which is conjugated to a **carrier**, and in which less than 50% of glucosamine amino groups of the polysaccharide are substituted with acetate.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) making (M1a) (I), comprising:

(a) ethanol precipitating a crude polysaccharide preparation from a concentrated bacterial cell body preparation;

(b) concurrently digesting the crude polysaccharide with lysozyme and lysostaphin followed by sequential digestion with a nuclease and proteinase K to form a digested polysaccharide preparation;

(c) size fractionating the digested polysaccharide preparation;

(d) isolating an acetylated polysaccharide fraction; and

(e) de-acetylating the acetylated polysaccharide fraction to produce a polysaccharide having less than 50% acetate substations;

(2) making (M1b) (I), comprising:

(a) preparing an impure polysaccharide from a bacterial culture;

(b) incubating the impure of polysaccharide with an acid or a base to produce a semi pure polysaccharide preparation;

(c) neutralizing the preparation;

(d) incubating the neutralized preparation in hydrofluoric acid; and

(i) isolating from the preparation a polysaccharide having less than 50% acetate substitutions; or

(ii) de-acetylating the acetylated polysaccharide to produce a polysaccharide having less than 50% acetate substitutions;

(3) **treating** or **preventing** (M2) a Staphylococcus **infection** in a non-rodent subject by administering (I) to induce an immune response;

(4) generating (M3a) antibodies specific for Staphylococcus by administering (I) to a subject and isolating antibodies from the subject;

(5) generating (M3b) monoclonal antibodies specific for Staphylococcus by administering (I) and an **adjuvant** to a subject and generating hybridomas by standard techniques using spleen cells harvested from the subject;

(6) producing (M3c) a polyclonal antibody to a bacterial polysaccharide by administering (I) and an **adjuvant** to a subject, and harvesting antibody from the subject;

(7) a composition (C2) comprising an isolated binding agent that binds to (I);

(8) identifying (M4) the presence in a sample of a bacterial

polysaccharide having less than 50% acetate substituents, comprising:

(a) contacting the sample with an isolated binding agent that binds (I); and

(b) **detecting** binding of the agent to the sample, where binding indicates that the bacterial polysaccharide is present in the sample; and

(9) **treating** (M5) a subject having or at risk of developing a Staphylococcus **infection**, by administering the isolated binding agent of (C2).

ACTIVITY - Antibacterial; **Immunostimulant**.

MECHANISM OF ACTION - Inducer of immune response against Staphylococcus (claimed).

Groups of ten mice (Swiss Webster; female, 5-7 weeks of age) were **immunized** subcutaneously, one week apart, with 1.5,0.75 or 0.15 micro g of conjugated polysaccharide of poly-N-acetyl glucosamine conjugated with diphtheria toxoid (PNAG-DTm) and deacetylated PNAG (dPNAG-DTm) in 0.1 ml of phosphate buffered saline (PBS) and bled weekly for four weeks after the third **immunization**. Control groups were **immunized** with a mixture of unconjugated polysaccharide and protein in the same ratio. The results showed that the mice **immunized** with dPNAG-DTm developed large titers whereas control groups developed no titers at any on the doses used.

USE - M2 and M5 are useful for treating or preventing Staphylococcus infection in a primate, horse, swine, cow, goat, sheep, dog or cat, especially in a human. M4 is useful for in vitro, in situ and in vivo diagnosis of pathological status, such as infection (all claimed).

ADVANTAGE - (I) of (C1) is poorly substituted with acetate residues and is highly immunogenic in vivo and preferentially elicits antibodies that mediate opsonic killing and protection from infection.

DESCRIPTION OF DRAWING(S) - The figure is a graph explaining opsonic killing titers of antibodies from sera of four rabbits against Staphylococcal strains.

Dwg.9/9

L19 ANSWER 7 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

ACCESSION NUMBER:	2004-315684 [29] WPIDS
DOC. NO. NON-CPI:	N2004-251554
DOC. NO. CPI:	C2004-119697
TITLE:	Identifying LPXTG-containing cell wall-anchored surface proteins from Gram positive bacteria, for **treating infection** caused by the bacteria, comprises searching sequence information database for the sequence having LPXTG-motif.
DERWENT CLASS:	B04 D16 S05 T01
INVENTOR(S):	BOWDEN, M G; HALL, A; HOOK, M; HUTCHINS, J T; PATTI, J M; PONNURAJ, K; SILLANPAA, J V; STHANAM, N; XU, Y
PATENT ASSIGNEE(S):	(BOWD-I) BOWDEN M G; (HALL-I) HALL A; (HOOK-I) HOOK M; (HUTC-I) HUTCHINS J T; (PATT-I) PATTI J M; (PONN-I) PONNURAJ K; (SILL-I) SILLANPAA J V; (STHA-I) STHANAM N; (XUYY-I) XU Y; (INHI-N) INHIBITEX INC; (UABR-N) UAB RES FOUND; (TEXA) UNIV TEXAS A & M SYSTEM
COUNTRY COUNT:	98

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2004025416	A2	20040325	(200429)*	EN	96

RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE
LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE
DK DM DZ EC EE ES FI GB GD GH GM HR HU ID IL IN IS JP KE KG KP
KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PL
PT RO RU SD SE SG SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZM ZW
US 2004101919 A1 20040527 (200435)
AU 2003274972 A1 20040430 (200462)
EP 1540559 A2 20050615 (200539) EN
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU
LV MC MK NL PT RO SE SI SK TR

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2004025416	A2	WO 2003-US28789	20030915
US 2004101919	A1 Provisional	US 2002-410303P	20020913
		US 2003-661809	20030915
AU 2003274972	A1	AU 2003-274972	20030915
EP 1540559	A2	EP 2003-759242	20030915
		WO 2003-US28789	20030915

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2003274972	A1 Based on	WO 2004025416
EP 1540559	A2 Based on	WO 2004025416

PRIORITY APPLN. INFO: US 2002-410303P 20020913; US 2003-661809 20030915

AN 2004-315684 [29] WPIDS

AB WO2004025416 A UPAB: 20040505

NOVELTY - Identifying LPXTG-containing cell wall-anchored surface proteins from Gram positive bacteria that bind to an extracellular matrix molecule comprises searching a database of sequence information for a putative protein sequence having the LPXTG-motif in its C-terminal region and analyzing the sequence for the presence of one or more Immunoglobulin (Ig)-like fold regions.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) an isolated protein or its A domain identified by the method above, or an isolated LPXTG-containing cell wall-anchored surface protein from Gram positive bacteria or its A domain having an amino acid sequence selected from 17 sequences of 400-10203 amino acids (SEQ ID NO: 2-7, 9, 11, 13, 15, 17, 19, and 20-24) given in the specification, and the A domains of the sequences;

(2) an isolated antibody that can bind to the protein in (1);

(3) an isolated nucleic acid sequence encoding the protein or the PXTG-containing cell wall-anchored surface protein or its A domain having a nucleic acid sequence selected from 6 sequences of 1422-3387 bp (SEQ ID NO: 8, 10, 12, 14, 16, and 18) given in the specification, or its degenerates;

(4) an isolated antisera containing the antibody above;

(5) a **diagnostic** kit comprising the antibody and means for **detecting** binding by that antibody;

(6) a pharmaceutical composition comprising the antibody in (2), the proteins or peptides above, and a pharmaceutical vehicle,

carrier or excipient;

(7) **diagnosing** an **infection** caused by a Gram positive bacteria;

(8) eliciting an immunogenic reaction in a human or animal;

(9) a **vaccine** comprising the protein in (1) and a pharmaceutical vehicle, **carrier** or excipient;

(10) assaying for the presence of antigens from Gram positive bacteria in a biological sample suspected of containing the antigens; and

(11) monitoring the level of Gram positive bacteria antigens in a human or animal patient suspected of containing the antigens.

ACTIVITY - Antibacterial. No biological data given.

MECHANISM OF ACTION - **Vaccine**; Gene **therapy**.

USE - The antibody is useful for **treating** or **preventing** an **infection** of Gram-positive bacteria in a human or animal patient (claimed). The method and the proteins are useful in generating antibodies for **treating** and **preventing** the spread of **infections** of Gram positive bacteria, for interfering with, or inhibiting binding interactions by Gram positive bacteria, for monitoring the level of gram positive bacterial antigens, or antibodies recognizing the antigens in a human or animal patients suspected of containing the antigens or antibodies, in **preventing** or reducing **infection** of medical devices and prosthesis caused by such organisms, and in **treating** or **preventing infections** in highly susceptible groups such as premature newborns, AIDS and debilitated cancer patients, and bone marrow transplantation.

Dwg.0/2

L19 ANSWER 8 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

ACCESSION NUMBER: 2004-239156 [22] WPIDS

CROSS REFERENCE: 2004-169460 [16]; 2004-180545 [17]; 2004-180546 [17]; 2004-180668 [17]; 2004-239150 [22]

DOC. NO. CPI: C2004-093639

TITLE: New mutant FrpB proteins for preparing a medicament for the generation of an immune response in an animal or for the **diagnosis, treatment** or **prevention** of Neisserial **infection.**

DERWENT CLASS: B04 D16

INVENTOR(S): BIEMANS, R; DENOEL, P; FERON, C; GORAJ, K; KORTEKAAS, J; POOLMAN, J; TOMMASSEN, J; WEYNANTS, V

PATENT ASSIGNEE(S): (GLAX) GLAXOSMITHKLINE BIOLOGICALS SA; (UYUT-N) RIJKSUNIV UTRECHT; (TECH-N) TECHNOLOGY FOUND STICHTING TECH WETENSCH

COUNTRY COUNT: 105

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2004020463	A2	20040311	(200422)*	EN	104
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW					
AU 2003287945	A1	20040319	(200462)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2004020463	A2	WO 2003-EP9634	20030828
AU 2003287945	A1	AU 2003-287945	20030828

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2003287945	A1 Based on	WO 2004020463

PRIORITY APPLN. INFO: GB 2002-20199 20020830
AN 2004-239156 [22] WPIDS
CR 2004-169460 [16]; 2004-180545 [17]; 2004-180546 [17]; 2004-180668 [17]; 2004-239150 [22]
AB WO2004020463 A UPAB: 20040928
NOVELTY - An FrpB protein having one or more deletions of non-conserved amino acids compared to a corresponding wild-type FrpB protein, or in which one or more of the amino acids of at least one of its loops has been deleted, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a polynucleotide encoding the new protein;
(2) an expression vector comprising the above polynucleotide;
(3) a host cell comprising the expression vector;
(4) producing the protein;
(5) refolding an FrpB protein;
(6) a refolding buffer comprising ethanolamine, SB-12 and, optionally, guandinium chloride for use in the method of (5);
(7) an isolated, refolded FrpB protein obtained or obtainable by the method in (5);
(8) **diagnosing, preventing** or **treating** Neisserial **infection;**
(9) an antibody immunospecific for the FrpB protein; and
(10) a pharmaceutical composition comprising at least one FrpB protein or the above antibody, and a pharmaceutical **carrier.**

ACTIVITY - Antibacterial.
No biological data given.
MECHANISM OF ACTION - Gene **Therapy; Vaccine.**
USE - The FrpB protein or the pharmaceutical composition is useful in preparing a medicament for the generation of an immune response in an animal or for the **treatment** or **prevention** of Neisserial **infection** (claimed). The composition and methods may also be used in **diagnosing** Neisserial **infection.**
Dwg.0/12

L19 ANSWER 9 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2004-239150 [22] WPIDS
CROSS REFERENCE: 2004-169460 [16]; 2004-180545 [17]; 2004-180546 [17]; 2004-180668 [17]; 2004-239156 [22]
DOC. NO. CPI: C2004-093633
TITLE: New refolded NspA protein, useful for preparing a composition for **diagnosing, treating** or **preventing infection** caused by Neisseria meningitidis or

Neisseria gonorrheae.
DERWENT CLASS: B04 D16
INVENTOR(S): BIEMANS, R; BOS, M; DENOEL, P; FERON, C; GORAJ, K; POOLMAN, J; TOMMASSEN, J; WEYNANTS, V; GORAJ, C
PATENT ASSIGNEE(S): (GLAX) GLAXOSMITHKLINE BIOLOGICALS SA; (UYUT-N) RIJKSUNIV UTRECHT
COUNTRY COUNT: 106
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2004020452	A2	20040311	(200422)*	EN	62
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW					
AU 2003273854	A1	20040319	(200462)		
EP 1532168	A2	20050525	(200535)	EN	
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2004020452	A2	WO 2003-EP10085	20030828
AU 2003273854	A1	AU 2003-273854	20030828
EP 1532168	A2	EP 2003-757819	20030828
		WO 2003-EP10085	20030828

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2003273854	A1 Based on	WO 2004020452
EP 1532168	A2 Based on	WO 2004020452

PRIORITY APPLN. INFO: GB 2002-20197 20020830
AN 2004-239150 [22] WPIDS
CR 2004-169460 [16]; 2004-180545 [17]; 2004-180546 [17]; 2004-180668 [17]; 2004-239156 [22]
AB WO2004020452 A UPAB: 20050603
NOVELTY - An isolated refolded NspA protein, is new.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:
(1) refolding an NspA protein;
(2) a refolding buffer comprising ethanolamine and SB-12 for refolding an NspA protein;
(3) a pharmaceutical composition comprising the refolded NspA protein and a **carrier**;
(4) **preventing** or **treating** Neisserial **infection**;
(5) an antibody immunospecific for the NspA protein; and
(6) **diagnosing** a Neisserial **infection**.
ACTIVITY - Antibacterial. No biological data given.
MECHANISM OF ACTION - Gene **therapy**; **Vaccine**.
No biological data given.

USE - The refolded NspA protein is useful for preparing a composition for **diagnosing, treating** or **preventing infection** caused by Neisseria meningitidis or Neisseria gonorrheae (claimed). Dwg.0/3

L19 ANSWER 10 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2004-180546 [17] WPIDS
CROSS REFERENCE: 2004-169460 [16]; 2004-180545 [17]; 2004-180668 [17]; 2004-239150 [22]; 2004-239156 [22]
DOC. NO. CPI: C2004-071431
TITLE: New immunogenic composition comprising different antigens from Neisserial adhesin, autotransporter, toxin, Fe acquisition protein or membrane associated protein, useful for **treating** or **preventing** Neisserial **infection**.
DERWENT CLASS: B04 D16
INVENTOR(S): BERTHET, F J; BIEMANS, R; DENOEL, P; FERON, C; GORAJ, K; POOLMAN, J; WEYNANTS, V; GORAJ, C
PATENT ASSIGNEE(S): (GLAX) GLAXOSMITHKLINE BIOLOGICALS SA
COUNTRY COUNT: 106
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2004014418	A2	20040219	(200417)*	EN	113
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW					
AU 2003250204	A1	20040225	(200456)		
EP 1524993	A2	20050427	(200529)	EN	
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR					
NO 2005000008	A	20050428	(200537)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2004014418	A2	WO 2003-EP8571	20030731
AU 2003250204	A1	AU 2003-250204	20030731
EP 1524993	A2	EP 2003-784153	20030731
		WO 2003-EP8571	20030731
NO 2005000008	A	WO 2003-EP8571	20030731
		NO 2005-8	20050103

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2003250204	A1 Based on	WO 2004014418
EP 1524993	A2 Based on	WO 2004014418

PRIORITY APPLN. INFO: GB 2003-5028 20030305; GB 2002-18035 20020802; GB

2002-18036	20020802; GB
2002-18037	20020802; GB
2002-18051	20020802; GB
2002-20197	20020830; GB
2002-20199	20020830; GB
2002-25524	20021101; GB
2002-25531	20021101; GB
2002-30164	20021224; GB
2002-30168	20021224; GB
2002-30170	20021224

AN 2004-180546 [17] WPIDS

CR 2004-169460 [16]; 2004-180545 [17]; 2004-180668 [17]; 2004-239150 [22]; 2004-239156 [22]

AB WO2004014418 A UPAB: 20050613

NOVELTY - A new immunogenic composition comprises two or more different antigens from Neisserial adhesin, Neisserial autotransporter, Neisserial toxin, Neisserial Fe acquisition protein or Neisserial membrane associated protein, preferably integral outer membrane protein.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a **vaccine** comprising the immunogenic composition and a **carrier**;

(2) a method for **treating** or **preventing** Neisserial disease;

(3) a genetically engineered Neisserial strain from which the outer membrane vesicle preparation is derived;

(4) a method of making the immunogenic composition;

(5) a method of making the **vaccine**;

(6) a method of preparing an immune globulin for **treating** or **preventing** Neisserial **infection**;

(7) an immune globulin prepared by the method of (6);

(8) a pharmaceutical composition comprising the immune globulin and a **carrier**; and

(9) a method of **treating** or **preventing** Neisserial **infection**.

ACTIVITY - Antibacterial. No biological data given.

MECHANISM OF ACTION - Gene **therapy**.

USE - The immunogenic composition is useful for **treating** or **preventing infection** caused by Neisseria meningitidis or Neisseria gonorrheae (claimed).

Dwg.0/9

L19 ANSWER 11 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

ACCESSION NUMBER: 2005-011161 [01] WPIDS

CROSS REFERENCE: 2005-180418 [19]

DOC. NO. CPI: C2005-003017

TITLE: New amide derivatives useful as gyrase and/or Topo IV inhibitors for **treating, preventing** or lessening severity of bacterial **infection** e.g. urinary tract **infections**, respiratory **infections**, pneumonia and prostatitis.

DERWENT CLASS: B02

INVENTOR(S): CHARIFSON, P S; DEININGER, D D; DRUMM, J; GRILLOT, A; LETIRAN, A; LIAO, Y; PEROLA, E; RONKIN, S M; STAMOS, D; WANG, T

PATENT ASSIGNEE(S): (CHAR-I) CHARIFSON P S; (DEIN-I) DEININGER D D; (DRUM-I) DRUMM J; (GRIL-I) GRILLOT A; (LETI-I) LETIRAN A; (LIAO-I) LIAO Y; (PERO-I) PEROLA E;

(RONK-I) RONKIN S M; (STAM-I) STAMOS D; (WANG-I) WANG T; (VERT-N) VERTEX PHARM INC

COUNTRY COUNT: 108

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2004235886	A1	20041125	(200501)*		148
WO 2005012292	A1	20050210	(200512)	EN	

RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2004235886	A1 Provisional	US 2003-443917P	20030131
		US 2004-767638	20040129
WO 2005012292	A1	WO 2004-US2541	20040129

PRIORITY APPLN. INFO: US 2003-443917P 20030131; US 2004-767638 20040129

AN 2005-011161 [01] WPIDS

CR 2005-180418 [19]

AB US2004235886 A UPAB: 20050321

NOVELTY - Amide derivatives (I) and their salts are new.

DETAILED DESCRIPTION - Amide derivatives of formula (I) and their salts are new;

W = N, CH or CF;

X = CH or CF;

Z = O or NH;

R1 = phenyl or a 5-6 membered heteroaryl ring having 1-3 heteroatoms of O, N or S (each substituted with 0-3 groups of -(T)y-Ar, R-a, oxo, C(O)R-a, CO2R-a, OR-a, N(R-a)2, SR-a, NO2, halo, CN, C(O)N(R-a)2, NR-aC(O)R-a, SO2R-a, SO2N(R-a)2 or NR-aSO2R-a (two substituents on adjacent position of R1 taken together form a 5-7 membered saturated, partially unsaturated or aryl ring having 0-3 heteroatoms of N, O or S);

y = 0-1;

T = 1-4C alkylidene chain, where one methylene unit of T is optionally replaced by -O-, -NH- or -S-;

R-a = H, 1-4C aliphatic or a 5-6 membered optionally saturated or aryl ring having 0-3 heteroatoms of N, O or S (each substituted with 0-3 groups of halo, oxo, R0, N(R0)2, OR0, CO2R0, NR0-C(O)R0, C(O)N(R0)2, SO2R0, SO2N(R0)2 or NR0SO2R0);

R0 = H, 1-4C aliphatic or a 5-6 membered optionally saturated or aryl ring having 0-3 heteroatoms of N, O or S;

Ar = a 3-8 membered optionally saturated or aryl ring, a 3-7 membered heterocyclic ring having 1-3 heteroatoms of N, O or S or a 5-6 membered heteroaryl ring having 1-3 heteroatoms of N, O or S (each substituted with 0-3 groups of R-a, oxo, CO2R-a, OR-a, N(R-a)2, SR-a, NO2, halo, CN, C(O)N(R-a)2, NR-aC(O)R-a, SO2R-a, C(O)R-a, SO2N(R-a)2 or NR-aSO2R-a;

R2 = H or a 1-3C aliphatic group; and

Ring A = a 5-6 membered heteroaryl ring having 1-4 heteroatoms of N, O or S, provided that the ring has a H-bond acceptor in the position adjacent to the point of attachment to Ring B, where the Ring A is substituted with 0-3 groups of R-a, oxo, CO2R-a, OR-a, N(R-a)2, SR-a, NO2, halo, CN, C(O)N(R-a)2, NR-aC(O)R-a, SO2R-a, SO2N(R-a)2, or NR-aSO2R-a (two substituents on adjacent positions of Ring A may be taken together to form a 5-7 membered saturated, partially unsaturated or aryl ring having 0-3 heteroatoms of N, O or S.

An INDEPENDENT CLAIM is also included for a composition (A) comprising (I) and **carrier**, **adjuvant** or vehicle.

ACTIVITY - Antibacterial; Uropathic; Respiratory-Gen.; Antiinflammatory; Dermatological; Vasotropic; **Immunostimulant**.

MECHANISM OF ACTION - Gyrase inhibitor; Topo IV inhibitor.

The ability of (I) to inhibit gyrase was assessed using gyrase ATPase assay. The results showed that the inhibitory constant value of (I) was less than 50 nM.

USE - (I) Are useful to **treat**, **prevent** or lessen the severity of a bacterial **infection** due to Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium, Klebsiella pneumoniae, Enterobacter sps. Proteus sps. Pseudomonas aeruginosa, E. coli, Serratia marcesens, Staphylococcus aureus, Coag. Neg. Staph, Haemophilus influenzae, Bacillus anthracis, Mycoplasma pneumoniae, Moraxella catarralis, Chlamydia pneumoniae, Legionella pneumophila, **Staphylococcus epidermidis**, Mycobacterium tuberculosis or Helcoibacter pylori. (such as a urinary tract **infection**, a respiratory **infection**, pneumonia, prostatitis, a skin or soft tissue **infection**, an intra-abdominal **infection**, a blood stream **infection** or an **infection** of febrile neutropenic patients) (all claimed).

ADVANTAGE - (I) Are potent inhibitors of gyrase and Topo IV.

Dwg.0/0

L19 ANSWER 12 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

ACCESSION NUMBER: 2004-580138 [56] WPIDS
CROSS REFERENCE: 2002-381255 [41]
DOC. NO. NON-CPI: N2004-458635
DOC. NO. CPI: C2004-211406
TITLE: New isolated polypeptide and encoding nucleic acid derived from **Staphylococcus epidermidis**, useful for **diagnosing**, **preventing** and/or **treating** an **S. epidermidis** bacterial **infection**.
DERWENT CLASS: B04 D16 T01
INVENTOR(S): BUSH, D; DOUCETTE-STAMM, L
PATENT ASSIGNEE(S): (BUSH-I) BUSH D; (DOUC-I) DOUCETTE-STAMM L
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2004147734	A1	20040729	(200456)*		741

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE

US 2004147734	A1	Provisional	US 1997-64964P	19971108
		CIP of	US 1998-134001	19980813
		Div ex	US 1999-450969	19991129
			US 2003-724972	20031201

FILING DETAILS:

PATENT NO	KIND		PATENT NO
US 2004147734	A1	CIP of	US 6380370

PRIORITY APPLN. INFO: US 1997-64964P 19971108; US 1998-134001 19980813; US 1999-450969 19991129; US 2003-724972 20031201

AN 2004-580138 [56] WPIDS
CR 2002-381255 [41]
AB US2004147734 A UPAB: 20040901
NOVELTY - An isolated nucleic acid comprising a nucleotide sequence with any of 3772 fully defined nucleotide sequences (SEQ ID NO: 1-3772) and encoding an **Staphylococcus epidermidis** polypeptide with any of 3772 fully defined amino acid sequences (SEQ ID NO: 3772-7544) as given in the specification, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) a recombinant expression vector comprising the nucleic acid cited above operably linked to a transcription regulatory element;

(2) a cell comprising a recombinant expression vector of (1);

(3) producing an **S. epidermidis** polypeptide, comprising culturing a cell of (2) to permit expression of the polypeptide;

(4) a probe comprising a nucleotide sequence consisting of at least 8 contiguous nucleotides of SEQ ID NO: 1-3772;

(5) an isolated nucleic acid comprising a nucleotide sequence of at least 8 nucleotides in length, where the sequence is hybridizable to a nucleic acid having nucleotide sequences of SEQ ID NO: 1-3772;

(6) a **vaccine** composition for **prevention** or **treatment** of an **S. epidermidis infection**, comprising a nucleic acid cited above and a **carrier**;

(7) **treating** a subject for **S. epidermidis infection**, comprising administering a **vaccine** composition of (6) or (9);

(8) a recombinant or substantially pure preparation of an **S. epidermidis** polypeptide or its fragment, where the polypeptide has any of SEQ ID NO: 3773-7544;

(9) a **vaccine** composition for **prevention** or **treatment** of an **S. epidermidis infection**, comprising an **S. epidermidis** polypeptide of (8) and a **carrier**;

(10) **detecting** the presence of a Staphylococcus nucleic acid in a sample, comprising contacting a sample with a nucleic acid cited above in which a hybrid can form between the probe and a Staphylococcus nucleic acid in the sample, and **detecting** the hybrid formed, where **detection** of a hybrid indicates the presence of a Staphylococcus nucleic acid in the sample;

(11) a computer readable medium having recorded in it the nucleotide sequences with SEQ ID NO: 1-3772 or its fragments;

(12) a computer based system for identifying fragments of the

Staphylococcus genome of commercial importance, comprising a data storage means having SEQ ID NO: 1-3772 or its fragments, a search means for comparing a target sequence to the nucleotide sequences of the data storage means to identify homologous sequences, and a retrieval means for obtaining the homologous sequences;

(13) a computer based system for identifying fragments of the Staphylococcus plasmids of commercial importance, comprising a data storage means having SEQ ID NO: 3703-7554 or its fragments, a search means for comparing a target sequence to the nucleotide sequences of the data storage means to identify homologous sequences, and a retrieval means for obtaining the homologous sequences;

(14) identifying commercially important nucleic acid fragments of the Staphylococcus genome and/or plasmids, comprising comparing a database having nucleotide or polypeptide sequences with SEQ ID NO: 1-3772 and/or SEQ ID NO: 3703-7544, respectively, or its fragments, with a target sequence to obtain a nucleic acid molecule comprised of a complementary nucleotide sequence to the target sequence, where the target sequence is not randomly selected; and

(15) identifying an expression modulating fragment of the Staphylococcus genome and/or plasmids, comprising comparing a database having nucleotide or polypeptide sequences with SEQ ID NO: 1-3772 and/or SEQ ID NO: 3703-7544, respectively, or its fragments, with a target sequence to obtain a nucleic acid molecule comprised of a complementary nucleotide sequence to the target sequence, where the target sequence comprises sequences known to regulate gene expression.

ACTIVITY - Antibacterial. Test details are described but no results given.

MECHANISM OF ACTION - **Vaccine**; Antisense-**Therapy**.

USE - The methods and compositions of the present invention are useful for the **diagnosis, prevention** and/or **treatment** of an **Staphylococcal epidermidis** bacterial **infection**.

Dwg.0/0

L19 ANSWER 13 OF 37 MEDLINE on STN

ACCESSION NUMBER:	2004205112 MEDLINE
DOCUMENT NUMBER:	PubMed ID: 15102827
TITLE:	The fibrinogen binding protein of **Staphylococcus epidermidis** is a target for opsonic antibodies.
AUTHOR:	Rennermalm Anna; Nilsson Martin; Flock Jan-Ingmar
CORPORATE SOURCE:	Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
SOURCE:	Infection and immunity, (2004 May) 72 (5) 3081-3. Journal code: 0246127. ISSN: 0019-9567.
PUB. COUNTRY:	United States
DOCUMENT TYPE:	Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:	English
FILE SEGMENT:	Priority Journals
ENTRY MONTH:	200406
ENTRY DATE:	Entered STN: 20040423 Last Updated on STN: 20040603 Entered Medline: 20040602

AB Antibodies against the fibrinogen binding protein (Fbe) of **Staphylococcus epidermidis** significantly increased macrophage phagocytosis. Antibodies against autolysin E were opsonic but to a lesser extent. Antibodies against a novel, putatively surface-located antigen were unable to enhance phagocytosis. The

severity of systemic **infection** of mice with **S. epidermidis** was reduced if the bacteria were preopsonized with anti-Fbe prior to administration. Fbe is thus a strong candidate for protein **vaccination** against **S. epidermidis infection**, and antibodies against Fbe can be used to **prevent** or **treat infections** caused by **S. epidermidis**.

L19 ANSWER 14 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2003-587257 [55] WPIDS
CROSS REFERENCE: 2003-721613 [68]
DOC. NO. CPI: C2003-158922
TITLE: New medicament comprising at least one MAb that binds to peptidoglycan (PepG) of gram-positive bacteria, useful for **treating** staphylococcal **infections**, including nosocomial **infections**.
DERWENT CLASS: B04 D16
INVENTOR(S): FISCHER, G W; FOSTER, S J; KOKAI-KUN, J F; SCHUMAN, R F; STINSON, J R; FOSTER, S
PATENT ASSIGNEE(S): (FISC-I) FISCHER G W; (FOST-I) FOSTER S J; (KOKA-I) KOKAI-KUN J F; (SCHU-I) SCHUMAN R F; (STIN-I) STINSON J R; (BIOS-N) BIOSYNEXUS INC
COUNTRY COUNT: 103
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2003059259	A2	20030724	(200355)*	EN	102
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SI SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW					
US 2003228322	A1	20031211	(200382)		
AU 2002364740	A1	20030730	(200421)		
EP 1470237	A2	20041027	(200471)	EN	
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR					
JP 2005524624	W	20050818	(200555)		66

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003059259	A2	WO 2002-US41032	20021223
US 2003228322	A1 Provisional	US 2001-343444P	20011221
		US 2002-323903	20021220
AU 2002364740	A1	AU 2002-364740	20021223
EP 1470237	A2	EP 2002-806494	20021223
		WO 2002-US41032	20021223
JP 2005524624	W	WO 2002-US41032	20021223
		JP 2003-559424	20021223

FILING DETAILS:

PATENT NO	KIND	PATENT NO

Text 2

AU 2002364740 A1 Based on WO 2003059259
EP 1470237 A2 Based on WO 2003059259
JP 2005524624 W Based on WO 2003059259

PRIORITY APPLN. INFO: US 2001-343444P 20011221; US
2001-341806P 20011221; US
2002-323903 20021220

AN 2003-587257 [55] WPIDS
CR 2003-721613 [68]
AB WO2003059259 A UPAB: 20050826
NOVELTY - A medicament comprising at least one MAb that binds to peptidoglycan (PepG) of gram-positive bacteria, where the MAb provides **therapeutically** beneficial outcome upon administration to a patient, is new.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:
(1) a method for **treating** a patient by administering the medicament or **vaccine** to a patient;
(2) a hybridoma cell line deposited at the American Type Culture Collection (ATCC) under accession number PTA-2492 or PTA-3659; and
(3) a **vaccine** comprising at least one purified PepG, peptides, fragments and their epitopes, in a **carrier**.
ACTIVITY - Antibacterial. No biological data given.
MECHANISM OF ACTION - **Vaccine**.
USE - The medicament and **vaccine** are useful for **treating** staphylococcal **infections**, including nosocomial **infections**.
Dwg.0/7

L19 ANSWER 15 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2003-586972 [55] WPIDS
DOC. NO. CPI: C2003-158795
TITLE: Protein powder composition useful for **treating infections** of mucosal membranes exhibits an antibody binding activity effect against Candida albicans and against a range of other antigens.
DERWENT CLASS: B04 C03 D13 D16
INVENTOR(S): HOBMAN, P G; HUTCHINSON, J C; WILLIAMS, C E
PATENT ASSIGNEE(S): (FONT-N) FONTERRA COOP GROUP LTD
COUNTRY COUNT: 102
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2003055502	A1	20030710	(200355)*	EN	16

RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AU 2002367161 A1 20030715 (200421)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE

WO 2003055502	A1	WO 2002-NZ293	20021224
AU 2002367161	A1	AU 2002-367161	20021224

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2002367161	A1 Based on	WO 2003055502

PRIORITY APPLN. INFO: NZ 2001-516422 20011224

AN 2003-586972 [55] WPIDS

AB WO2003055502 A UPAB: 20030828

NOVELTY - A protein powder composition which exhibits an antibody binding activity effect against Candida albicans and against a range of other antigens, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:

(1) a milk protein powder concentrate composition having increased levels of IgA and IgG, and elevated antibody binding activity against Candida albicans and a number of other antigens;

(2) **immunizing** a lactating mammal against a range of pathogens by specifically **immunizing** the mammal against a specific pathogen (preferably Candida albicans) to increase the levels of IgA specific to the pathogen; and

(3) production of a powder composition having a broad antibody binding activity effect involving completing an **immunization** protocol targeted at a specific antigen in a lactating mammal; collecting the milk produced by the mammal; and concentrating the milk into a powder composition.

ACTIVITY - Antibacterial; Antimicrobial.

MECHANISM OF ACTION - Microbial growth inhibitor; Microbial adherence inhibitor.

The efficacy of a dairy protein powder prepared by **immunization** of cows against Candida albicans to inhibit microbial adherence to mucosal membrane was evaluated by incubating 35S-radiolabeled C. albicans (A) with the protein powder and then with a nylon membrane having human salivary proteins adhered to it. After incubation the membrane was analyzed for binding of (A) to the salivary proteins. The protein powder showed greater than 90% of inhibition of adherence of (A). The results showed that the protein powder through IgA and IgG effect inhibited microbial adherence to the mucosal surface.

USE - For the **treatment** of **infections** of mucosal membranes e.g. gastrointestinal tract (including the oral cavity and throat), skin, nasal passages and the vagina caused by and for enhancing antibody effect against Candida albicans, Enterobacter aerogenes, **Staphylococcus epidermidis**, E. coli, Proteus vulgaris, Shigella flexnerii, Corynebacterium ovis, Helicobacter pylori, and Clostridium spp. (e.g. Clostridium difficle). For **immunizing** lactating mammal (e.g. cow, goat or sheep) (claimed).

ADVANTAGE - The composition increases the levels of IgA specific to the pathogen in the mammal. The amount of IgA in the powder composition is elevated as a result of an **immunization** protocol targeted at Candida albicans. There is a synergistic antigenic effect between the IgA and IgG in the powder composition resulting in increased antigenic activity against anyone of a number of antigens. The antibody (IgG and IgA) effect of the composition is enhanced against a broad range of bacteria.

Dwg.0/8

L19 ANSWER 16 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2003-671313 [63] WPIDS
DOC. NO. CPI: C2003-183027
TITLE: New isolated Staphylococcus aureus exopolysaccharide useful for inducing an immune response.
DERWENT CLASS: A96 B04 C06 D16
INVENTOR(S): ABEYGUNAWARDANA, C; COOK, J C; COPE, L D; GRIMM, K M; HEPLER, R W; IP, C C; JANSEN, K U; JOYCE, J G; KELLER, P M; PRZYSIECKI, C T; ROPER, K; XU, Q; ROPER, D K; XU, Q W
PATENT ASSIGNEE(S): (MERI) MERCK & CO INC; (ABEY-I) ABEYGUNAWARDANA C; (COOK-I) COOK J C; (COPE-I) COPE L D; (GRIM-I) GRIMM K M; (HEPL-I) HEPLER R W; (IPCC-I) IP C C; (JANS-I) JANSEN K U; (JOYC-I) JOYCE J G; (KELL-I) KELLER P M; (PRZY-I) PRZYSIECKI C T; (ROPE-I) ROPER D K; (XUQW-I) XU Q W
COUNTRY COUNT: 28
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2003053462	A2	20030703	(200363)*	EN	17
RW: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR					
W: CA JP US					
EP 1455817	A2	20040915	(200460)	EN	
R: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR					
US 2004259838	A1	20041223	(200504)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003053462	A2	WO 2002-US39079	20021206
EP 1455817	A2	EP 2002-790044	20021206
		WO 2002-US39079	20021206
US 2004259838	A1 Provisional	US 2002-355941P	20020211
		WO 2002-US39079	20021206
		US 2004-498070	20040609

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1455817	A2 Based on	WO 2003053462

PRIORITY APPLN. INFO: US 2002-355941P 20020211; US 2001-346755P 20011211
AN 2003-671313 [63] WPIDS
AB WO2003053462 A UPAB: 20031001
NOVELTY - An isolated Staphylococcus aureus exopolysaccharide (SAE) (I) is new.
DETAILED DESCRIPTION - An isolated Staphylococcus aureus exopolysaccharide (SAE) of formula (I) is new.
R1 = H or COCH3;
R2 = H or C4H6O4; and

provided that:
(1) 40 - 60% of R1 is H and the remainder of R1 is COCH3;
(2) 75 - 95% of R2 is H and the remainder of R2 is C4H6O4; and
(3) n is such that the molecular weight is at least 300,000 Da.
INDEPENDENT CLAIMS are included for the following:
(i) an immunogenic composition comprising (I) optionally covalently coupled to an immunogenic protein **carrier**; and
(ii) preparation of (I).
ACTIVITY - Antimicrobial; **Immunostimulant.**
MECHANISM OF ACTION - **Vaccine.**
Balb/c mice were rested for 1 week, then **immunized** with Native SAE-OMPC and sized SAE-OMPC (0.05 micro l) in 1X Merck Aluminium **adjuvant**. The animals were split into 8 groups and received either 8, 0.8, 0.08 or 0.008 micro g either native or sized SAE-OMPC conjugated antigen absorbed onto 1X Merck Aluminium **adjuvant**. A control group were **immunized** with 1X Merck Aluminium **adjuvant** alone. Groups were **immunized** with antigens on days 0 and 14. The animals were challenged with S. epidermis strain RP62A (9.88x108 CFU) by IP injection. The number of survivors was followed for 7 days. After 7 days % survival was 26/27/30/20/20 for (micro g Native SAE-OPMC) 8/0.8/0/08/0.08/control respectively.
USE - (I) is used as a high molecular weight polysaccharide antigen for inducing an immune response (claimed); as a **vaccine** for **preventing** Staphylococcus **infections**. It can be used for both humans and animals.
ADVANTAGE - (I) is produced by simple, robust method to facilitate **vaccine** production. The source of isolated SAE is other than **S. epidermidis**, namely S. aureus.
Dwg.0/6

L19 ANSWER 17 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2003-332796 [31] WPIDS
DOC. NO. CPI: C2003-086226
TITLE: New 3-substituted 6,7-dihydroxytetrahydroisoquinoline compounds are antibacterial agents.
DERWENT CLASS: B02
INVENTOR(S): BURRI, K; ISLAM, K; SCHMITT, L
PATENT ASSIGNEE(S): (ARPI-N) ARPIDA AG; (BURR-I) BURRI K; (ISLA-I) ISLAM K; (SCHM-I) SCHMITT L
COUNTRY COUNT: 101
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2003018017	A1	20030306	(200331)*	EN	34
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW					
EP 1427417	A1	20040616	(200439)	EN	
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR					
AU 2002333377	A1	20030310	(200452)		
US 2004266817	A1	20041230	(200503)		
MX 2004001773	A1	20040601	(200504)		

NO 2004000821	A	20040426 (200508)	
CN 1549716	A	20041124 (200516)	
JP 2005503392	W	20050203 (200516)	58

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003018017	A1	WO 2002-EP8916	20020809
EP 1427417	A1	EP 2002-796217	20020809
		WO 2002-EP8916	20020809
AU 2002333377	A1	AU 2002-333377	20020809
US 2004266817	A1	WO 2002-EP8916	20020809
		US 2004-487877	20040818
MX 2004001773	A1	WO 2002-EP8916	20020809
		MX 2004-1773	20040225
NO 2004000821	A	WO 2002-EP8916	20020809
		NO 2004-821	20040225
CN 1549716	A	CN 2002-816853	20020809
JP 2005503392	W	WO 2002-EP8916	20020809
		JP 2003-522535	20020809

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1427417	A1 Based on	WO 2003018017
AU 2002333377	A1 Based on	WO 2003018017
MX 2004001773	A1 Based on	WO 2003018017
JP 2005503392	W Based on	WO 2003018017

PRIORITY APPLN. INFO: WO 2001-EP9846 20010827

AN 2003-332796 [31] WPIDS

AB WO2003018017 A UPAB: 20030516

NOVELTY - 3-substituted 6,7-dihydroxytetrahydroisoquinoline compounds (I) and their salts are new.

DETAILED DESCRIPTION - 3-substituted 6,7-dihydroxytetrahydroisoquinoline compounds of formula (I) and their salts are new:

R1 = H or lower alkyl;

R2 = H, aryl, aryl-lower alkyl, heteroaryl or heteroaryl-lower alkyl; (aryl and heteroaryl groups are optionally mono-, di- or tri-substituted by lower alkyl, OH, lower alkoxy, halo, CF3, NH2, lower alkylamino or lower alkylenedioxy);

R3 = (CH2)m-O-(CH2)n-Ar1, (CH2)m-NH-(CH2)n-Ar1, (CH2)m-S-(CH2)n-Ar1, (CH=CH)-(CH2)n-Ar1, CHOH-(CH2)n-Ar1, (CH2)n-Ar2, (CH2)n-Ar3 or (CH2)n-Ar4;

m = 1-3;

n = 0-3;

Ar1 = H or aryl or heteroaryl optionally substituted by 1-3 D groups;

D = OH, lower alkyl, lower alkoxy, lower alkylenedioxy, aryl, aryloxy, lower alkyl sulfanyl, arylsulfanyl, halo, NH2, lower alkylamino, lower di-alkylamino or CF3;

Ar2 = aryl or heteroaryl group substituted by 2 or 3 groups D;

Ar3 = aryl or heteroaryl monosubstituted by aryl, aryloxy, arylsulfanyl, lower alkyl-sulfanyl, CF3 or lower alkylenedioxy; and

Ar4 = aryl or heteroaryl monosubstituted by Ar1 with the proviso that Ar1 is not H.

INDEPENDENT CLAIMS are also included for:
(1) pharmaceutical compositions for the **treatment** of **infections** containing (I) and **carrier** material and **adjuvants**; and
(2) manufacturing the pharmaceutical composition by mixing with excipients.
ACTIVITY - Antibacterial.
USE - (I) are used to **treat infections** caused by gram positive and gram negative bacteria including Staphylococcus aureus, **Staphylococcus epidermidis**, Enterococcus faecalis or Streptococcus pneumoniae.
Dwg.0/0

L19 ANSWER 18 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2003-256434 [25] WPIDS
DOC. NO. CPI: C2003-066479
TITLE: New antigenic polypeptides from Staphylococcus aureus or **S. epidermidis**, useful as a **vaccine** for **immunizing** humans against e.g. bacteremia, septic shock, septicemia, tuberculosis, meningitis, pneumonia, gonorrhea or impetigo.
DERWENT CLASS: B04 D16
INVENTOR(S): BRUMMEL, K; CLARKE, S; FOSTER, S; MCDOWELL, P; MOND, J
PATENT ASSIGNEE(S): (BIOS-N) BIOSYNEXUS INC; (UYSH-N) UNIV SHEFFIELD
COUNTRY COUNT: 101
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2003011899	A2	20030213	(200325)*	EN	189
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW					
EP 1412379	A2	20040428	(200429)	EN	
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR					
AU 2002355677	A1	20030217	(200452)		
JP 2004536885	W	20041209	(200481)		374

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003011899	A2	WO 2002-GB3606	20020802
EP 1412379	A2	EP 2002-751380	20020802
		WO 2002-GB3606	20020802
AU 2002355677	A1	AU 2002-355677	20020802
JP 2004536885	W	WO 2002-GB3606	20020802
		JP 2003-517090	20020802

FILING DETAILS:

PATENT NO	KIND	PATENT NO

EP 1412379 A2 Based on WO 2003011899
AU 2002355677 A1 Based on WO 2003011899
JP 2004536885 W Based on WO 2003011899

PRIORITY APPLN. INFO: GB 2002-349 20020109; GB 2001-18825 20010802
AN 2003-256434 [25] WPIDS
AB WO2003011899 A UPAB: 20030416
NOVELTY - An antigenic polypeptide or its part, which is for use as a **vaccine**, is new. The antigenic polypeptide is encoded by an isolated DNA molecule that comprises any of the Staphylococcus aureus or **S. epidermidis** partial gene sequences fully defined in the specification; and which encodes a polypeptide expressed by a pathogenic organism.

DETAILED DESCRIPTION - An antigenic polypeptide or its part, which is for use as a **vaccine**, is new. The antigenic polypeptide is encoded by an isolated DNA molecule that:

(a) comprises any of the Staphylococcus aureus or **S. epidermidis** partial gene sequences fully defined in the specification (designated dnaSA and dnaSE, respectively);

(b) hybridizes with (a), and which encodes a polypeptide expressed by a pathogenic organism; or

(c) are degenerate to (a) or (b) as a result of the genetic code.

INDEPENDENT CLAIMS are also included for the following:

(1) a **vaccine** composition comprising at least one antigenic polypeptide;

(2) a method of **immunizing** an animal against a disease or condition caused by a pathogenic microbe by administering the antigenic polypeptide or the **vaccine**;

(3) an antibody or its binding part obtainable by the method above;

(4) preparing a hybridoma cell line producing monoclonal antibodies;

(5) a hybridoma cell line produced by the method of (4); and

(6) identifying opsonic antigens expressed by a pathogenic microbe.

ACTIVITY - Antibacterial; Neuroprotective; Immunosuppressive; Antiinflammatory; Antiulcer; **Immunostimulant**; Ophthalmological.Test details are described but no results are given.

MECHANISM OF ACTION - **Vaccine**.

USE - The antigenic polypeptide or **vaccine** is useful for **immunizing** an animal (specifically a human) against a disease or condition caused by a pathogenic microbe, e.g. bacteremia, septic shock, organ **infection**, skin **infection**, bacterial basal colonization, bacterial eye **infections**, septicemia, tuberculosis, bacteria-associated food poisoning, blood **infections**, peritonitis, endocarditis, sepsis, meningitis, pneumonia, stomach ulcers, gonorrhea, strep throat, streptococcal-associated toxic shock, necrotizing fasciitis, impetigo, histoplasmosis, Lyme disease, gastro-enteritis, dysentery, shigellosis, S. aureus-associated septicemia, food-poisoning, skin disorders, **S. epidermidis**-associated septicemia, peritonitis or endocarditis (all claimed).
Dwg.0/0

L19 ANSWER 19 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2003-777975 [73] WPIDS
CROSS REFERENCE: 2002-415201 [44]

DOC. NO. CPI: C2003-214028
TITLE: Pharmaceutical composition, useful for **treating, preventing** or inhibiting an **infection** or disease caused by a gram-positive organism, comprises a lipoteichoic acid, or an antibody that binds to a lipoteichoic acid.
DERWENT CLASS: B04 D16 D21
INVENTOR(S): DRABICK, J J
PATENT ASSIGNEE(S): (DRAB-I) DRABICK J J
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2003157133	A1	20030821	(200373)*		11

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2003157133	A1 Provisional	US 2000-231959P	20000912
	Cont of	US 2001-948553	20010910
		US 2003-370596	20030224

PRIORITY APPLN. INFO: US 2000-231959P 20000912; US 2001-948553 20010910; US 2003-370596 20030224
AN 2003-777975 [73] WPIDS
CR 2002-415201 [44]
AB US2003157133 A UPAB: 20031112
NOVELTY - A pharmaceutical composition for **treating, preventing** or inhibiting an **infection** or disease caused by a gram-positive organism comprises a lipoteichoic acid, or an antibody that binds to a lipoteichoic acid, and a **carrier**, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a **vaccine** for providing a protection against an **infection** or a disease caused by a gram-positive organism, comprising a lipoteichoic acid or an immunogenic composition comprising a lipoteichoic acid;

(2) **treating, preventing** or inhibiting an **infection** or disease caused by a gram-positive organism in a subject by administering the pharmaceutical composition or the **vaccine** to the subject;

(3) **immunizing** a subject against an **infection** or disease caused by a gram-positive organism by administering to the subject an immunogenic amount of lipoteichoic acid; and

(4) a kit for **treating, preventing** or inhibiting an **infection** or disease caused by a gram-positive organism in a subject, comprising a composition of a **therapeutic** amount of lipoteichoic acid, or an antibody that specifically binds to lipoteichoic acid.

ACTIVITY - Antibacterial; Antiinflammatory; Immunosuppressive; Gastrointestinal-Gen; Ophthalmological; Antiarthritic. No biological data given.

MECHANISM OF ACTION - Gene **therapy**.

USE - The compositions, a **vaccine**, methods and kits are useful for **treating**, **preventing** or inhibiting an **infection** or disease caused by a gram-positive organism, e.g. septicemia, septic shock toxic shock syndrome, multiple organ failure, an **infection** due to a medical device, osteomyelitis, cellulites, pharyngitis, a wound **infection**, pneumonia, gastroenteritis, conjunctivitis, endocarditis, myositis, necrotizing fasciitis, bronchitis, septic arthritis, septic bursitis, neonatal sepsis, bacteremia, an abcess, suppurative phlebitis, sialoadenitis, dental caries, meningitis or sinusitis (claimed).
Dwg.0/1

L19 ANSWER 20 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2003-810882 [76] WPIDS
DOC. NO. CPI: C2003-225222
TITLE: Protecting immune-compromised human from Staphylococcal or Enterococcal **infection**, by administering **vaccine** having glycoconjugate of polysaccharide or glycopeptide bacterial surface antigen and immunocarrier.
DERWENT CLASS: B04 D16
INVENTOR(S): FATTOM, A I; NASO, R B
PATENT ASSIGNEE(S): (NABI-N) NABI; (NABI-N) NABI BIOPHARMACEUTICALS; (FATT-I) FATTOM A I; (NASO-I) NASO R B
COUNTRY COUNT: 102
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2003113350	A1	20030619	(200376)*		11
WO 2003061558	A2	20030731	(200376)	EN	
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW					
AU 2002365253	A1	20030902	(200422)		
EP 1427442	A2	20040616	(200439)	EN	
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR					
BR 2002012554	A	20041019	(200476)		
KR 2004070331	A	20040807	(200480)		
JP 2005515237	W	20050526	(200535)		24
ZA 2004002185	A	20050629	(200552)		41

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2003113350	A1	US 2001-955585	20010919
WO 2003061558	A2	WO 2002-US29601	20020919
AU 2002365253	A1	AU 2002-365253	20020919
EP 1427442	A2	EP 2002-806591	20020919
		WO 2002-US29601	20020919
BR 2002012554	A	BR 2002-12554	20020919
		WO 2002-US29601	20020919
KR 2004070331	A	KR 2004-703967	20040318

JP 2005515237	W	WO 2002-US29601	20020919
		JP 2003-561504	20020919
ZA 2004002185	A	ZA 2004-2185	20040318

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2002365253	A1 Based on	WO 2003061558
EP 1427442	A2 Based on	WO 2003061558
BR 2002012554	A Based on	WO 2003061558
JP 2005515237	W Based on	WO 2003061558

PRIORITY APPLN. INFO: US 2001-955585 20010919
AN 2003-810882 [76] WPIDS
AB US2003113350 A UPAB: 20031125
NOVELTY - Protecting (M1) immune-compromised human from Staphylococcal or Enterococcal bacterial **infection**, by administering **vaccine** comprising glycoconjugate of polysaccharide or glycopeptide bacterial surface antigen and immunocarrier, the **vaccine** comprising glycoconjugates of type 5 and Type 8 polysaccharide antigens of Staphylococcus aureus, or negatively-charged Staphylococcal polysaccharide antigens.

DETAILED DESCRIPTION - Protecting (M1) an immune-compromised human from at least one of Staphylococcal and Enterococcal bacterial **infection**, involves administering a **vaccine** comprising a glycoconjugate of a polysaccharide or glycopeptide bacterial surface antigen and an immunocarrier to an immune-compromised human, where the **vaccine** comprises glycoconjugates of both type 5 and Type 8 polysaccharide antigens of Staphylococcus aureus, a glycoconjugate of a negatively-charged Staphylococcal polysaccharide antigen that comprises beta -linked hexosamine as a major carbohydrate component and contains no O-acetyl groups, a glycoconjugate of Staphylococcal glycopeptide antigen that comprises amino acids and a N-acetylated hexosamine in an alpha configuration, that contains no O-acetyl groups, and that contains no hexose, a glycoconjugate of an acidic Staphylococcal polysaccharide antigen that is obtained from an isolate of **S. epidermidis** that agglutinates antisera to ATCC 55254, glycoconjugate of an Enterococcus faecalis antigen that comprises 2-acetamido-2-deoxy-glucose and rhamnose in a 1:2 molar ratio, or a trisaccharide repeat which comprises a 6-deoxy sugar, a glycoconjugate of E.faecium antigen that comprises 2-acetamido-2-deoxy-galactose and galactose in a 2:1 molar ratio, or a glycoconjugate of an E.faecium antigen that reacts with antibodies to ATCC 202016 or ATCC 202017.

ACTIVITY - Antibacterial. Protection of patients with end stage renal disease (ESRD) with Staphylococcus aureus Type 5/Type 8 polysaccharide **vaccine** was done as follows. Subjects (18 years or older) were recruited at 73 hemodialysis centers. The **vaccine** was composed of S.aureus Type 5 and Type 8 CPS (100 micro g/type/ml) conjugated to an equal weight of recombinant Pseudomonas aeruginosa non-toxic exotoxin A (rEPA), in 0.01 percent polysorbate 80 and sodium phosphate buffered saline, pH 7.4. This dose was selected on the basis of studies in patients with ESRD. **Vaccine** and placebo were supplied as 1 ml of clear liquid in identical vials, each bearing a unique code. Sera were obtained prior to 6, 26, 54 and 67 weeks after **vaccination**. Antibodies to the S.aureus Type 5 and Type 8 CPS were measured by enzyme linked immunosorbent assay (ELISA), Fattom et al., Infect Immun 1990;

58:67-74 and Fattom et al., Infect Immun 1993; 61:1023-32. A **vaccine** response was defined as a concentration of antibody of at least 25 micro g/ml and at least two-fold greater than the prevaccination level. A total of 1804 of 1991 **screened** subjects recruited at the 73 hemodialysis centers were randomized and received **vaccine** (n = 894) or placebo (n = 910). Among 187 **screened** subjects who were not **immunized**, the reasons were failure to meet eligibility criteria or failure to comply with the protocol (n = 81), withdrawal of consent (n = 71), change in health status (n = 22), and other reasons (n = 13). The **vaccinees** and controls contributed a median time on study of 75 weeks and 74 weeks, respectively, with 76% of the subjects in each group on study for at least 54 weeks. Six subjects were excluded from the efficacy analyses. Three controls died within the first two weeks, and two **vaccines** and one control had **infections** within two weeks before injection. No subject was excluded from safety evaluations. The two groups were similar in pretreatment demographics and clinical characteristics. At **vaccination**, 69% of subjects in both groups had graft access, and 22% were nasal **carriers** in both groups. The mean age in both groups was 58.3 years. There were no statistically significant differences in the number of deaths between the **vaccine** and control groups.

MECHANISM OF ACTION - **Vaccine** (claimed).

USE - (M1) is useful for protecting an immune-compromised human from at least one of Staphylococcal and Enterococcal bacterial **infection**. The immune-compromised human is a end stage renal disease (ESRD) patient, cancer patient on immunosuppressive **therapy**, AIDS patient, diabetic patient, neonate, the elderly in extended care facilities, patients with autoimmune disease on immunosuppressive **therapy**, transplant patient, patient with invasive surgical procedures, burn patient and other patients in acute care settings. Preferably, the immune-compromised human is neonate. The immune-compromised human suffers from end stage renal disease (claimed).

ADVANTAGE - The **vaccine** is well-tolerated in healthy adults and in patients with end-stage renal disease.

Dwg.0/0

L19 ANSWER 21 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

ACCESSION NUMBER:	2003-067575 [06] WPIDS
CROSS REFERENCE:	2003-221756 [21]; 2003-300870 [29]; 2004-122985 [12]
DOC. NO. CPI:	C2003-017657
TITLE:	Recovering immunogenic outer membrane associated polypeptides from microbial cells, useful for inducing passive or active **immunization** against bacterial, fungal or protozoan **infection**, comprises culturing cells in iron-starved conditions.
DERWENT CLASS:	B04 C07 D16
INVENTOR(S):	SCOTT, D L; SMALLS, F; THOMAS, C B; WILLIAMS, M
PATENT ASSIGNEE(S):	(DSQU-N) D-SQUARED BIOTECHNOLOGIES INC
COUNTRY COUNT:	100

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002083843	A2	20021024 (200306)*		EN	91

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE
DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG
KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM
PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ
VN YU ZA ZM ZW
AU 2002258746 A1 20021028 (200433)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002083843	A2	WO 2002-US11110	20020410
AU 2002258746	A1	AU 2002-258746	20020410

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2002258746	A1 Based on	WO 2002083843

PRIORITY APPLN. INFO: US 2001-304390P 20010710; US
2001-282809P 20010410; US
2001-298975P 20010617; US
2001-304156P 20010710

AN 2003-067575 [06] WPIDS
CR 2003-221756 [21]; 2003-300870 [29]; 2004-122985 [12]
AB WO 200283843 A UPAB: 20040525
NOVELTY - Recovering immunogenic outer membrane associated polypeptides (OMAPs) from microbial cells comprises:
(a) culturing microbial cells or bacterial cells in iron-starved conditions to up-regulate OMAPs;
(b) harvesting membranes from cells, and solubilizing (bacterial) membrane proteins;
(c) purifying OMAPs from contaminating immunosuppressive endotoxins; and
(d) purifying OMAPs from their binding ligands.
DETAILED DESCRIPTION - Recovering immunogenic outer membrane associated polypeptides (OMAPs) from microbial cells comprises:
(a) culturing microbial cells or bacterial cells in iron-starved conditions to up-regulate OMAPs;
(b) harvesting membranes from cells, and solubilizing (bacterial) membrane proteins;
(c) purifying OMAPs from contaminating immunosuppressive endotoxins; and
(d) purifying OMAPs from their binding ligands.
The purified OMAPs from the microbial cells are substantially endotoxin-free and ligand-free, and are capable of generating an OMAP specific immunoresponse when injected into a host. The OMAPs comprise the Scott-Thomas domain and the D2 domain, where the D2 domain is selected from the group of D2 domain 1, D2 domain 3, or D2 domain 4.
INDEPENDENT CLAIMS are also included for the following:
(1) Isolated nucleotide sequence that encodes an epitope of FptA that contains a siderophore binding site;
(2) Producing (M1) anti-OMAPs antibody;
(3) **Vaccine** for **immunizing** an animal against microbial **infection** comprising a non-iron-regulated OMAP recovered by M1, and a physiologic **carrier**;
(4) **Immunizing** (M2) an animal against a bacterial **infection**;

(5) **Diagnostic** kits for **detecting** OMAPs in a biological sample comprising:

(a) primer pair for amplifying a nucleic acid, where the oligonucleotide primers are at least 14 bases in length; or

(b) oligonucleotide probe that binds under high stringency conditions to the isolated nucleic acid cited above; and

(c) containers for each of the primers, or for the probe;

(6) Recovering (M3) OMAPs from fungi, gram-negative bacteria and gram-positive bacteria species;

(7) Actively **immunizing** (M4) a host animal or human using OMAPs of (6) for the recovery of surface exposed immunogenic polypeptides from gram-negative bacteria and gram-positive bacteria species;

(8) Inducing (M5) passive **immunization** of a host, where one or more surface exposed immunogenic fragments comprising any one of 15 sequences consisting of 19-350 amino acids fully defined in the specification, generate specific antibodies in an animal or human and provide prophylaxis or **treatment** of disease and **infection** caused by gram-negative and gram-positive bacteria species; and

(9) **Preventing** (M6) or **treating** wound **infections** or sepsis caused by gram-negative and gram-positive bacteria species.

ACTIVITY - Antibacterial; Fungicide; Protozoacide; **Immunostimulant**.

No biological data given.

MECHANISM OF ACTION - **Vaccine**.

USE - The methods are useful for recovering immunogenic OMAPs for inducing passive or active **immunization** against bacterial, fungal or protozoan **infections**. The antibodies are useful for **diagnosing**, **preventing** and **treating** bacterial, fungal or protozoan **infections** (claimed).

Dwg.0/12

L19 ANSWER 22 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

ACCESSION NUMBER: 2003-018771 [01] WPIDS

DOC. NO. CPI: C2003-004551

TITLE: New composition comprising a collagen-binding GehD lipase, useful for **treating** or **preventing** a staphylococcal **infection**, or for reducing staphylococci **infection** on indwelling medical devices or implants.

DERWENT CLASS: B04 D16

INVENTOR(S): BOWDEN, M; HOOK, M

PATENT ASSIGNEE(S): (BOWD-I) BOWDEN M; (HOOK-I) HOOK M; (TEXA) UNIV TEXAS A & M SYSTEM

COUNTRY COUNT: 100

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002074324	A1	20020926	(200301)*	EN	56

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

US 2002169288 A1 20021114 (200301)
AU 2002255745 A1 20021003 (200432)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002074324	A1	WO 2002-US7807	20020315
US 2002169288	A1 Provisional	US 2001-275718P	20010315
		US 2002-98174	20020315
AU 2002255745	A1	AU 2002-255745	20020315

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2002255745	A1 Based on	WO 2002074324

PRIORITY APPLN. INFO: US 2001-275718P 20010315; US 2002-98174 20020315

AN 2003-018771 [01] WPIDS

AB WO 200274324 A UPAB: 20030101

NOVELTY - A **therapeutic** composition (I) for **treating** or **preventing** a staphylococcal **infection** comprising a collagen-binding GehD lipase, and a vehicle, excipient or **carrier**, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) an antibody (II) that can recognize collagen-binding GehD lipase from **Staphylococcus epidermidis**;

(2) a **vaccine** (III) comprising an immunogenic amount of collagen-binding GehD lipase and a pharmaceutical vehicle, excipient or **carrier**;

(3) antibody or antisera (IV) raised against GehD lipase and a vehicle, excipient or **carrier**;

(4) a composition comprising (II);

(5) a **diagnostic** kit for **determining** the presence of GehD proteins in a sample suspected of containing such proteins, comprising (II) a means for introducing the antibody to the sample, and a means for **determining** the presence of binding of the antibodies and GehD proteins in a sample;

(6) a **diagnostic** kit for **determining** the presence of GehD antibodies in a sample suspected of containing such antibodies, comprising isolated GehD proteins, a means for introducing the proteins to the sample, and a means for **determining** the presence of binding of the GehD proteins and antibodies to GehD in a sample; and

(7) **preventing** (M2) the binding of a staphylococcal bacteria to collagen in a human or animal patient by administering (II) to the patient.

ACTIVITY - Antibacterial.

No supporting data given.

MECHANISM OF ACTION - **Vaccine**.

No supporting data given.

USE - The composition comprising collagen-binding GehD lipase is useful for **treating** or **preventing** staphylococcal **infections** in a human or animal patient, for reducing staphylococci **infection** on indwelling medical devices or implants, as a **vaccine** against staphylococcal bacteria such

as **S. epidermidis**, and for generating antibodies which can be used in blocking staphylococcal adhesion to collagen. The antibody can also be used to **treat** or **prevent** a staphylococcal **infection** in a human (all claimed). The compositions may also be used to protect against complications caused by localized **infections** (e.g. sinusitis, mastoiditis, parapharygeal abscesses, cellulites, necrotizing fascitis, myositis, streptococcal toxic shock syndrome, pneumonitis endocarditis, meningitis or osteomylitis), non-suppurative conditions (e.g. acute rheumatic fever, acute glomerulonephritis, obsessive/compulsive neurological disorders or exacerbations of forms of psoriasis such as psoriasis vulgaris). The antibodies may be used for specific **detection** of collagen-binding proteins, for the **prevention** of **infection** from staphylococci, for the **treatment** of **infection**, as research tools, or for developing anti-staphylococcal **vaccines** for active and passive **immunization**. The methods are useful for **diagnosing** staphylococcal **infections**.
Dwg.0/8

L19 ANSWER 23 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2002-643387 [69] WPIDS
DOC. NO. CPI: C2004-014233
TITLE: Modifying a bacterium to enhance immunogenicity, as **vaccines** for **preventing** bacterial **infections**, e.g. tuberculosis comprises reducing the activity of an anti-apoptotic enzyme, e.g. superoxide dismutase produced by the bacterium.
DERWENT CLASS: B04 D16
INVENTOR(S): BOCHAN, M R; KERNODLE, D S
PATENT ASSIGNEE(S): (UYVA-N) UNIV VANDERBILT; (USGO) US DEPT VETERANS AFFAIRS; (BOCH-I) BOCHAN M R; (KERN-I) KERNODLE D S
COUNTRY COUNT: 100
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002062298	A2	20020815	(200269)*	EN	164
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW					
EP 1361794	A2	20031119	(200377)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR					
AU 2002240269	A1	20020819	(200427)		
US 2004109875	A1	20040610	(200438)		
ZA 2003006058	A	20040825	(200466)		162
JP 2005504502	W	20050217	(200513)		263

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002062298	A2	WO 2002-US3451	20020207
EP 1361794	A2	EP 2002-706163	20020207

		WO 2002-US3451	20020207
AU 2002240269	A1	AU 2002-240269	20020207
US 2004109875	A1	WO 2002-US3451	20020207
		US 2004-467644	20040120
ZA 2003006058	A	ZA 2003-6058	20030806
JP 2005504502	W	JP 2002-562306	20020207
		WO 2002-US3451	20020207

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1361794	A2 Based on	WO 2002062298
AU 2002240269	A1 Based on	WO 2002062298
JP 2005504502	W Based on	WO 2002062298

PRIORITY APPLN. INFO: US 2001-322989P 20010918; US 2001-267328P 20010207; US 2004-467644 20040120

AN 2002-643387 [69] WPIDS

AB WO 200262298 A UPAB: 20040505

NOVELTY - Modifying (M1) a bacterium to enhance immunogenicity of the bacterium comprising reducing the activity of an anti-apoptotic enzyme produced by the bacterium, where the bacterium has enhanced immunogenicity in a subject, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) a modified bacterium (I) made by (M1);

(2) an immunogenic composition comprising (I);

(3) an attenuated intracellular bacterium, further modified to reduce the activity of an anti-apoptotic enzyme of the bacterium;

(4) modifying a bacterium (M2) so it retains or increases immunogenicity but loses or reduces pathogenicity in a subject, comprising reducing but not eliminating an activity of an enzyme produced by the bacterium, where reducing the activity of the enzyme attenuates the bacterium;

(5) bacteria modified by (M2);

(6) a composition (II) comprising any of the bacterium, and a **carrier**;

(7) producing (M3) an immune response by an immune cell of the subject, comprising contacting the cell wall with (II) or administering (II) to the subject; and

(8) **preventing** (M4) an infectious disease in a subject, comprising administering to the subject (II).

ACTIVITY - Antibacterial; Tuberculostatic.

No biological data given.

MECHANISM OF ACTION - **Vaccine**; Superoxide dismutase inhibitor.

USE - (M1) is useful for **preventing** bacterial **infections**, e.g. tuberculosis (claimed). The attenuated intracellular bacterium is useful as a **vaccine** for **preventing** bacterial **infections**.

Dwg.0/25

L19 ANSWER 24 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

ACCESSION NUMBER: 2003-075410 [07] WPIDS

DOC. NO. CPI: C2003-019499

TITLE: Identifying, isolating and producing hyperimmune serum-reactive antigens from a pathogen, for preparing **vaccine** or medicament for

treating or **preventing** e.g. staphylococcal **infections**, comprises providing antibody preparation.

DERWENT CLASS: B04 C06 D16

INVENTOR(S): DRYLA, A; ETZ, H; HAFNER, M; HENICS, T; KLADE, C; MEINKE, A; MINH, D B; NAGY, E; TEMPELMAIER, B; VON AHSEN, U; VYTVYTSKA, O; WEICHHART, T; ZAUNER, W; FRASER, C M; GILL, S; GILL, S F

PATENT ASSIGNEE(S): (CIST-N) CISTEM BIOTECHNOLOGIES GMBH; (INTE-N) INTERCELL AG; (DRYL-I) DRYLA A; (ETZH-I) ETZ H; (FRAS-I) FRASER C M; (GILL-I) GILL S; (HAFN-I) HAFNER M; (HENI-I) HENICS T; (KLAD-I) KLADE C; (MEIN-I) MEINKE A; (MINH-I) MINH D B; (NAGY-I) NAGY E; (TEMP-I) TEMPELMAIER B; (VAHS-I) VON AHSEN U; (VYTV-I) VYTVYTSKA O; (WEIC-I) WEICHHART T; (ZAUN-I) ZAUNER W

COUNTRY COUNT: 101

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002059148	A2	20020801	(200307)*	EN	252
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW					
AT 2001000130	A	20021215	(200308)		
AT 410798	B	20030615	(200348)		
NO 2003003364	A	20030924	(200373)		
EP 1355930	A2	20031029	(200379)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR					
KR 2003082574	A	20031022	(200415)		
AU 2002247641	A1	20020806	(200427)		
CZ 2003002201	A3	20040317	(200430)		
BR 2002007067	A	20040615	(200440)		
SK 2003001049	A3	20040707	(200447)		
JP 2004531476	W	20041014	(200467)		614
ZA 2003005764	A	20040929	(200468)		283
US 2005037444	A1	20050217	(200514)		
HU 2004002048	A2	20050128	(200519)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002059148	A2	WO 2002-EP546	20020121
AT 2001000130	A	AT 2001-130	20010126
AT 410798	B	AT 2001-130	20010126
NO 2003003364	A	WO 2002-EP546	20020121
		NO 2003-3364	20030725
EP 1355930	A2	EP 2002-716669	20020121
		WO 2002-EP546	20020121
KR 2003082574	A	KR 2003-709882	20030725
AU 2002247641	A1	AU 2002-247641	20020121
CZ 2003002201	A3	WO 2002-EP546	20020121

Searcher : Shears 571-272-2528

		CZ 2003-2201	20020121
BR 2002007067	A	BR 2002-7067	20020121
		WO 2002-EP546	20020121
SK 2003001049	A3	WO 2002-EP546	20020121
		SK 2003-1049	20020121
JP 2004531476	W	JP 2002-559450	20020121
		WO 2002-EP546	20020121
ZA 2003005764	A	ZA 2003-5764	20030725
US 2005037444	A1	WO 2002-EP546	20020121
		US 2004-470048	20040206
HU 2004002048	A2	WO 2002-EP546	20020121
		HU 2004-2048	20020121

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AT 410798	B Previous Publ.	AT 2001000130
EP 1355930	A2 Based on	WO 2002059148
AU 2002247641	A1 Based on	WO 2002059148
CZ 2003002201	A3 Based on	WO 2002059148
BR 2002007067	A Based on	WO 2002059148
SK 2003001049	A3 Based on	WO 2002059148
JP 2004531476	W Based on	WO 2002059148
HU 2004002048	A2 Based on	WO 2002059148

PRIORITY APPLN. INFO: AT 2001-130 20010126
AN 2003-075410 [07] WPIDS
AB WO 200259148 A UPAB: 20030129
NOVELTY - Identifying, isolating and producing (M1) hyperimmune serum-reactive antigens from a pathogen, tumor,

allergen, a tissue or host prone to auto-immunity, where the antigens are used in a **vaccine**, comprises providing antibody preparation from a plasma pool of a type of animal, or individual sera with antibodies against the specific pathogen, tumor, allergen, tissue or host prone to auto-immunity.

DETAILED DESCRIPTION - Identifying, isolating and producing hyperimmune serum-reactive antigens from a pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity, where the antigens are used in a **vaccine** for humans or a given type of animal, comprises providing an antibody preparation from a plasma pool of the given type of animal, from a human plasma pool or individual sera with antibodies against the specific pathogen, tumor, allergen or tissue or host prone to auto-immunity.

The method comprises:

(a) providing an antibody preparation from a plasma pool of the given type of animal, from a human plasma pool or individual sera with antibodies against the specific pathogen, tumor, allergen or tissue or host prone to auto-immunity;

(b) providing at least one expression library of the specific pathogen, tumor, allergen or tissue or host prone to auto-immunity;

(c) **screening** at least one expression library with the antibody preparation;

(d) identifying antigens that bind in (c) to antibodies in the antibody preparation;

(e) **screening** the identified antigens with individual antibody preparations from the individual sera cited above;

(f) identifying the hyperimmune serum-reactive antigen portion of the identified antigens, where the hyperimmune serum-reactive antigens

bind to a relevant portion of the individual antibody preparations from the individual sera; and

(g) optionally, isolating and producing the hyperimmune serum-reactive antigens by chemical or recombinant methods.

INDEPENDENT CLAIMS are also included for the following:

(1) a hyperimmune serum-reactive antigen obtained by (M1) comprising any of the amino acid sequences within Staphylococcus aureus antigens containing highly promiscuous T helper epitopes, or S. aureus or **Staphylococcus epidermidis** immunogenic proteins identified by bacterial surface and ribosome display, preferably selected from the group of 53 sequences of 53-2261 amino acids fully defined in the specification, or their hyperimmune fragments;

(2) a hyperimmune fragment of a hyperimmune serum-reactive antigen selected from the group of peptides given fully defined in the specification;

(3) helper epitopes of the antigen or its fragment cited above, comprising fragments selected from peptides comprising aa 6-40, 583-598, 620-646 or 871-896 of a sequence of 895 aa fully defined in the specification, aa 24-53 of a sequence of 1117 aa fully defined in the specification, aa 240-260 of a sequence of 267 aa fully defined in the specification, aa 1660-1682 or 1746-1790 of a sequence of 1992 aa fully defined in the specification, aa 1-29, 680-709, or 878-902 of a sequence of 1245 aa fully defined in the specification, aa 96-136 of a sequence of 265 aa fully defined in the specification, aa 1-29, 226-269, or 275-326 of a sequence of 322 aa fully defined in the specification, aa 23-47 or 107-156 of a sequence of 160 aa fully defined in the specification, or aa 24-53 of a sequence of 645 aa fully defined in the specification, or their fragments being T-cell epitopes;

(4) a **vaccine** comprising the hyperimmune serum-reactive antigen or its fragment;

(5) a preparation (C1) comprising antibodies against at least one antigen or its fragment;

(6) a method for producing (C1) comprising:

(a) initiating an immune response in a non-human animal by administering the antigen or its fragment;

(b) removing the spleen or spleen cells from the animal;

(c) producing hybridoma cells of the spleen or spleen cells;

(d) selecting and cloning hybridoma cells specific for the antigen; and

(e) producing the antibody preparation by cultivation of the clone hybridoma cells and optionally further purification steps; or

(f) initiating an immune response in a non-human animal by administering the antigen or its fragment;

(g) removing an antibody-containing body fluid from the animal; and

(h) producing the antibody preparation by subjecting the antibody-containing body fluid to further purification steps; and

(7) a **screening** method assessing the consequences of functional inhibition of at least one antigen or its fragment.

ACTIVITY - Antibacterial; Virucide; Fungicide; Protozoacide; Cytostatic; Anti-HIV.

No biological data given.

MECHANISM OF ACTION - Vaccine.

No biological data provided.

USE - The hyperimmune serum-reactive antigens comprising any of the sequences cited above, or any of 62 sequences of 53-2261 amino acids fully defined in the specification, or their hyperimmune

fragments are useful for the manufacture of a pharmaceutical preparation, particularly a vaccine against staphylococcal infections or colonization against S. aureus or S. epidermidis. The preparation of antibodies is useful for the manufacture of a medicament for treating or preventing staphylococcal infections or colonization against S. aureus or S. epidermidis (all claimed). The antibody preparations may also be used for diagnostic and imaging purposes. Other conditions that can be treated include cancer, autoimmune diseases or infections caused by viral (e.g. HIV, hepatitis A, B or C), fungal or protozoan pathogens.

ADVANTAGE - The present method allows an efficient and fast biological screening of a given pathogen. Identification of the relevant antigens can help to generate passive immunization (humanized monoclonal antibody therapy), which can replace human immunoglobulin administration.

Dwg.0/10

L19 ANSWER 25 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2002-415201 [44] WPIDS
CROSS REFERENCE: 2003-777975 [73]
DOC. NO. CPI: C2002-117183
TITLE: Pharmaceutical composition useful in the **treatment** of **infections** caused by gram-positive organism comprises lipoteichoic acid and a **carrier.**
DERWENT CLASS: B04 B05 D16
INVENTOR(S): DRABICK, J J
PATENT ASSIGNEE(S): (USSA) US ARMY MEDICAL RES & MATERIAL COMMAND; (DRAB-I) DRABICK J J
COUNTRY COUNT: 97
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2002051793	A1	20020502	(200244)*		11
WO 2002045742	A2	20020613	(200245)	EN	
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2001088961	A	20020618	(200262)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2002051793	A1 Provisional	US 2000-231959P	20000912
		US 2001-948553	20010910
WO 2002045742	A2	WO 2001-US28217	20010910
AU 2001088961	A	AU 2001-88961	20010910

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2001088961	A Based on	WO 2002045742

Searcher : Shears 571-272-2528

PRIORITY APPLN. INFO: US 2000-231959P 20000912; US 2001-948553 20010910
AN 2002-415201 [44] WPIDS
CR 2003-777975 [73]
AB US2002051793 A UPAB: 20031112
NOVELTY - A pharmaceutical composition (a) comprises lipoteichoic acid and a **carrier**.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a pharmaceutical composition comprising an antibody which specifically binds to a lipoteichoic acid;

(2) a **vaccine** comprising a lipoteichoic acid or an immunogenic composition comprising lipoteichoic acid;

(3) a kit comprising (a); and

(4) a kit comprising an antibody which specifically binds to a lipoteichoic acid.

ACTIVITY - Antibacterial; Immunosuppressive; Osteopathic; Antiinflammatory; Ophthalmological; Vulnerary; Antiarthritic; Neuroprotective.

MECHANISM OF ACTION - Gram positive **infection** inhibitor.

USE - For **treating, immunizing, preventing** or inhibiting an **infection** or disease such as septicemia, septic shock, toxic shock syndrome, multiple organ failure, an **infection** due to a medical device, osteomyelitis, cellulitis, pharyngitis, a wound **infection**, pneumonia, gastroenteritis, conjunctivitis, endocarditis, myositis, necrotizing fasciitis, bronchitis, septic arthritis, septic bursitis, neonatal sepsis, bacteremia, an abscess, suppurative phlebitis, sialoadenitis, dental caries, meningitis and sinusitis; diseases caused by a gram positive organism such as Streptococcus, Micrococcus, Lactobacillus, Staphylococcus, Bacillus or Listeria, (preferably Streptococcus group A, B, C or G, especially group A Streptococcus, e.g. S. aureus, **S. epidermidis**, S. pyogenes, N. cereus and L. monocytogenes) in a subject (preferably human) (all claimed).

ADVANTAGE - The lipoteichoic acid induces protective anti-adherence and/or opsonophagocytic antibodies against a gram-positive organism in a subject. The composition inhibits gram positive **infections** without complications due to cross-reactive antibodies.

Dwg.0/0

L19 ANSWER 26 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2002-106544 [14] WPIDS
DOC. NO. NON-CPI: N2002-079213
DOC. NO. CPI: C2002-032821
TITLE: Identifying antigenic polypeptides expressed by pathogenic organisms e.g., Staphylococcus aureus during **infection**, by SEREX (serological identification of antigens by recombinant expression cloning) techniques.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): BRUMMELL, K; CLARKE, S; FOSTER, S; MCDOWELL, P
PATENT ASSIGNEE(S): (BIOS-N) BIOSYNEXUS INC; (UYSH-N) UNIV SHEFFIELD; (BRUM-I) BRUMMELL K; (CLAR-I) CLARKE S; (FOST-I) FOSTER S; (MCDO-I) MCDOWELL P
COUNTRY COUNT: 97

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001098499	A1	20011227	(200214)*	EN	85
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2001074248	A	20020102	(200230)		
NO 2002005838	A	20030218	(200321)		
EP 1292681	A1	20030319	(200322)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR					
BR 2001011823	A	20030610	(200341)		
US 2003186275	A1	20031002	(200365)		
CN 1437653	A	20030820	(200374)		
JP 2004500883	W	20040115	(200410)		103

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001098499	A1	WO 2001-GB2685	20010620
AU 2001074248	A	AU 2001-74248	20010620
NO 2002005838	A	WO 2001-GB2685	20010620
		NO 2002-5838	20021205
EP 1292681	A1	EP 2001-940746	20010620
		WO 2001-GB2685	20010620
BR 2001011823	A	BR 2001-11823	20010620
		WO 2001-GB2685	20010620
US 2003186275	A1	WO 2001-GB2685	20010620
		US 2003-311879	20030318
CN 1437653	A	CN 2001-811545	20010620
JP 2004500883	W	WO 2001-GB2685	20010620
		JP 2002-504647	20010620

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 2001074248	A	Based on	WO 2001098499
EP 1292681	A1	Based on	WO 2001098499
BR 2001011823	A	Based on	WO 2001098499
JP 2004500883	W	Based on	WO 2001098499

PRIORITY APPLN. INFO: GB 2000-14907 20000620

AN 2002-106544 [14] WPIDS

AB WO 200198499 A UPAB: 20020301

NOVELTY - A method for identifying antigenic polypeptides expressed by pathogenic organisms e.g., Staphylococcus aureus during **infection**, by SEREX (serological identification of antigens by recombinant expression cloning) techniques, is new.

DETAILED DESCRIPTION - Identifying (M1) antigenic polypeptides by providing a nucleic acid (NA) library encoding genes/partial gene sequences (GP) of pathogenic organisms (P), transforming/transfecting

the library into host cells, contacting the polypeptides expressed by the GP with autologous antisera (AA) derived from an animal infected with, or has been infected with (P) and purifying NA encoding the polypeptide or partial polypeptide binding to AA.

INDEPENDENT CLAIMS are also included for the following:

(1) an isolated NA molecule (I) comprising:

(i) a DNA sequence which has a fully defined sequence of 2260, 2902, 2792, 2478, 2070, 2394, 2033, 2794, 505, 673, 2238, 7975 or 2001 (S1)-(S13) nucleotides as given in the specification;

(ii) DNA sequences which hybridize to (S1)-(S13) and which encode a polypeptide expressed by (P); or

(iii) DNA sequences which are degenerate as a result of the genetic code to the above mentioned DNA sequences;

(2) a vector (II) comprising (I);

(3) a cell (III) transformed or transfected with (II);

(4) a polypeptide (IV) identified by (M1);

(5) producing (M2) (IV) involves providing (III) and with cell culture conditions; and purifying the polypeptide from the cell, or its growth environment;

(6) a **vaccine** (V) comprising (IV);

(7) an antibody (VI) or its part which binds at least with a selective part of (IV);

(8) a vector (VII) which is adapted for the expression of (VI);

(9) a cell (VIII) which has been transformed or transfected with (VII);

(10) producing (VI) involves providing (VIII) under appropriate culture conditions, and purifying the antibody from the cell, or its growth environment;

(11) a hybridoma cell line which produces (VI); and

(12) preparing (M3) a hybridoma cell-line producing (VI) involves:

(i) **immunizing** an immunocompetent mammal with an immunogen comprising (IV) having a fully defined sequence of 106, 960, 386, 325, 157 or 345 amino acids (S14)-(S19) as given in the specification, or its fragments;

(ii) fusing lymphocytes of the **immunized** immunocompetent mammal with myeloma cells to form hybridoma cells;

(iii) **screening** monoclonal antibodies produced by the hybridoma cells for binding activity to the amino acid sequence of (IV);

(iv) culturing the hybridoma cells to proliferate and/or secrete the monoclonal antibody; and

(v) recovering the monoclonal antibody from the culture supernatant.

ACTIVITY - Antibacterial; antiinflammatory; dermatological; antiulcer; tuberculostatic; immunosuppressive.

MECHANISM OF ACTION - **Vaccine**.

No supporting data is given.

USE - (IV) or (V) is useful for **immunizing** an animal (preferably human) against a pathogenic microbe. (VI) is useful for manufacturing a medicament for **treating** Staphylococcus aureus-associated septicemia, food poisoning or skin disorders; or **Staphylococcus epidermidis**-associated septicemia, peritonitis, endocarditis (claimed).

The antibodies are also useful for **treating** e.g. tuberculosis, blood **infections**, sepsis, meningitis, pneumonia, stomach ulcers, gonorrhea, necrotizing facitis, impetigo, Lyme disease, gastro-enteritis, dysentery and shigellosis.

Dwg.0/0

L19 ANSWER 27 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2001-607512 [69] WPIDS
DOC. NO. NON-CPI: N2001-453496
DOC. NO. CPI: C2001-180527
TITLE: Novel isolated antibody which recognizes collagen-binding peptide such as CNA19 peptide from Staphylococcus aureus, useful for **preventing** or **treating** Staphylococcus aureus or epidermidis **infection**.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): CASOLINI, F; DOMANSKI, P; HOOK, M; PATEL, P; PATTI, J; SPEZIALE, P; VISAI, L; XU, Y
PATENT ASSIGNEE(S): (INHI-N) INHIBITEX INC; (UYPA-N) UNIV PAVIA; (TEXA) UNIV TEXAS A & M SYSTEM
COUNTRY COUNT: 95
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001070267	A1	20010927	(200169)*	EN	107
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW					
AU 2001056958	A	20011003	(200210)		
EP 1267930	A1	20030102	(200310)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR					
JP 2003527440	W	20030916	(200362)		90

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001070267	A1	WO 2001-US8554	20010319
AU 2001056958	A	AU 2001-56958	20010319
EP 1267930	A1	EP 2001-930420	20010319
		WO 2001-US8554	20010319
JP 2003527440	W	JP 2001-568463	20010319
		WO 2001-US8554	20010319

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 2001056958	A	Based on	WO 2001070267
EP 1267930	A1	Based on	WO 2001070267
JP 2003527440	W	Based on	WO 2001070267

PRIORITY APPLN. INFO: US 2000-225402P 20000815; US 2000-189968P 20000317; US 2000-199370P 20000425
AN 2001-607512 [69] WPIDS
AB WO 200170267 A UPAB: 20011126
NOVELTY - An isolated antibody (I) which recognizes a collagen-binding peptide such as CNA19 peptide from Staphylococcus aureus, is new.

Searcher : Shears 571-272-2528

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) isolated antisera (II) containing (I);

(2) a **diagnostic** kit (III) comprising (I) and unit for **detecting** binding by (I);

(3) a pharmaceutical composition (IV) for **treating** or **preventing** an **infection** of S.aureus or **S. epidermidis** comprises an effective amount of (I);

(4) inducing (M1) an immunological response involves administering to a patient an isolated S.aureus CNA19 peptide;

(5) identifying (M2) antibodies capable of displacing bacteria bound to surface proteins on the extracellular matrix or antibodies capable of displacing bacteria that can attach themselves to specific proteins, involves labeling the surface proteins of the extracellular matrix or proteins that are known to be bound by bacteria, combining the labeled proteins with bacteria known to be capable of binding the proteins for a time sufficient to ensure that the bacteria will bind to the labeled proteins, harvesting the bacteria bound to labeled proteins, introducing antibodies suspected of having displacement activity to the bacteria bound to labeled proteins, and identifying antibodies which cause the displacement of the bacteria from the proteins;

(6) an isolated displacing antibody (V) produced by M2;

(7) an isolated cross-reactive antibody (VI) that is generated against region 151-318 of the collagen binding domain of the S.aureus CNA protein;

(8) a **diagnostic** kit (VII) for immunodetection comprising, in a suitable container, (I) and an immunodetection reagent;

(9) an isolated monoclonal antibody (VIII) raised against CNA protein from S.aureus; and

(10) isolated antisera (IX) containing (VIII);

ACTIVITY - Antibacterial. Female Balb/C mice were **treated** with a single 0.5 ml intraperitoneal (IP) injection of monoclonal antibody 9G3, 3B12, or were untreated. On day 0, approx. 7 multiply 107 colony forming units (CFU) Staphylococcus aureus were administered to all animals through the tail vein. Twenty-four hours after IgG administration, the mice were challenged with a single intravenous (IV) injection of S.aureus. The mice were followed for 10 days at which point all remaining mice were sacrificed. Significant differences in the survival times between **treatment** groups were **detected**. The results showed that 67% of the mice that received 9G3 survived the bacterial challenge, and in contrast only 20% of the untreated mice survived the entire study period. 70% of the mice that received 3B12 survived the bacterial challenge. In contrast, only 27% of the control mice survived the ten day study.

MECHANISM OF ACTION - Inhibitor of binding of S.aureus or **S.epidermidis** to a collagen binding site (claimed); **Vaccine**.

USE - (I) is useful for **preventing** or **treating** S.aureus or **S.epidermidis infection** in human or animal, and for displacing S.aureus or **S. epidermidis** bound to collagen (claimed). (I) is useful for **treating** medical instruments in order to reduce or eliminate the possibility of their becoming infected or further spreading the **infection**. (I) is useful for developing antibody compositions that are effective in **preventing** or **treating** **infections** from more than one species of Staphylococcal bacteria. (I) is useful for interfering with, modulating, and

inhibiting binding interactions between Staphylococcal bacteria, collagen, for **detecting** the presence of Staphylococcal bacteria or Staphylococcal collagen or binding proteins, to **diagnose** Staphylococcal **infection**, as research tools, for development of **vaccine** for passive **immunization** against Staphylococcal **infections**, and in production facilities or laboratories to isolate additional quantities of collagen-binding proteins.
Dwg.0/16

L19 ANSWER 28 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2001-522586 [57] WPIDS
DOC. NO. CPI: C2001-156044
TITLE: New protein isolated from **Staphylococcus epidermidis**, useful for production of **vaccine** against Staphylococcal **infections**.
DERWENT CLASS: B04 D16
INVENTOR(S): DAI-QING, L; LJUNGH, A; LUNDBERG, F
PATENT ASSIGNEE(S): (BIOS-N) BIOSTAPRO AB; (DAIQ-I) DAI-QING L; (LJUN-I) LJUNGH A; (LUND-I) LUNDBERG F
COUNTRY COUNT: 95
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001060852	A1	20010823	(200157)*	EN	24
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2001034299	A	20010827	(200176)		
EP 1261631	A1	20021204	(200280)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR					
US 2003082200	A1	20030501	(200331)		
JP 2003523191	W	20030805	(200353)		31

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001060852	A1	WO 2001-SE340	20010216
AU 2001034299	A	AU 2001-34299	20010216
EP 1261631	A1	EP 2001-906475	20010216
		WO 2001-SE340	20010216
US 2003082200	A1	WO 2001-SE340	20010216
		US 2002-203613	20020816
JP 2003523191	W	JP 2001-560235	20010216
		WO 2001-SE340	20010216

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 2001034299	A	Based on	WO 2001060852
EP 1261631	A1	Based on	WO 2001060852

Searcher : Shears 571-272-2528

JP 2003523191 W Based on WO 2001060852

PRIORITY APPLN. INFO: SE 2000-514 20000217
AN 2001-522586 [57] WPIDS
AB WO 200160852 A UPAB: 20011005
NOVELTY - A protein (I) isolated from **Staphylococcus epidermidis** having an approximate molecular weight of 52 kilo Dalton (kD) as **determined** by sodium dodecyl sulfate-gel electrophoresis (SDS-PAGE) and an N-terminal amino acid sequence and antigenic **determinant**-containing fragments of (I), is new.

DETAILED DESCRIPTION - In (I), the N-terminal amino acid sequence is TADPPADKTS.

INDEPENDENT CLAIMS are also included for the following:

(1) a recombinant DNA molecule (II) coding for (I) or its fragment;

(2) a vector (III) selected from plasmids, phages or phagemids comprising (II) or its corresponding RNA molecule;

(3) an antibody or antigen binding peptide (IV) that recognizes and specifically binds to (I) or its fragment;

(4) a **vaccine** (V) against Staphylococcal **infections** comprising (III), or (I) or its fragment as **immunizing** component; and

(5) a medicament (VI) for the passive **immunization** of a mammal against Staphylococcal **infections** comprising (IV).

ACTIVITY - Antibacterial.

MECHANISM OF ACTION - **Vaccine** (claimed). No supporting data is given.

USE - (I) or (III) is useful for the production of **vaccine** against Staphylococcal **infections**. (IV) is useful for the production of a medicament for the passive **immunization** of a mammal against Staphylococcal **infections**. (V) is useful for prophylactic and/or **therapeutic treatment** of Staphylococcal **infections** in a mammal (claimed). (IV) is useful in **diagnostic** purposes.

Dwg.0/2

L19 ANSWER 29 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2000-647115 [62] WPIDS
DOC. NO. NON-CPI: N2000-479608
DOC. NO. CPI: C2000-195697
TITLE: Staphylococcus antigen useful as a **vaccine** for protecting against Staphylococcus **infection** and in **diagnostic** assays for **detecting** the presence of the antigen.
DERWENT CLASS: B04 D16 P34 S03
INVENTOR(S): FATTOM, A I; PAVLIAK, V
PATENT ASSIGNEE(S): (NABI-N) NABI; (NABI-N) NABI BIOPHARMACEUTICALS
COUNTRY COUNT: 93
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000056357	A2	20000928	(200062)*	EN	36

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD

SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
AU 2000037513 A 20001009 (200103)
EP 1162997 A2 20011219 (200206) EN
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
BR 2000009157 A 20020416 (200234)
JP 2002539272 W 20021119 (200281) 37
NZ 514455 A 20031128 (200382)
AU 773226 B2 20040520 (200462)
MX 2001009476 A1 20030801 (200464)
US 2005118190 A1 20050602 (200537)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000056357	A2	WO 2000-US6922	20000317
AU 2000037513	A	AU 2000-37513	20000317
EP 1162997	A2	EP 2000-916405	20000317
		WO 2000-US6922	20000317
BR 2000009157	A	BR 2000-9157	20000317
		WO 2000-US6922	20000317
JP 2002539272	W	JP 2000-606261	20000317
		WO 2000-US6922	20000317
NZ 514455	A	NZ 2000-514455	20000317
		WO 2000-US6922	20000317
AU 773226	B2	AU 2000-37513	20000317
MX 2001009476	A1	WO 2000-US6922	20000317
		MX 2001-9476	20010919
US 2005118190	A1 Div ex	US 1999-272359	19990319
		US 2004-14997	20041220

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 2000037513	A	Based on	WO 2000056357
EP 1162997	A2	Based on	WO 2000056357
BR 2000009157	A	Based on	WO 2000056357
JP 2002539272	W	Based on	WO 2000056357
NZ 514455	A	Based on	WO 2000056357
AU 773226	B2	Previous Publ.	AU 2000037513
		Based on	WO 2000056357
MX 2001009476	A1	Based on	WO 2000056357

PRIORITY APPLN. INFO: US 1999-272359 19990319; US 2004-14997 20041220

AN 2000-647115 [62] WPIDS

AB WO 200056357 A UPAB: 20040405

NOVELTY - An isolated Staphylococcus antigen (I), comprising amino acids and a N-acetylated hexosamine in an alpha configuration, containing no O-acetyl groups **detectable** by nuclear magnetic resonance (NMR) spectroscopy and specifically binding with antibodies to a Staphylococcus strain deposited under ATCC 202176, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) an antigen-**carrier** conjugate (II) comprising (I) bonded to an immunocarrier;

(2) a composition comprising (I);

(3) a hyperimmune globulin containing antibodies directed against (I);

(4) a monoclonal antibody (II) directed against (I);

(5) a **vaccine** (III) that comprises cells of Staphylococcus which carry (I) and a **carrier**;

(6) a kit for **detecting** the presence of anti-Staphylococcus antibody in a sample, comprising (I) and instructions for mixing the antigen with a sample suspected of containing Staphylococcus-specific antibody;

(7) a catheter coated with (I); and

(8) an immunotherapeutic agent against Staphylococcus **infection**, comprising antibodies prepared by **immunizing** subjects with (I) and harvesting antibodies from plasma of the **immunized** subjects.

ACTIVITY - Antibiotic.

The prophylactic effect of antigen-specific monoclonal antibody was evaluated in a mouse model using slime-producing **Staphylococcus epidermidis** strain 97 that carries the antigen for the challenge. Groups of mice were **immunized** subcutaneously with either 0.5 mg or 1.0 mg of **Staphylococcus epidermidis** antigen-specific monoclonal antibody, 1 mg of Escherichia coli-specific monoclonal antibody, or 1 mg of **Staphylococcus epidermidis** slime-specific monoclonal antibody. Twenty-four hours after **immunization**, mice were challenged intraperitoneally with 1 multiply 108 CFU (colony forming units) of bacteria in 6% hog mucin and mice were monitored for morbidity and mortality. The results showed dose-dependent protection by a monoclonal antibody specific to the antigen. Neither antibody specific to slime nor antibody specific to Escherichia coli provided protection against the bacterial challenge.

MECHANISM OF ACTION - **Vaccine**.

USE - (I) is useful for preparing an immunotherapeutic agent against Staphylococcus **infections** by **immunizing** a subject with a composition comprising (I) and harvesting a hyperimmune globulin that contains antibodies directed against Staphylococcus from plasma collected from the **immunized** subject. The harvested hyperimmune globulin is useful for immunotherapy. (I) immobilized on a solid matrix is useful in **diagnostic** assays for **detecting** the presence of anti-Staphylococcus antibody in a sample. Similarly monoclonal antibody immobilized on a solid matrix specific for a Staphylococcus antigen is useful for **detecting** the presence of anti-Staphylococcus antigen in a sample. (I) is also useful for **preventing** adherence of Staphylococcus bacteria to a catheter by coating the catheter with (I) (claimed). (II) and (III) by passive **immunization** are useful for inducing an immune response for the **prevention** or **treatment** of **infection** by Staphylococcus strains.

Dwg.0/2

L19 ANSWER 30 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2000-072664 [06] WPIDS
DOC. NO. NON-CPI: N2000-056832
DOC. NO. CPI: C2000-020832
TITLE: Compound used for the **diagnosis** of bacterial **infections**.
DERWENT CLASS: A26 A96 B04 D16 S03
INVENTOR(S): ELLIOTT, T S J; LAMBERT, P A
PATENT ASSIGNEE(S): (OXOI-N) OXOID LTD; (ELLI-I) ELLIOTT T S J; (LAMB-I) LAMBERT P A

COUNTRY COUNT: 20
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9961913	A2	19991202	(200006)*	EN	49
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE					
W: US					
EP 1112495	A2	20010704	(200138)	EN	
R: CH DE ES FR GB IT LI SE					
US 2003096790	A1	20030522	(200336)		
EP 1112495	B1	20030813	(200355)	EN	
R: CH DE ES FR GB IT LI SE					
DE 69910409	E	20030918	(200369)		
ES 2205827	T3	20040501	(200431)		
US 2004137554	A1	20040715	(200447)		

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 9961913	A2		WO 1999-GB1650	19990526
EP 1112495	A2		EP 1999-923760	19990526
			WO 1999-GB1650	19990526
US 2003096790	A1		WO 1999-GB1650	19990526
			US 2001-701289	20010529
EP 1112495	B1		EP 1999-923760	19990526
			WO 1999-GB1650	19990526
DE 69910409	E		DE 1999-610409	19990526
			EP 1999-923760	19990526
			WO 1999-GB1650	19990526
ES 2205827	T3		EP 1999-923760	19990526
US 2004137554	A1	Cont of	WO 1999-GB1650	19990526
		Cont of	US 2001-701289	20010529
			US 2004-751947	20040107

FILING DETAILS:

PATENT NO	KIND		PATENT NO
EP 1112495	A2	Based on	WO 9961913
EP 1112495	B1	Based on	WO 9961913
DE 69910409	E	Based on	EP 1112495
		Based on	WO 9961913
ES 2205827	T3	Based on	EP 1112495

PRIORITY APPLN. INFO: GB 1998-11347 19980528
AN 2000-072664 [06] WPIDS
AB WO 9961913 A UPAB: 20000203
NOVELTY - An isolated compound (I) is new.
DETAILED DESCRIPTION - The isolated compound is of formula (I).
n = 3-10;
X = H, OH, alkyl, aryl, amyl, optionally substituted amino acid residue or optionally substituted sugar residue;
R and/or R' = hydrophobic hydrocarbon or fatty acid chains
INDEPENDENT CLAIMS are also included for the following:
(1) a composition comprising a compound of formula (I);
(2) a method of testing for a Gram positive (+ve) bacterial **infection** in a mammalian (typically human) subject,

comprising:
(a) contacting a body fluid sample with a composition comprising (I); and
(b) **detecting** binding of antibodies to the sample;
(3) a **diagnostic** test kit for **diagnosing** the presence of a Gram +ve **infection**;
(4) a **Staphylococcus epidermidis** strain CAN 6KIII deposited under accession number NCIMB 40896;
(5) a **Staphylococcus epidermidis** strain HAR 6KIV deposited under accession number NCIMB 40945;
(6) a **Staphylococcus epidermidis** strain COS 6KV deposited under accession number NCIMB 40946;
(7) a **Staphylococcus epidermidis** strain MIL 6LI deposited under accession number NCIMB 40947;
(8) a **Staphylococcus epidermidis** strain HED 6LI deposited under accession number NCIMB 40948;
(9) a Staphylococcus haemolyticus strain ONE 6KVI deposited under accession number NCIMB 40949; and
(10) a Micrococcus kristinae strain MAT 6LIII deposited under accession number NCIMB 40950.
ACTIVITY - Antibacterial.
MECHANISM OF ACTION - **Vaccine**.
USE - The compound is used for the **diagnosis** of bacterial **infections**. The compounds are also used in a method of inducing antibodies in a human.
Dwg.0/7

L19 ANSWER 31 OF 37 MEDLINE on STN
ACCESSION NUMBER: 2001225630 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11207545
TITLE: Fibronectin-binding protein acts as Staphylococcus aureus invasin via fibronectin bridging to integrin alpha5beta1.
AUTHOR: Sinha B; Francois P P; Nusse O; Foti M; Hartford O M; Vaudaux P; Foster T J; Lew D P; Herrmann M; Krause K H
CORPORATE SOURCE: Division of Infectious Diseases, Geneva Medical School, Swizterland.. Bhanu.Sinha@gmx.de
SOURCE: Cellular microbiology, (1999 Sep) 1 (2) 101-17. Journal code: 100883691. ISSN: 1462-5814.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200104
ENTRY DATE: Entered STN: 20010502
Last Updated on STN: 20010502
Entered Medline: 20010426
AB The ability of Staphylococcus aureus to invade mammalian cells may explain its capacity to colonize mucosa and to persist in tissues after bacteraemia. To date, the underlying molecular mechanisms of cellular invasion by S. aureus are unknown, despite its high prevalence and difficulties in **treatment**. Here, we show cellular invasion as a novel function for an S. aureus adhesin, previously implicated solely in attachment. S. aureus, but not **S. epidermidis**, invaded epithelial 293 cells in a temperature- and F-actin-dependent manner. Formaldehyde-fixed and live bacteria were equally invasive, suggesting that no active bacterial process was involved. All clinical S. aureus isolates analysed, but only a subset of laboratory strains, were invasive.

Fibronectin-binding proteins (FnBPs) acted as S. aureus invasins, because: (i) FnBP deletion mutants of invasive laboratory strains lost invasiveness; (ii) expression of FnBPs in noninvasive strains conferred invasiveness; and (iii) the soluble isolated fibronectin-binding domain of FnBP (D1-D4) completely blocked invasion. Integrin alpha5beta1 served as host cell receptor, which interacted with staphylococcal FnBPs through cellular or soluble fibronectin. FnBP-deficient mutants lost invasiveness for epithelial cells, endothelial cells and fibroblasts. Thus, fibronectin-dependent bridging between S. aureus FnBPs and host cell integrin alpha5beta1 is a conserved mechanism for S. aureus invasion of human cells. This may prove useful in developing new **therapeutic** and **vaccine** strategies for S. aureus **infections**.

L19 ANSWER 32 OF 37 MEDLINE on STN
ACCESSION NUMBER: 97019396 MEDLINE
DOCUMENT NUMBER: PubMed ID: 8865907
TITLE: Does the response to hepatitis B **vaccination** predict CAPD-associated **infections**?.
AUTHOR: Holley J L
CORPORATE SOURCE: Renal-Electrolyte Division, University of Pittsburgh Medical Center, Pennsylvania, USA.
SOURCE: Advances in peritoneal dialysis. Conference on Peritoneal Dialysis, (1996) 12 218-20.
Journal code: 9104803. ISSN: 1197-8554.
PUB. COUNTRY: Canada
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199701
ENTRY DATE: Entered STN: 19970219
Last Updated on STN: 19970219
Entered Medline: 19970130

AB Rates of peritoneal dialysis-associated catheter **infections** and peritonitis were compared in continuous ambulatory peritoneal dialysis patients grouped on the basis of their response to hepatitis B **vaccination** with Engerix to assess the usefulness of **vaccination** in predicting patients at risk for peritonitis and catheter **infections**. Engerix was given intramuscularly in a dose of 40 micrograms at 0, 1, 2, and 6 months. Sixty-three percent (20/32) of patients developed hepatitis B surface antibodies (converters). Converters and nonconverters were not different in proportions of women, whites, diabetics, or Staphylococcus aureus nasal **carriers**; mean age and mean months on peritoneal dialysis were also not different. Overall, peritonitis (0.46/year vs 0.33/year) and catheter **infection** (0.53/year vs 0.54/year) rates were not different among converters and nonconverters, respectively. Nonconverters had higher S. aureus peritonitis rates (0.12/year vs 0.04/year, $p < 0.05$) but lower **S. epidermidis** peritonitis rates (0.03/year vs 0.18/year, $p < 0.02$). However, when the patient with recurrent **S. epidermidis** peritonitis was excluded from analysis, **S. epidermidis** peritonitis rates among converters and nonconverters were not different (0.13/year vs 0.03/year, respectively, $p < 0.09$). These data suggest that the development of surface antibodies with hepatitis B **vaccination** does not predict a reduced risk of **S. epidermidis** peritonitis. The possibility that nonconverters are more likely to be S. aureus nasal **carriers** and therefore at greater risk of S.

aureus peritonitis deserves further study.

L19 ANSWER 33 OF 37 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 96071305 EMBASE
DOCUMENT NUMBER: 1996071305
TITLE: Polysaccharide conjugate **vaccines** for the **prevention** of gram-positive bacterial **infections**.
AUTHOR: Naso R.; Fattom A.
CORPORATE SOURCE: W. W. Karakawa MPL, Univax Biologics, Inc., 12280 Wilkins Avenue,Rockville, MD 20852, United States
SOURCE: Advances in Experimental Medicine and Biology, (1996) Vol. 397, pp. 133-138.
ISSN: 0065-2598 CODEN: AEMBAP
COUNTRY: United States
DOCUMENT TYPE: Journal; Conference Article
FILE SEGMENT: 004 Microbiology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 960319
Last Updated on STN: 960319

AB In summary, the type 5 and type 8 capsular polysaccharides of S. aureus are characterized as having properties conducive to their use as **vaccines** to **prevent** and/or **treat** S. aureus **infections** or for use as **immunizing** agents to raise specific polyclonal antibodies for passive **immunization** of those at risk for S. aureus **infections**. These properties of the type 5 and type 8 S. aureus capsular polysaccharides are summarized as follows. Compared to proteins, S. aureus capsular polysaccharides have a simple structure - they are polymers of repeating units and the polymers vary in length. The repeat units of the polysaccharides contain one mole of mannoseamineuronic acid and two moles of fucosamine. The immunodeterminants on the capsular polysaccharide are directed primarily to glycosidic bonds and antigenic side groups such as O-acetylation sites. The capsular polysaccharides are surface components, they are available exposed on the bacterial surface, and they are formed preferentially under growth conditions of low phosphate and in late log and stationary phase of growth. Capsular polysaccharides are virulence promoting factors and they protect S. aureus against phagocytosis and complement mediated killing. Type 5 and type 8 capsular polysaccharides make up approximately 90% of all clinical S. aureus isolates. Low titers of antibodies to type 5 and type 8 capsular polysaccharides are present in many healthy humans, but capsular polysaccharides alone are poor, T-cell independent immunogens. The capsular polysaccharides can be made immunogenic by conjugation to **carrier** proteins and the immunogenicity of the conjugates can be increased through the use of **adjuvants**. Capsular polysaccharide conjugate **vaccines** are safe and immunogenic in humans, and antibodies to capsular polysaccharides are opsonic and induce opsonophagocytosis in vitro. Active **immunization** with a capsular polysaccharide conjugate **vaccine** (StaphVAX) and passive **immunization** with antibodies to StaphVAX (StaphGAM) can provide protection against S. aureus challenge in animal models. While the impressive results in animal models, may or may not be predictive of the value of active and passive **immunization** in humans, we are optimistic that

vaccines to Gram-positive bacteria, such as S. aureus can be made and will be effective. Results in the next few years from clinical trials of StaphVAX and StaphGAM should be forthcoming and will **determine** the true promise of this approach to **preventing** serious bacterial **infections**. Univax is also well along in developing similar **vaccines** for **S** . **epidermidis** and for enterococci. A combination **vaccine** and a combination specific polyclonal antibody addressing these three Gram-positive pathogens may be extremely important armaments in the war against nosocomial bacterial **infections**.

L19 ANSWER 34 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 1993-288361 [36] WPIDS
CROSS REFERENCE: 1993-320895 [40]
DOC. NO. NON-CPI: N1993-221784
DOC. NO. CPI: C1993-128715
TITLE: Human immunoglobulin against **Staphylococcal epidermidis** - used to **prevent** or **treat infection** in adults and neonates.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): FISCHER, G W
PATENT ASSIGNEE(S): (JACK-N) JACKSON FOUND ADVANCEMENT MILITARY MED; (USSA) US SEC OF ARMY; (JACK-N) JACKSON HENRY M FOUND ADVANCEMENT MILITARY MEDICINE; (FISC-I) FISCHER G W
COUNTRY COUNT: 38
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9317044	A1	19930902	(199336)*	EN	39
RW: AT BE CH DE DK ES FR GB GR IE IT LI LU MC MW NL OA RU SD SE					
W: AU BB BG BR CA CS FI HU JP KP KR LK MG MN NO PL RO US					
AU 9332718	A	19930913	(199403)		
EP 628056	A1	19941214	(199503)	EN	
R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE					
JP 08504167	W	19960507	(199646)		28
AU 673508	B	19961114	(199702)		
EP 628056	A4	19970305	(199729)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9317044	A1	WO 1992-US9830	19921109
AU 9332718	A	AU 1993-32718	19921109
EP 628056	A1	WO 1992-US9830	19921109
		EP 1993-901435	19921109
JP 08504167	W	WO 1992-US9830	19921109
		JP 1993-514800	19921109
AU 673508	B	AU 1993-32718	19921109
EP 628056	A4	EP 1993-901435	

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9332718	A	Based on	WO 9317044

Searcher : Shears 571-272-2528

EP 628056	A1	Based on	WO 9317044
JP 08504167	W	Based on	WO 9317044
AU 673508	B	Previous Publ.	AU 9332718
		Based on	WO 9317044

PRIORITY APPLN. INFO: US 1992-804317 19920225
AN 1993-288361 [36] WPIDS
CR 1993-320895 [40]
AB WO 9317044 A UPAB: 19971030
A directed human immunoglobulin (I) is used for the **treatment** or **prevention** of Staphylococcus epidermis **infections**

.

Also new are:- (1) a pharmaceutical compsn. containing an effective amount of (I) and a pharamceutically acceptable **carrier**; (2) a method of preparing (I) by **screening** serum, plasma or an Ig pool by S. epidermis ELISA or Opsonic assays; (3) a method of preparing (I) comprising **immunising** plasma donors and removing the plasma; (4) a method of assessing the protective level of (I) using an immature or intralipid induced lethal model to provide minimum protective standard comprising:- (a) **screening** with in vitro assays; and (b) using animal lethality tests to ensure that the Ig preparation provides antibody to S. epidermis; (5) a method of **treating** a host with a **therapeutically** effective amount of (I) by intravenous or intramuscular administration.

(I) pref. contains a measured level of anti-staphylococcal IgG antibodies that react with surface antigens of S. epidermis and promote phagocytosis and killing of said bacteria in vitro and/or protection in vivo. The opsonic activity of the antibodies is 80-100%. In the method of (5) the intravenous method is used prior to **infection** and the intramuscular method post-**infection**

.

USE - (I) is used to **prevent** or **treat** staphylococcal **infections** such as S. epidermis. It can be used in neonates and adults in intensitve care units or patients with in-dwelling foreign bodies e.g. venous and arterial catheters or ventricular shunt
Dwg.0/3

L19 ANSWER 35 OF 37 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 1993-182251 [22] WPIDS
DOC. NO. CPI: C1993-080686
TITLE: Compsn. of **Staphylococcus epidermidis** type I and II surface antigens - useful as a **vaccine** for **treating** and **preventing S. epidermidis infections.**
DERWENT CLASS: B04 D16
INVENTOR(S): FATTOM, A I; KARAKAWA, W W; WRIGHT, D C; FATTOM, A; WRIGHT, C D
PATENT ASSIGNEE(S): (NABI-N) NORTH AMERICAN BIOLOGICALS INC; (FATT-I) FATTOM A I; (UNIV-N) UNIVAX BIOLOGICS INC; (WRIG-I) WRIGHT D C; (WRIG-I) WRIGHT D; (NABI-N) NABI BIOPHARMACEUTICALS; (NABI-N) NABI
COUNTRY COUNT: 24
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9309811	A1	19930527	(199322)*	EN	29

```
   RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE
    W: AU BR CA FI JP KR NO
AU 9230747      A  19930615 (199340)
FI 9402359      A  19940520 (199429)
NO 9401877      A  19940616 (199429)
EP 648127       A1 19950419 (199520)  EN
    R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE
JP 07508498     W  19950921 (199546)       13
EP 648127       A4 19950614 (199616)
AU 681573       B  19970904 (199744)
US 5866140      A  19990202 (199912)
US 5961975      A  19991005 (199948)
EP 648127       B1 20030416 (200328)  EN
    R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE
DE 69233012     E  20030522 (200341)
FI 111336       B1 20030715 (200353)
ES 2198405      T3 20040201 (200414)
JP 2004155789   A  20040603 (200436)       13
NO 319013       B1 20050606 (200537)
CA 2123811      C  20050705 (200545)  EN
```

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 9309811	A1		WO 1992-US9784	19921120
AU 9230747	A		AU 1992-30747	19921120
FI 9402359	A		WO 1992-US9784	19921120
			FI 1994-2359	19940520
NO 9401877	A		WO 1992-US9784	19921120
			NO 1994-1877	19940519
EP 648127	A1		EP 1992-924432	19921120
			WO 1992-US9784	19921120
JP 07508498	W		WO 1992-US9784	19921120
			JP 1993-509411	19921120
EP 648127	A4		EP 1992-924432	
AU 681573	B		AU 1992-30747	19921120
US 5866140	A	Cont of	US 1991-796252	19911122
		Cont of	US 1993-142117	19931028
			US 1994-361821	19941222
US 5961975	A	Cont of	US 1991-796252	19911122
		Cont of	US 1993-142117	19931028
		Cont of	US 1994-361821	19941222
			US 1995-472211	19950607
EP 648127	B1		EP 1992-924432	19921120
			WO 1992-US9784	19921120
DE 69233012	E		DE 1992-633012	19921120
			EP 1992-924432	19921120
			WO 1992-US9784	19921120
FI 111336	B1		WO 1992-US9784	19921120
			FI 1994-2359	19940520
ES 2198405	T3		EP 1992-924432	19921120
JP 2004155789	A	Div ex	JP 1993-509411	19921120
			JP 2003-428138	20031224
NO 319013	B1		WO 1992-US9784	19921120
			NO 1994-1877	19940519
CA 2123811	C		CA 1992-2123811	19921120
			WO 1992-US9784	19921120

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9230747	A	Based on	WO 9309811
EP 648127	A1	Based on	WO 9309811
JP 07508498	W	Based on	WO 9309811
AU 681573	B	Previous Publ.	AU 9230747
		Based on	WO 9309811
EP 648127	B1	Based on	WO 9309811
DE 69233012	E	Based on	EP 648127
		Based on	WO 9309811
FI 111336	B1	Previous Publ.	FI 9402359
ES 2198405	T3	Based on	EP 648127
NO 319013	B1	Previous Publ.	NO 9401877
CA 2123811	C	Based on	WO 9309811

PRIORITY APPLN. INFO: US 1991-796252 19911122; US
1993-142117 19931028; US
1994-361821 19941222; US
1995-472211 19950607

AN 1993-182251 [22] WPIDS

AB WO 9309811 A UPAB: 19931115

Compsn. contains at least one type I or type II surface antigen (sAg) of **Staphylococcus epidermidis**. Also new are (1) serotyping of **S. epidermidis** isolated by agglutination with anti-(type I and type II) specific antibodies; (2) **vaccines** containing (A) plus an acceptable **carrier**; (3) hyperimmune globulin containing antibodies against **S. epidermidis**; (4) antibodies (Ab) which bind to sAg; (5) kits for serotyping.

Pref. sAg is bound to an immunocarrier and pref. (A) have both types of antigens bound to the same **carrier**.

USE/ADVANTAGE - The **vaccines**, hyperimmune globulin and Ab are useful in immunotherapy to **prevent** or **treat** **S. epidermidis infection**. Where derived from both serotypes they are effective against most clinically pathogenic strains of the bacterium.

Dwg.0/0

L19 ANSWER 36 OF 37 MEDLINE on STN DUPLICATE 1

ACCESSION NUMBER: 93025260 MEDLINE
DOCUMENT NUMBER: PubMed ID: 1407258
TITLE: Peritonitis **prevention** in continuous ambulatory peritoneal dialysis.
AUTHOR: Luzar M A
CORPORATE SOURCE: National Institute of Allergy and Infections Diseases, RIH, Bethesda, Maryland.
SOURCE: Nephrologie, (1992) 13 (4) 171-7. Ref: 58
Journal code: 8011169. ISSN: 0250-4960.
PUB. COUNTRY: Switzerland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199211
ENTRY DATE: Entered STN: 19930122
Last Updated on STN: 19930122

Searcher : Shears 571-272-2528

Entered Medline: 19921106

AB Although peritonitis remains the major cause of morbidity in CAPD, peritonitis rates are declining in European and other countries. This article reviews approaches that are both decisive and promising concerning the **prevention** of peritonitis in CAPD. Clinical results with both reusable and single-use Y sets are discussed. These systems appear to have a significant impact on the reduction of intraluminal contamination, particularly **Staphylococcus epidermidis**. The importance of the flush-before-fill technique is reviewed in the context of the new disposable Y sets. In vitro studies confirm that 100 mls of fresh dialysate flushed from the new bag to the drainage bag at the appropriate time during the exchange can eliminate microorganisms that do not possess adherence factors, providing long periods of incubation are not encountered. Future **prevention** measures for the reduction of Staphylococcus aureus peritonitis are discussed in light of evidence identifying pre-CAPD nasal **carriers** as high risk patients for subsequent exit-site **infection** and S. aureus peritonitis. These measures include methods such as the application of antibiotics such as mupirocin to the anterior nares before and during CAPD. The roles of intraperitoneal IgG **therapY** and staphylococcal **vaccination** as additional **therapeutic** approaches to **infection** control in peritoneal dialysis are also discussed.

L19 ANSWER 37 OF 37 MEDLINE on STN DUPLICATE 2
ACCESSION NUMBER: 87047323 MEDLINE
DOCUMENT NUMBER: PubMed ID: 3096189
TITLE: [Aerobic bacterial flora of the nasal cavity of rabbits].
Flore bacterienne aerobie des cavites nasales du lapin d'elevage.
AUTHOR: Duclos P; Caillet J; Javelot P
SOURCE: Annales de recherches veterinaires. Annals of veterinary research, (1986) 17 (2) 185-90.
Journal code: 1267230. ISSN: 0003-4193.
PUB. COUNTRY: France
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: French
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198612
ENTRY DATE: Entered STN: 19900302
Last Updated on STN: 19900302
Entered Medline: 19861208

AB On the basis of bacteriological examinations carried out in April 1984 on 60 intranasal swabs, aerobic respiratory microbes were studied in rabbits. Differences in flora between animals with and without respiratory diseases were studied. Fourteen bacterial species were identified with no difference due to the pathological status. They were: Bordetella bronchiseptica, **Staphylococcus epidermidis**, Streptococcus faecalis, Pasteurella multocida, Staphylococcus aureus, Bacillus sp., Branhamella catarrhalis, Micrococcus sp., Enterobacter agglomerans, Proteus mirabilis, Pseudomonas paucimobilis, Pseudomonas diminuta, Alcaligenes faecalis and Escherichia coli. However, young weaned rabbits were more often Pasteurella **carriers** than adult females in maternity. The usefulness of performing only Pasteurella and Bordetella cultures in rabbits is questionable as is use of **vaccines** in order to **prevent** bacterial respiratory syndrome. It is emphasised that

myxomatosis should be pursued in the investigation of respiratory **infections** in rabbit.

FILE 'USPATFULL' ENTERED AT 11:34:52 ON 07 SEP 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 6 Sep 2005 (20050906/PD)
FILE LAST UPDATED: 6 Sep 2005 (20050906/ED)
HIGHEST GRANTED PATENT NUMBER: US6941576
HIGHEST APPLICATION PUBLICATION NUMBER: US2005193458
CA INDEXING IS CURRENT THROUGH 6 Sep 2005 (20050906/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 6 Sep 2005 (20050906/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2005

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

L24 183 SEA FILE=USPATFULL ABB=ON PLU=ON ((STAPHYLOCOCC? OR S)(W)EPIDERMID?)(5A)(TREAT? OR THERAP? OR PREVENT? OR DIAGNOS? OR DETERM? OR DETECT? OR DET## OR SCREEN?)
L25 17 SEA FILE=USPATFULL ABB=ON PLU=ON L24(S)(ADJUVANT OR IMMUNOADJUVANT OR IMMUNOACTIVAT? OR IMMUNOSTIMUL? OR IMMUN?(W)(ACTIVAT? OR STIMUL?) OR VACCIN? OR IMMUNIS? OR IMMUNIZ?)
L26 2 SEA FILE=USPATFULL ABB=ON PLU=ON L25(S)CARRIER

L24 183 SEA FILE=USPATFULL ABB=ON PLU=ON ((STAPHYLOCOCC? OR S)(W)EPIDERMID?)(5A)(TREAT? OR THERAP? OR PREVENT? OR DIAGNOS? OR DETERM? OR DETECT? OR DET## OR SCREEN?)
L25 17 SEA FILE=USPATFULL ABB=ON PLU=ON L24(S)(ADJUVANT OR IMMUNOADJUVANT OR IMMUNOACTIVAT? OR IMMUNOSTIMUL? OR IMMUN?(W)(ACTIVAT? OR STIMUL?) OR VACCIN? OR IMMUNIS? OR IMMUNIZ?)
L27 16 SEA FILE=USPATFULL ABB=ON PLU=ON L25(S)INFECTION

Searcher : Shears 571-272-2528

L28 16 L26 OR L27

L28 ANSWER 1 OF 16 USPATFULL on STN

ACCESSION NUMBER:	2005:30345 USPATFULL
TITLE:	Capsular polysaccharide adhesin antigen, preparation, purification and use
INVENTOR(S):	Pier, Gerald B., Brookline, MA, UNITED STATES
PATENT ASSIGNEE(S):	The Brigham And Women's Hospital, Inc., Boston, MA, 02115 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005025775	A1	20050203
APPLICATION INFO.:	US 2004-856123	A1	20040528 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-93582, filed on 8 Mar 2002, GRANTED, Pat. No. US 6743431 Division of Ser. No. US 1999-393832, filed on 10 Sep 1999, GRANTED, Pat. No. US 6399066 Division of Ser. No. US 1994-336688, filed on 7 Nov 1994, GRANTED, Pat. No. US 5980910 Continuation of Ser. No. US 1993-33756, filed on 18 Mar 1993, ABANDONED Continuation of Ser. No. US 1991-727982, filed on 10 Jul 1991, ABANDONED Division of Ser. No. US 1988-250417, filed on 28 Sep 1988, GRANTED, Pat. No. US 5055455

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Patrick R.H. Waller, WOLF GREENFIELD & SACKS PC, 600 Atlantic Avenue, Boston, MA, 02210-2211
NUMBER OF CLAIMS:	5
EXEMPLARY CLAIM:	CLM-01-30
NUMBER OF DRAWINGS:	5 Drawing Page(s)
LINE COUNT:	788

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A substantially pure capsular exopolysaccharide adhesin of coagulase-negative staphylococcal strains, and a gonoral method to prepare such adhesins, are described. Vaccines composed of such adhesins, and uses of such adhesins to produce polyclonal and monoclonal antibodies against such adhesins, are also disclosed. The adhesins are useful in coating polymoric medical materials to prevent colonization by coagulase-negative staphylococcal strains, and as a probe in selecting desirable polymeric medical materials. Such adhesin antibodies are useful in vivo to prevent infection by nosocomial coagulase-negative staphylococcal strains, in assays for the detection of such bacteria, in assays for the estimation of such adhesins in complex mixtures, and as an affinity chromatography matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 2 OF 16 USPATFULL on STN

ACCESSION NUMBER:	2004:190960 USPATFULL
TITLE:	Nucleic acid and amino acid sequences relating to staphylococcus epidermidis for diagnostics and therapeutics
INVENTOR(S):	Doucette-Stamm, Lynn, Framingham, MA, UNITED STATES Bush, David, Somerville, MA, UNITED STATES

	NUMBER	KIND	DATE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004147734	A1	20040729
APPLICATION INFO.:	US 2003-724972	A1	20031201 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-450969, filed on 29 Nov 1999, PENDING Continuation-in-part of Ser. No. US 1998-134001, filed on 13 Aug 1998, GRANTED, Pat. No. US 6380370

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-64964P	19971108 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OSCIENT THERAPEUTICS CORPORATION, 100 BEAVER STREET, WALTHAM, MA, 02453
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
LINE COUNT: 3207
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 3 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2004:59932 USPATFULL
TITLE: Staphylococcus epidermidis nucleic acids and proteins
INVENTOR(S): Kimmerly, William John, Encinitas, CA, United States
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6703492	B1	20040309
APPLICATION INFO.:	US 2000-710279		20001109 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-164258P	19991109 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Brusca, John S.
ASSISTANT EXAMINER: Zhou, Shubo "Joe"
LEGAL REPRESENTATIVE: Conger, Michael M.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1782
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB S epidermidis polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing

such polypeptides and DNA (RNA) for the treatment of infection, particularly infections arising from S epidermidis. Antagonists against the function of such polypeptides and their use as therapeutics to treat infection are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of S epidermidis nucleic acid sequences and the polypeptides in a host. Also disclosed are diagnostic assays for detecting polynucleotides and polypeptides related to S epidermidis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 4 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2004:59775 USPATFULL
TITLE: Multicomponent vaccines
INVENTOR(S): Patti, Joseph M., Cumming, GA, United States
Foster, Timothy J., Dublin, IRELAND
Hook, Magnus, Houston, TX, United States
PATENT ASSIGNEE(S): Inhibitex, Inc., Alpharetta, GA, United States (U.S. corporation)
The Provost Fellows and Scholars of the College of The Holy and Undivided Trinity of Queen Elizabeth near Dublin, Dublin, IRELAND (non-U.S. corporation)
The Texas A&M University System, College Station, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6703025	B1	20040309	
APPLICATION INFO.:	US 1999-386959		19990831	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-98439P	19980831 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Graser, Jennifer E.
LEGAL REPRESENTATIVE: Larson & Taylor PLC
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 4053
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Multicomponent vaccines are provided which aid in the prevention and treatment of staphylococcal infections and which include certain selected combinations of bacterial binding proteins or fragments thereof, or antibodies to those proteins or fragments. By careful selection of the proteins, fragments, or antibodies, a vaccine is provided that imparts protection against a broad spectrum of Staphylococcus bacterial strains and against proteins that are expressed at different stages of the logarithmic growth curve. In one embodiment of the invention, a composition is provided that includes at least a collagen binding protein or peptide (or an appropriate site directed mutated sequence thereof) such as CNA, or a protein or fragment with sufficiently high homology thereto, in combination with a fibrinogen binding protein, preferably Clumping factor A ("ClfA") or Clumping factor B ("ClfB"), or a useful fragment thereof or a protein or fragment with sufficiently high homology thereto. The vaccines and products of the present invention are advantageous in that they respond to the urgent need of the

medical community for a substitute for small molecule antibiotics, which are rapidly losing effectiveness and provide effective combinations of the large number of known bacterial surface adhesins which can impart effective protection against a broad spectrum of bacterial infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 5 OF 16 USPATFULL on STN

ACCESSION NUMBER:	2004:41341 USPATFULL
TITLE:	Staphylococcal immunotherapeutics via donor selection and donor stimulation
INVENTOR(S):	Patti, Joseph M., Cumming, GA, United States Foster, Timothy J., Dublin, IRELAND Hook, Magnus, Houston, TX, United States
PATENT ASSIGNEE(S):	Inhibitex, Inc., Alpharetta, GA, United States (U.S. corporation) The Provost Fellows and Scholars of The College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin, Dublin, IRELAND (non-U.S. corporation) The Texas A&M University System, College Station, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6692739	B1	20040217	
APPLICATION INFO.:	US 1999-386960		19990831	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-98449P	19980831 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Smith, Lynette R. F.
ASSISTANT EXAMINER:	Portner, Ginny Allen
LEGAL REPRESENTATIVE:	Larson & Taylor PLC
NUMBER OF CLAIMS:	26
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT:	2969

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method and composition for the passive immunization of patients infected with or susceptible to infection from Staphylococcus bacteria such as S. aureus and S. epidermidis infection is provided that includes the selection or preparation of a donor plasma pool with high antibody titers to carefully selected Staphylococcus adhesins or MSCRAMMs, or fragments or components thereof, or sequences with substantial homology thereto. The donor plasma pool can be prepared by combining individual blood or blood component samples which have higher than normal titers of antibodies to one or more of the selected adhesins or other proteins that bind to extracellular matrix proteins, or by administering carefully selected proteins or peptides to a host to induce the expression of desired antibodies, and subsequently recovering the enhanced high titer serum or plasma pool from the treated host. In either case, the donor plasma pool is preferably purified and concentrated prior to intravenous introduction into the patient, and the present invention is advantageous in that a patient can be immunized against a wide variety of potentially dangerous staphylococcal infections.

Kits for identifying potential donor with high titers of the selected adhesins are also provided. The present invention thus provides methods and compositions which can be highly effective against infections associated with Staphylococcus bacteria.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 6 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2003:273226 USPATFULL
TITLE: Directed human immune globulin for the prevention and treatment of staphylococcal infections
INVENTOR(S): Fischer, Gerald W., Bethesda, MD, United States
PATENT ASSIGNEE(S): Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6632432	B1	20031014
APPLICATION INFO.:	US 1995-460622		19950602 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-296133, filed on 26 Aug 1994, now abandoned Continuation of Ser. No. US 1992-804317, filed on 25 Feb 1992, now abandoned Continuation of Ser. No. US 1990-601089, filed on 22 Oct 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Graser, Jennifer E.
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett, and Dunner, L.L.P.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 656
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to a Directed Human Immunoglobulin and compositions thereof for preventing or treating staphylococcal infections such as S. epidermidis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 7 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2002:287138 USPATFULL
TITLE: Staphylococcal immunotherapeutics via donor selection and donor stimulation
INVENTOR(S): Patti, Joseph M., Cumming, GA, UNITED STATES
Foster, Timothy J., Dublin, IRELAND
Hook, Magnus, Houston, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002159997	A1	20021031
APPLICATION INFO.:	US 2002-91494	A1	20020307 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-386960, filed on 31 Aug 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-98449P	19980831 (60)

Tab 3

10/724972

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LARSON & TAYLOR, PLC, 1199 NORTH FAIRFAX STREET, SUITE 900, ALEXANDRIA, VA, 22314
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 2978
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method and composition for the passive immunization of patients infected with or susceptible to infection from Staphylococcus bacteria such as S. aureus and S. epidermidis infection is provided that includes the selection or preparation of a donor plasma pool with high antibody titers to carefully selected Staphylococcus adhesins or MSCRAMMs, or fragments or components thereof, or sequences with substantial homology thereto. The donor plasma pool can be prepared by combining individual blood or blood component samples which have higher than normal titers of antibodies to one or more of the selected adhesins or other proteins that bind to extracellular matrix proteins, or by administering carefully selected proteins or peptides to a host to induce the expression of desired antibodies, and subsequently recovering the enhanced high titer serum or plasma pool from the treated host. In either case, the donor plasma pool is preferably purified and concentrated prior to intravenous introduction into the patient, and the present invention is advantageous in that a patient can be immunized against a wide variety of potentially dangerous staphylococcal infections. Kits for identifying potential donor with high titers of the selected adhesins are also provided. The present invention thus provides methods and compositions which can be highly effective against infections associated with Staphylococcus bacteria.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 8 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2002:250792 USPATFULL
TITLE: Capsular polysaccharide adhesin antigen, preparation, purification and use
INVENTOR(S): Pier, Gerald B., Brookline, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002136730	A1	20020926
	US 6743431	B2	20040601
APPLICATION INFO.:	US 2002-93582	A1	20020308 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-393832, filed on 10 Sep 1999, GRANTED, Pat. No. US 6399066 Division of Ser. No. US 1994-336688, filed on 7 Nov 1994, GRANTED, Pat. No. US 5980910 Continuation of Ser. No. US 1993-33756, filed on 18 Mar 1993, ABANDONED Continuation of Ser. No. US 1991-727982, filed on 10 Jul 1991, ABANDONED Division of Ser. No. US 1988-250417, filed on 28 Sep 1988, GRANTED, Pat. No. US 5055455
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Maria A. Trevisan, Wolf, Greenfield & Sacks, P.C., Federal Reserve Plaza, 600 Atlantic Avenue, Boston, MA, 02210

Searcher : Shears 571-272-2528

NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 860
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A substantially pure capsular exopolysaccharide adhesin of coagulaso-negative staphylococcal strains, and a general method to prepare such adhesins, are described. Vaccines composed of such adhesins, and uses of such adhesins to produce polyclonal and mono-clonal antibodies against such adhesins, are also disclosed. The adhesins are useful in coating polymeric medical materials to prevent colonization by coagulase-negative staphylococcal strains, and as a probe in selecting desirable polymeric medical materials. Such adhesin antibodies are useful in vivo to prevent infection by noso-comial coagulase-negative staphylococcal strains, in assays for the detection of such bacteria, in assays for the estimation of such adhesins in complex mixtures, and as an affinity chromatography matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 9 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2002:129527 USPATFULL
TITLE: Capsular polysaccharide adhesin antigen, preparation, purification and use
INVENTOR(S): Pier, Gerald B., Brookline, MA, United States
PATENT ASSIGNEE(S): The Brigham and Women's Hospital, Inc., Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6399066	B1	20020604
APPLICATION INFO.:	US 1999-393832		19990910 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-336688, filed on 7 Nov 1994, now patented, Pat. No. US 5980910 Continuation of Ser. No. US 1993-33756, filed on 18 Mar 1993, now abandoned Continuation of Ser. No. US 1991-727982, filed on 10 Jul 1991, now abandoned Division of Ser. No. US 1988-250417, filed on 28 Sep 1988, now patented, Pat. No. US 5055455
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Graser, Jennifer E.
LEGAL REPRESENTATIVE: Wolf, Greenfield and Sacks, P.C.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 845
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A substantially pure capsular exopolysaccharide adhesin of coagulase-negative staphylococcal strains, and a general method to prepare such adhesins, are described. Vaccines composed of such adhesins, and uses of such adhesins to produce polyclonal and monoclonal antibodies against such adhesins, are also disclosed. The adhesins are useful in coating polymeric medical materials to prevent colonization by coagulase-negative staphylococcal strains, and as a probe in selecting desirable polymeric medical materials. Such adhesin antibodies are useful in vivo to prevent infection by nosocomial coagulase-negative staphylococcal strains, in assays for

the detection of such bacteria, in assays for the estimation of such adhesins in complex mixtures, and as an affinity chromatography matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 10 OF 16 USPATFULL on STN

ACCESSION NUMBER:	2002:95942 USPATFULL
TITLE:	Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
INVENTOR(S):	Doucette-Stamm, Lynn A., Framingham, MA, United States Bush, David, Somerville, MA, United States
PATENT ASSIGNEE(S):	Genome Therapeutics Corporation, Waltham, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6380370	B1	20020430
APPLICATION INFO.:	US 1998-134001		19980813 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-64964P	19971108 (60)
	US 1997-55779P	19970814 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Campbell, Eggerton A.
LEGAL REPRESENTATIVE:	Burns, Doane, Swecker & Mathis L.L.P.
NUMBER OF CLAIMS:	10
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT:	3041

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 11 OF 16 USPATFULL on STN

ACCESSION NUMBER:	1999:141317 USPATFULL
TITLE:	Capsular polysaccharide adhesion antigen preparation, purification and use
INVENTOR(S):	Pier, Gerald B., Brookline, MA, United States
PATENT ASSIGNEE(S):	Brigham and Women's Hospital, Inc., Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5980910		19991109
APPLICATION INFO.:	US 1994-336688		19941107 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-33756, filed on 18 Mar 1993, now abandoned which is a continuation of		

Ser. No. US 1991-727982, filed on 10 Jul 1991, now abandoned which is a division of Ser. No. US 1988-250417, filed on 28 Sep 1988, now patented, Pat. No. US 5055455
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chin, Christopher L.
ASSISTANT EXAMINER: Graser, Jennifer
LEGAL REPRESENTATIVE: Wolf, Greenfield & Sacks, P.C.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 864
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A substantially pure capsular exopolysaccharide adhesin of coagulase-negative staphylococcal strains, and a general method to prepare such adhesins, are described. Vaccines composed of such adhesins, and uses of such adhesins to produce polyclonal and monoclonal antibodies against such adhesins, are also disclosed. The adhesins are useful in coating polymeric medical materials to prevent colonization by coagulase-negative staphylococcal strains, and as a probe in selecting desirable polymeric medical materials. Such adhesin antibodies are useful in vivo to prevent infection by nosocomial coagulase-negative staphylococcal strains, in assays for the detection of such bacteria, in assays for the estimation of such adhesins in complex mixtures, and as an affinity chromatography matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 12 OF 16 USPATFULL on STN
ACCESSION NUMBER: 1999:120879 USPATFULL
TITLE: Type I surface antigen associated with staphylococcus epidermidis
INVENTOR(S): Fattom, Ali Ibrahim, Rockville, MD, United States
Karakawa, Walter W., Pennsylvania Furnace, PA, United States Judith Kane, legal representative
Wright, D. Craig, Gaithersburg, MD, United States
PATENT ASSIGNEE(S): Nabi, Boca Raton, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5961975		19991005
APPLICATION INFO.:	US 1995-472211		19950607 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-361821, filed on 22 Dec 1994 which is a continuation of Ser. No. US 1993-142117, filed on 28 Oct 1993, now abandoned which is a continuation of Ser. No. US 1991-796252, filed on 22 Nov 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Housel, James C.
ASSISTANT EXAMINER: Shaver, Jennifer
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 710
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process is disclosed for culturing clinical Staphylococcus epidermidis cells that reproducibly enables identification of a limited number of predominant serotypes. Two predominant serotypes common to most clinical cases of S. epidermidis have been identified and are denoted Type I and Type II. A particular polysaccharide surface antigen is associated with each of the Type I and Type II serotypes. The surface antigens can be used to provide active and passive **immunization** against S. epidermidis **infection** and to produce a hyperimmune immunoglobulin or antibodies for **treatment** of **S. epidermidis infection.**

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 13 OF 16 USPATFULL on STN
ACCESSION NUMBER: 1999:113362 USPATFULL
TITLE: Directed human immune globulin for the prevention and treatment of staphylococcal infections
INVENTOR(S): Fischer, Gerald W., Bethesda, MD, United States
PATENT ASSIGNEE(S): Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5955074		19990921
APPLICATION INFO.:	US 1995-459164		19950602 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-296133, filed on 26 Aug 1994, now abandoned which is a continuation of Ser. No. US 1992-804317, filed on 25 Feb 1992, now abandoned which is a continuation of Ser. No. US 1990-601089, filed on 22 Oct 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Spiegel, Carol A.
ASSISTANT EXAMINER: Portner, Ginny Allen
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 717
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to a Directed Human Immoglobulin and compositions thereof for preventing or treating staphylococcal infections such as S. epidermidis in neonates.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 14 OF 16 USPATFULL on STN
ACCESSION NUMBER: 1999:15500 USPATFULL
TITLE: Type I surface antigen associated with staphylococcus epidermidis
INVENTOR(S): Fattom, Ali Ibrahim, Rockville, MD, United States
Karakawa, deceased, Walter W., late of Pennsylvania Furnace, PA, United States by Walter W. Karakawa, legal representative
Wright, D. Craig, Gaithersburg, MD, United States
PATENT ASSIGNEE(S): Nabi, Boca Raton, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5866140		19990202
APPLICATION INFO.:	US 1994-361821		19941222 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-142117, filed on 28 Oct 1993, now abandoned which is a continuation of Ser. No. US 1991-796252, filed on 22 Nov 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Loring, Susan A.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 696
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process is disclosed for culturing clinical Staphylococcus epidermidis cells that reproducibly enables identification of a limited number of predominant serotypes. Two predominant serotypes common to most clinical cases of S. epidermidis have been identified and are denoted Type I and Type II. A particular polysaccharide surface antigen is associated with each of the Type I and Type II serotypes. The surface antigens can be used to provide active and passive **immunization** against S. epidermidis **infection** and to produce a hyperimmune immunoglobulin or antibodies for **treatment** of **S. epidermidis infection.**

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 15 OF 16 USPATFULL on STN
ACCESSION NUMBER: 96:101283 USPATFULL
TITLE: Broadly reactive opsonic antibodies that react with common staphylococcal antigens
INVENTOR(S): Fischer, Gerald W., Bethesda, MD, United States
PATENT ASSIGNEE(S): The U.S. Government, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5571511		19961105
APPLICATION INFO.:	US 1994-219238		19940328 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-854027, filed on 19 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-804317, filed on 25 Feb 1992, now abandoned which is a continuation of Ser. No. US 1990-601089, filed on 22 Oct 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Housel, James C.
ASSISTANT EXAMINER: Portner, Ginny Allen
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 1513
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the identification, making, and isolation of immunoglobulin and antigen that is useful to prevent, diagnose, or treat Staphylococcus infections. The invention further relates to an in vivo animal model for testing the efficacy of pharmaceutical compositions, including the pharmaceutical compositions of immunoglobulin and isolated antigen described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 16 OF 16 USPATFULL on STN
ACCESSION NUMBER: 91:82203 USPATFULL
TITLE: Capsular polysaccharide adhesin antigen, preparation, purification and use
INVENTOR(S): Pier, Gerald B., Brookline, MA, United States
PATENT ASSIGNEE(S): Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5055455		19911008	
APPLICATION INFO.:	US 1988-250417		19880928	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Griffin, Ronald W.
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 768
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A substantially pure capsular exopolysaccharide adhesin of coagulase-negative staphyhlococcal strains, and a general method to prepare such adhesins, are described. Vaccines composed of such adhesins, and uses of such adhesins to produce polyclonal and monoclonal antibodies against such adhesins, are also disclosed. The adhesins are useful in coating polymeric medical materials to prevent colonization by coagulase-negative staphylococcal strains, and as a probe in selecting desirable polymeric medical materials. Such adhesin antibodies are useful in vivo to prevent infection by nosocomial coagulase-negative staphylococcal strains, in assays for the detection of such bacteria, in assays for the estimation of such adhesins in complex mixtures, and as an affinity chromatography matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

FILE 'MEDLINE' ENTERED AT 11:39:42 ON 07 SEP 2005

FILE LAST UPDATED: 6 SEP 2005 (20050906/UP). FILE COVERS 1950 TO DATE.

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP RLOAD at an arrow promt (=>). See also:

http://www.nlm.nih.gov/mesh/
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

OLDMEDLINE now back to 1950.

Searcher : Shears 571-272-2528

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

L29 21681 SEA FILE=MEDLINE ABB=ON PLU=ON "ADJUVANTS, IMMUNOLOGIC"/CT
L30 3465 SEA FILE=MEDLINE ABB=ON PLU=ON "STAPHYLOCOCCUS EPIDERMIDIS"/CT
L31 5 SEA FILE=MEDLINE ABB=ON PLU=ON L29 AND L30

L31 ANSWER 1 OF 5 MEDLINE on STN
ACCESSION NUMBER: 2005129487 MEDLINE
DOCUMENT NUMBER: PubMed ID: 15761379
TITLE: Different pro-inflammatory and immunogenic potentials of Propionibacterium acnes and Staphylococcus epidermidis: implications for chronic inflammatory acne.
AUTHOR: Bialecka Anna; Mak Monika; Biedron Rafal; Bobek Malgorzata; Kasprowicz Andrzej; Marcinkiewicz Janusz
CORPORATE SOURCE: Department of Immunology, Jagiellonian University Medical College, Cracow, Poland.
SOURCE: Archivum immunologiae et therapiae experimentalis, (2005 Jan-Feb) 53 (1) 79-85.
Journal code: 0114365. ISSN: 0004-069X.
PUB. COUNTRY: Poland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200506
ENTRY DATE: Entered STN: 20050312
Last Updated on STN: 20050701
Entered Medline: 20050630
ED Entered STN: 20050312
Last Updated on STN: 20050701
Entered Medline: 20050630
AB INTRODUCTION: Propionibacterium acnes (PA) and Staphyloccocus epidermidis (SE) are two major bacterial strains isolated from acne lesions. Nevertheless, only PA seems to be implicated in the pathogenesis of inflammatory acne vulgaris. Evidence for this, however, remains indirect and the precise role of PA in inflammatory acne is still a matter for conjecture. The aim of this study was to compare some pro-inflammatory and adjuvant properties of PA and SE. MATERIAL/METHODS: To determine some of the pathogenic, immunostimulatory, and pro-inflammatory proper of PA and SE, two experimental models of inflammation were used. In vivo; chronic inflammation was induced by intradermal injection of living bacteria into the ear. In vitro; peritoneal macrophages elicited by the bacteria were examined for their ability to generate reactive oxygen species (ROS), nitric oxide (NO), and cytokines. RESULTS: PA, but not SE, evoked mild local inflammation of infected ears. Macrophages elicited with PA produced more tumor necrosis factor alpha and interleukin IL-12 than those induced with SE, while SE was a stronger inducer of IL-10 production. Both bacteria equally induced the generation of NO and ROS. In contrast, only PA showed adjuvant proper-ties. CONCLUSIONS: The results of these studies indicate that SE, in contrast to PA, does not exert pro-inflammatory properties.

Searcher : Shears 571-272-2528

Thus it is unlikely that SE may be implicated in the pathogenesis of inflammatory acne vulgaris.

L31 ANSWER 2 OF 5 MEDLINE on STN
ACCESSION NUMBER: 93117328 MEDLINE
DOCUMENT NUMBER: PubMed ID: 1475343
TITLE: Effect of various microbial preparations on P-388 mouse lymphocytic leukemia.
AUTHOR: Antoun M D; Caballero R; Robledo I; Lavergne J
CORPORATE SOURCE: Department of Pharmaceutical Sciences, School of Pharmacy, UPR, San Juan 00936-5067.
CONTRACT NUMBER: RR-03051 (NCRR)
SO7RR05419-28 (NCRR)
SOURCE: Puerto Rico health sciences journal, (1992 Dec) 11 (3) 135-8.
Journal code: 8303541. ISSN: 0738-0658.
PUB. COUNTRY: Puerto Rico
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199302
ENTRY DATE: Entered STN: 19930219
Last Updated on STN: 19930219
Entered Medline: 19930201
ED Entered STN: 19930219
Last Updated on STN: 19930219
Entered Medline: 19930201
AB Four bacteria-derived immunopotentiators were tested for their protective effect on a P-388 mouse lymphocytic leukemia model. The microbial test products were prepared from the following bacterial strains: ATCC 35983 Staphylococcus epidermidis isolated from a patient with IV catheter; ATCC 31874, a patented strain listed as Staphylococcus epidermidis isolated from the urine of a cancer patient; ATCC 25615 Staphylococcus hominis obtained from a child with lymphocytic leukemia, and ATCC 25614 Staphylococcus warneri, an isolate from a patient with adenocarcinoma of the breast. A limited degree of protection and prolongation in survival time was observed in the animal group treated with the bacterial strain ATCC 31874.

L31 ANSWER 3 OF 5 MEDLINE on STN
ACCESSION NUMBER: 89354758 MEDLINE
DOCUMENT NUMBER: PubMed ID: 3334561
TITLE: Immunomodulating properties of newer cephalosporins: a preliminary classification.
AUTHOR: Labro M; Bryskier A
CORPORATE SOURCE: Inserm U. 294, Laboratoire d'Hematologie et d'Immunologie, CHU Xavier Bichat 16, Paris, France.
SOURCE: Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, (1987 Jun) 6 (2 Suppl) 219-21.
Journal code: 8401667. ISSN: 0392-906X.
PUB. COUNTRY: Italy
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198910
ENTRY DATE: Entered STN: 19900309
Last Updated on STN: 19900309
Entered Medline: 19891011

Searcher : Shears 571-272-2528

ED Entered STN: 19900309
Last Updated on STN: 19900309
Entered Medline: 19891011

L31 ANSWER 4 OF 5 MEDLINE on STN
ACCESSION NUMBER: 88121896 MEDLINE
DOCUMENT NUMBER: PubMed ID: 3431512
TITLE: Immunostimulating cell surface substance from Staphylococcus epidermidis strain ATCC-31432 prevents metastatic lung colonization in Balb/c-mice.
AUTHOR: Ohshima Y; Ko H L; Beuth J; Ichiman Y; Yoshida K; Pulverer G
CORPORATE SOURCE: Department of Microbiology, St. Marianna University School of Medicine, Kawasaki, Japan.
SOURCE: Medical microbiology and immunology, (1987) 176 (6) 281-7.
Journal code: 0314524. ISSN: 0300-8584.
PUB. COUNTRY: GERMANY, WEST: Germany, Federal Republic of
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198802
ENTRY DATE: Entered STN: 19900308
Last Updated on STN: 19900308
Entered Medline: 19880226
ED Entered STN: 19900308
Last Updated on STN: 19900308
Entered Medline: 19880226
AB The antineoplastic activity of cell surface substance from Staphylococcus epidermidis ATCC-31432 (CSS-subfraction 2) in mice and its influence on the activation of human leucocytes was studied. After in vitro incubation with CSS-subfraction 2, human polymorphonuclear leucocytes were evidently stimulated. In vivo (Balb/c-mice) intraperitoneal application of subfraction 2 of CSS induced a considerable splenomegaly and greatly increased IgM levels indicating a strong immuno-stimulating activity. In order to evaluate antineoplastic effects of CSS-subfraction 2, we used sarcoma L-1 cells (Balb/c-mouse origin) which cause heavy tumor colonization of the lung. After single systemic injection of subfraction 2 of CSS, the number of lung tumor-cell colonies drastically decreased. The combination of this immunomodulating therapy with a temporary anticoagulation resulted in a further reduction of tumor colonies in the lungs of Balb/c-mice.

L31 ANSWER 5 OF 5 MEDLINE on STN
ACCESSION NUMBER: 86186006 MEDLINE
DOCUMENT NUMBER: PubMed ID: 3914249
TITLE: Chlormethine in small doses as immunostimulator--LPS synergism.
AUTHOR: Garbulinski T; Debowy J; Obminska-Domoradzka B; Switala M; Wilczek J
SOURCE: Archivum immunologiae et therapiae experimentalis, (1985) 33 (6) 727-34.
Journal code: 0114365. ISSN: 0004-069X.
PUB. COUNTRY: Poland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198604

Searcher : Shears 571-272-2528

ENTRY DATE: Entered STN: 19900321
Last Updated on STN: 19900321
Entered Medline: 19860428

ED Entered STN: 19900321
Last Updated on STN: 19900321
Entered Medline: 19860428

AB Normothermic rabbits and rabbits with LPS induced fever were treated with chlormethine (Nitrogranulogen, Ntg) in the doses of 1 microgram/kg and 10 micrograms/kg. The blood was collected 4, 24, 48 hrs and 4, 7, 10 days after Ntg injection. Following indices of immunity were studied: T and B cells number, number of IgM producing cells after immunization with SRBC, serum IgG level, killing activity of neutrophils and number of phagocytized bacteria. It was observed that both doses of Ntg injected intravenously to normothermic rabbits, significantly increased the number of T and B lymphocytes and of IgM producing lymphocytes a well as the level of IgG in the serum, number of phagocytized bacteria and killing activity of neutrophils. Ntg in combination with LPS shortened the period of fever, and through the synergistic effect, significantly increased T lymphocytes number in the blood, IgG level in the serum, number of phagocytized bacteria and killing activity of neutrophils.

(FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH, JICST-EPLUS, JAPIO, USPATFULL' ENTERED AT 11:41:10 ON 07 SEP 2005)

L32 518 SEA ABB=ON PLU=ON ("DOUCETTE STAMM L"? OR "STAMM DOUCETTE L"? OR "STAMM L"? OR "DOUCETTE L"?)/AU
L33 1785 SEA ABB=ON PLU=ON "BUSH D"?/AU
L34 30 SEA ABB=ON PLU=ON L32 AND L33
L35 10 SEA ABB=ON PLU=ON (L34 OR L32 OR L33) AND L13
L36 8 DUP REM L35 (2 DUPLICATES REMOVED)

- Author (s)

L36 ANSWER 1 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2005:158196 USPATFULL
TITLE: Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for **diagnostics** and **therapeutics**
INVENTOR(S): **Doucette-Stamm, Lynn A.**, Framingham, MA, UNITED STATES
Bush, David, Somerville, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005136404	A1	20050623
APPLICATION INFO.:	US 2003-617320	A1	20030710 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-107433, filed on 30 Jun 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-51553P	19970702 (60)
	US 1998-85131P	19980512 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Robert L. Spadafora, Genome Therapeutics Corporation, 100 Beaver Street, Waltham, MA, 02453, US
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1

LINE COUNT: 12957
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumonia that are useful in **diagnosis** and **therapy** of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the **detection, prevention** and **treatment** of pathological conditions resulting from bacterial infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L36 ANSWER 2 OF 8 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN DUPLICATE 1
ACCESSION NUMBER: 2004-580138 [56] WPIDS
CROSS REFERENCE: 2002-381255 [41]
DOC. NO. NON-CPI: N2004-458635
DOC. NO. CPI: C2004-211406
TITLE: New isolated polypeptide and encoding nucleic acid derived from **Staphylococcus epidermidis**, useful for **diagnosing, preventing** and/or **treating** an **S. epidermidis** bacterial infection.
DERWENT CLASS: B04 D16 T01
INVENTOR(S): **BUSH, D; DOUCETTE-STAMM, L**
PATENT ASSIGNEE(S): (BUSH-I) BUSH D; (DOUC-I) DOUCETTE-STAMM L
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2004147734	A1	20040729	(200456)*		741

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
US 2004147734	A1	Provisional	US 1997-64964P	19971108
		CIP of	US 1998-134001	19980813
		Div ex	US 1999-450969	19991129
			US 2003-724972	20031201

FILING DETAILS:

PATENT NO	KIND		PATENT NO
US 2004147734	A1	CIP of	US 6380370

PRIORITY APPLN. INFO: US 1997-64964P 19971108; US 1998-134001 19980813; US 1999-450969 19991129; US 2003-724972 20031201
AN 2004-580138 [56] WPIDS
CR 2002-381255 [41]
AB US2004147734 A UPAB: 20040901
NOVELTY - An isolated nucleic acid comprising a nucleotide sequence with any of 3772 fully defined nucleotide sequences (SEQ ID NO: 1-3772) and encoding an **Staphylococcus epidermidis** polypeptide with any of 3772 fully defined amino acid sequences (SEQ

ID NO: 3772-7544) as given in the specification, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) a recombinant expression vector comprising the nucleic acid cited above operably linked to a transcription regulatory element;

(2) a cell comprising a recombinant expression vector of (1);

(3) producing an **S. epidermidis** polypeptide, comprising culturing a cell of (2) to permit expression of the polypeptide;

(4) a probe comprising a nucleotide sequence consisting of at least 8 contiguous nucleotides of SEQ ID NO: 1-3772;

(5) an isolated nucleic acid comprising a nucleotide sequence of at least 8 nucleotides in length, where the sequence is hybridizable to a nucleic acid having nucleotide sequences of SEQ ID NO: 1-3772;

(6) a **vaccine** composition for **prevention** or **treatment** of an **S. epidermidis** infection, comprising a nucleic acid cited above and a carrier;

(7) **treating** a subject for **S. epidermidis** infection, comprising administering a **vaccine** composition of (6) or (9);

(8) a recombinant or substantially pure preparation of an **S. epidermidis** polypeptide or its fragment, where the polypeptide has any of SEQ ID NO: 3773-7544;

(9) a **vaccine** composition for **prevention** or **treatment** of an **S. epidermidis** infection, comprising an **S. epidermidis** polypeptide of (8) and a carrier;

(10) **detecting** the presence of a Staphylococcus nucleic acid in a sample, comprising contacting a sample with a nucleic acid cited above in which a hybrid can form between the probe and a Staphylococcus nucleic acid in the sample, and **detecting** the hybrid formed, where **detection** of a hybrid indicates the presence of a Staphylococcus nucleic acid in the sample;

(11) a computer readable medium having recorded in it the nucleotide sequences with SEQ ID NO: 1-3772 or its fragments;

(12) a computer based system for identifying fragments of the Staphylococcus genome of commercial importance, comprising a data storage means having SEQ ID NO: 1-3772 or its fragments, a search means for comparing a target sequence to the nucleotide sequences of the data storage means to identify homologous sequences, and a retrieval means for obtaining the homologous sequences;

(13) a computer based system for identifying fragments of the Staphylococcus plasmids of commercial importance, comprising a data storage means having SEQ ID NO: 3703-7554 or its fragments, a search means for comparing a target sequence to the nucleotide sequences of the data storage means to identify homologous sequences, and a retrieval means for obtaining the homologous sequences;

(14) identifying commercially important nucleic acid fragments of the Staphylococcus genome and/or plasmids, comprising comparing a database having nucleotide or polypeptide sequences with SEQ ID NO: 1-3772 and/or SEQ ID NO: 3703-7544, respectively, or its fragments, with a target sequence to obtain a nucleic acid molecule comprised of a complementary nucleotide sequence to the target sequence, where the target sequence is not randomly selected; and

(15) identifying an expression modulating fragment of the Staphylococcus genome and/or plasmids, comprising comparing a database having nucleotide or polypeptide sequences with SEQ ID NO: 1-3772 and/or SEQ ID NO: 3703-7544, respectively, or its fragments, with a target sequence to obtain a nucleic acid molecule comprised of a complementary nucleotide sequence to the target sequence, where the

target sequence comprises sequences known to regulate gene expression.
ACTIVITY - Antibacterial. Test details are described but no results given.
MECHANISM OF ACTION - **Vaccine**; Antisense-**Therapy**.
USE - The methods and compositions of the present invention are useful for the **diagnosis, prevention** and/or **treatment** of an **Staphylococcal epidermidis** bacterial infection.
Dwg.0/0

L36 ANSWER 3 OF 8 USPATFULL on STN
ACCESSION NUMBER: 2004:250212 USPATFULL
TITLE: Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for **diagnostics** and **therapeutics**
INVENTOR(S): **Doucette-Stamm, Lynn A.**, Framingham, MA, United States
Bush, David, Somerville, MA, United States
PATENT ASSIGNEE(S): Genome Therapeutics Corporation, Waltham, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6800744	B1	20041005
APPLICATION INFO.:	US 1998-107433		19980630 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-85131P	19980512 (60)
	US 1997-51553P	19970702 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Brusca, John S.
ASSISTANT EXAMINER: Zhou, Shubo "Joe "
LEGAL REPRESENTATIVE: Genome Therapeutics Corporation
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 11545
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumonia that are useful in **diagnosis** and **therapy** of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the **detection, prevention** and **treatment** of pathological conditions resulting from bacterial infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L36 ANSWER 4 OF 8 USPATFULL on STN
ACCESSION NUMBER: 2004:141216 USPATFULL
TITLE: Nucleic acid sequences relating to Candida albicans for **diagnostics** and **therapeutics**
INVENTOR(S): Weinstock, Keith G., Westborough, MA, United States
Bush, David, Somerville, MA, United States

PATENT ASSIGNEE(S): Genome Therapeutics Corporation, Waltham, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6747137	B1	20040608
APPLICATION INFO.:	US 1999-248796		19990212 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-96409P	19980813 (60)
	US 1998-74725P	19980213 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Marschel, Ardin H.
LEGAL REPRESENTATIVE: Genome Therapeutics Corporation
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 36816
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated polypeptide and nucleic acid sequences derived from Candida albicans that are useful in **diagnosis** and **therapy** of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the **detection, prevention** and **treatment** of pathological conditions resulting from fungal infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L36 ANSWER 5 OF 8 USPATFULL on STN
ACCESSION NUMBER: 2003:240330 USPATFULL
TITLE: Nucleic acid and amino acid sequences relating to Enterococcus faecalis for **diagnostics** and **therapeutics**
INVENTOR(S): **Doucette-Stamm, Lynn A.**, 14 Flanagan Dr., Framingham, MA, United States 01701
Bush, David, 205 Holland St., Somerville, MA, United States 02144

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6617156	B1	20030909
APPLICATION INFO.:	US 1998-134000		19980813 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-55778P	19970815 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Mosher, Mary E.
LEGAL REPRESENTATIVE: Genome Therapeutics Corporation
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1,5,14
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 13738
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated polypeptide and nucleic acid

sequences derived from Enterococcus faecalis that are useful in **diagnosis** and **therapy** of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the **detection, prevention** and **treatment** of pathological conditions resulting from bacterial infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L36 ANSWER 6 OF 8 USPATFULL on STN
ACCESSION NUMBER: 2003:169096 USPATFULL
TITLE: Nucleic acid sequences and expression system relating to Enterococcus faecium for **diagnostics** and **therapeutics**
INVENTOR(S): **Doucette-Stamm, Lynn A.**, Framingham, MA, United States
Bush, David, Somerville, MA, United States
PATENT ASSIGNEE(S): Genome Therapeutics Corporation, Waltham, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6583275	B1	20030624
APPLICATION INFO.:	US 1998-107532		19980630 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-85598P	19980514 (60)
	US 1997-51571P	19970702 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Marschel, Ardin H.
LEGAL REPRESENTATIVE: Genome Therapeutics Corporation
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 15265
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated polypeptide and nucleic acid sequences derived Enterococcus faecium that are useful in **diagnosis** and **therapy** of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the **detection, prevention** and **treatment** of pathological conditions resulting from bacterial infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L36 ANSWER 7 OF 8 USPATFULL on STN
ACCESSION NUMBER: 2003:108972 USPATFULL
TITLE: Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for **diagnostics** and **therapeutics**
INVENTOR(S): Rubenfield, Marc J., Framingham, MA, United States
Nolling, Jork, Ouincy, MA, United States
Deloughery, Craig, Medford, MA, United States
Bush, David, Somerville, MA, United States

PATENT ASSIGNEE(S): Genome Therapeutics Corporation, Waltham, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6551795	B1	20030422
APPLICATION INFO.:	US 1999-252991		19990218 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-74788P	19980218 (60)
	US 1998-94190P	19980727 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Allen, Marianne P.
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 21431
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated polypeptide and nucleic acid sequences derived from Pseudomonas aeruginosa that are useful in **diagnosis** and **therapy** of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the **detection, prevention** and **treatment** of pathological conditions resulting from bacterial infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L36 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2002:327941 CAPLUS
DOCUMENT NUMBER: 136:351426
TITLE: Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
INVENTOR(S): Doucette-Stamm, Lynn A.; Bush, David
PATENT ASSIGNEE(S): Genome Therapeutics Corporation, USA
SOURCE: U.S., 267 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 6380370	B1	20020430	US 1998-134001		19980813
US 2004147734	A1	20040729	US 2003-724972		20031201
PRIORITY APPLN. INFO.:			US 1997-55779P	P	19970814
			US 1997-64964P	P	19971108
			US 1998-134001	A2	19980813
			US 1999-450969	A3	19991129

AB The invention provides isolated polypeptide and nucleic acid sequences

derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathol. conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. Thus, the sequences of 2837 protein-coding contigs from the genome of S. epidermidis strain 19804 are provided. The invention also provides methods for the detection, prevention and treatment of pathol. conditions resulting from bacterial infection.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

FILE 'HOME' ENTERED AT 11:48:40 ON 07 SEP 2005

```
=> d his ful

     (FILE 'HOME' ENTERED AT 11:19:06 ON 07 SEP 2005)
               SET COST OFF

     FILE 'CAPLUS' ENTERED AT 11:19:13 ON 07 SEP 2005
L1           486 SEA ABB=ON  PLU=ON  ((STAPHYLOCOCC? OR S)(W)EPIDERMID?)(S)I
                 NFECTION
L2             2 SEA ABB=ON  PLU=ON  L1 AND IMMUNOGEN?(3A)(COMPOSITION OR
                 COMP##)
                 D KWIC
L3             7 SEA ABB=ON  PLU=ON  ((STAPHYLOCOCC? OR S)(W)EPIDERMID?)
                 AND IMMUNOGEN?(3A)(COMPOSITION OR COMP##)
L4             0 SEA ABB=ON  PLU=ON  L3 AND BUSH D?/AU
L5             7 SEA ABB=ON  PLU=ON  (BUSH D? AND (DOUCETTE? OR STAMM?))/AU

L6             1 SEA ABB=ON  PLU=ON  L5 AND EPIDERMID?
                 D TI AU
                 D .BEVSTR1
L7             1 SEA ABB=ON  PLU=ON  L1 AND L5
L8            17 SEA ABB=ON  PLU=ON  L1 AND (ADJUVANT OR IMMUNOADJUVANT OR
                 IMMUNOACTIVAT? OR IMMUNOSTIMUL? OR IMMUN?(W)(ACTIVAT? OR
                 STIMUL?))
L9             0 SEA ABB=ON  PLU=ON  L5 AND L8
                 D KWIC
L10           53 SEA ABB=ON  PLU=ON  (STAPHYLOCOCC? OR S)(W)EPIDERMID? AND
                 (ADJUVANT OR IMMUNOADJUVANT OR IMMUNOACTIVAT? OR IMMUNOSTIM
                 UL? OR IMMUN?(W)(ACTIVAT? OR STIMUL?))
L11            0 SEA ABB=ON  PLU=ON  L10 AND L5
L12         2638 SEA ABB=ON  PLU=ON  (STAPHYLOCOCC? OR S)(W)EPIDERMID? AND
                 (TREAT? OR THERAP? OR PREVENT? OR DIAGNOS? OR DETERM? OR
                 DETECT? OR DET## OR SCREEN?)
L13          107 SEA ABB=ON  PLU=ON  L12 AND (ADJUVANT OR IMMUNOADJUVANT OR
                 IMMUNOACTIVAT? OR IMMUNOSTIMUL? OR IMMUN?(W)(ACTIVAT? OR
                 STIMUL?) OR VACCIN? OR IMMUNIS? OR IMMUNIZ?)
L14            1 SEA ABB=ON  PLU=ON  L5 AND L13
L15            0 SEA ABB=ON  PLU=ON  L14 AND CARRIER
L16           69 SEA ABB=ON  PLU=ON  L13 AND INFECTION
L17           16 SEA ABB=ON  PLU=ON  L16 AND CARRIER

     FILE 'CAPLUS' ENTERED AT 11:32:06 ON 07 SEP 2005
               D QUE
               D 1-16 .BEVERLY

     FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
     JICST-EPLUS, JAPIO' ENTERED AT 11:32:09 ON 07 SEP 2005
L18           40 SEA ABB=ON  PLU=ON  L17
L19           37 DUP REM L18 (3 DUPLICATES REMOVED)
                 D 1-37 IBIB ABS

     FILE 'USPATFULL' ENTERED AT 11:34:52 ON 07 SEP 2005
L20         3188 SEA ABB=ON  PLU=ON  ((STAPHYLOCOCC? OR S)(W)EPIDERMID?)(L)(
                 TREAT? OR THERAP? OR PREVENT? OR DIAGNOS? OR DETERM? OR
                 DETECT? OR DET## OR SCREEN?)
L21         1006 SEA ABB=ON  PLU=ON  L20(L)(ADJUVANT OR IMMUNOADJUVANT OR
                 IMMUNOACTIVAT? OR IMMUNOSTIMUL? OR IMMUN?(W)(ACTIVAT? OR
                 STIMUL?) OR VACCIN? OR IMMUNIS? OR IMMUNIZ?)
L22          899 SEA ABB=ON  PLU=ON  L21(L)INFECTION
L23          785 SEA ABB=ON  PLU=ON  L22(L)CARRIER
```

```
L24          183 SEA ABB=ON  PLU=ON  ((STAPHYLOCOCC? OR S)(W)EPIDERMID?)(5A)
                 (TREAT? OR THERAP? OR PREVENT? OR DIAGNOS? OR DETERM? OR
                 DETECT? OR DET## OR SCREEN?)
L25           17 SEA ABB=ON  PLU=ON  L24(S)(ADJUVANT OR IMMUNOADJUVANT OR
                 IMMUNOACTIVAT? OR IMMUNOSTIMUL? OR IMMUN?(W)(ACTIVAT? OR
                 STIMUL?) OR VACCIN? OR IMMUNIS? OR IMMUNIZ?)
L26            2 SEA ABB=ON  PLU=ON  L25(S)CARRIER
L27           16 SEA ABB=ON  PLU=ON  L25(S)INFECTION
                 D QUE L26
                 D QUE L27
L28           16 SEA ABB=ON  PLU=ON  L26 OR L27
                 D 1-16 IBIB ABS

     FILE 'MEDLINE' ENTERED AT 11:39:42 ON 07 SEP 2005
                 E "ADJUVANTS, IMMUNOLOGIC"/CT 6
L29        21681 SEA ABB=ON  PLU=ON  "ADJUVANTS, IMMUNOLOGIC"/CT
                 E STAPHYLOCOCCUS EPIDERMIDIS/CT 5
L30         3465 SEA ABB=ON  PLU=ON  "STAPHYLOCOCCUS EPIDERMIDIS"/CT
L31            5 SEA ABB=ON  PLU=ON  L29 AND L30
                 D QUE
                 D 1-5 .BEVERLYMED

     FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
     JICST-EPLUS, JAPIO, USPATFULL' ENTERED AT 11:41:10 ON 07 SEP 2005
L32          518 SEA ABB=ON  PLU=ON  ("DOUCETTE STAMM L"? OR "STAMM
                 DOUCETTE L"? OR "STAMM L"? OR "DOUCETTE L"?)/AU
L33         1785 SEA ABB=ON  PLU=ON  "BUSH D"?/AU
L34           30 SEA ABB=ON  PLU=ON  L32 AND L33
L35           10 SEA ABB=ON  PLU=ON  (L34 OR L32 OR L33) AND L13
L36            8 DUP REM L35 (2 DUPLICATES REMOVED)
                 D 1-8 IBIB ABS

     FILE 'HOME' ENTERED AT 11:48:40 ON 07 SEP 2005


     FILE HOME

     FILE CAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storin
     of this information, without the prior written consent of CAS, is
     strictly prohibited.

     FILE COVERS 1907 - 7 Sep 2005  VOL 143 ISS 11
     FILE LAST UPDATED: 6 Sep 2005  (20050906/ED)

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

       This file contains CAS Registry Numbers for easy and accurate
       substance identification.

     FILE MEDLINE
      FILE LAST UPDATED: 6 SEP 2005 (20050906/UP).  FILE COVERS 1950 TO DAT
```

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP RLOAD at an arrow promt (=>). See also:

http://www.nlm.nih.gov/mesh/
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS
FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 31 August 2005 (20050831/ED)

FILE RELOADED: 19 October 2003.

FILE EMBASE
FILE COVERS 1974 TO 1 Sep 2005 (20050901/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE WPIDS
FILE LAST UPDATED: 2 SEP 2005 <20050902/UP>
MOST RECENT DERWENT UPDATE: 200556 <200556/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE http://thomsonderwent.com/coverage/latestupdates/ <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER GUIDES, PLEASE VISIT:
http://thomsonderwent.com/support/userguides/ <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX FIRST VIEW - FILE WPIFV.
FOR FURTHER DETAILS: http://www.thomsonderwent.com/dwpifv <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501. PLEASE CHECK:
http://thomsonderwent.com/support/dwpiref/reftools/classification/code FOR DETAILS. <<<

Searcher : Shears 571-272-2528

FILE CONFSCI
FILE COVERS 1973 TO 25 May 2005 (20050525/ED)

FILE SCISEARCH

FILE COVERS 1974 TO 1 Sep 2005 (20050901/ED)

SCISEARCH has been reloaded, see HELP RLOAD for details.

FILE JICST-EPLUS
FILE COVERS 1985 TO 22 AUG 2005 (20050822/ED)

THE JICST-EPLUS FILE HAS BEEN RELOADED TO REFLECT THE 1999 CONTROLLED TERM (/CT) THESAURUS RELOAD.

FILE JAPIO
FILE LAST UPDATED: 5 SEP 2005 <20050905/UP>
FILE COVERS APR 1973 TO APRIL 28, 2005

<<< GRAPHIC IMAGES AVAILABLE >>>

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 6 Sep 2005 (20050906/PD)
FILE LAST UPDATED: 6 Sep 2005 (20050906/ED)
HIGHEST GRANTED PATENT NUMBER: US6941576
HIGHEST APPLICATION PUBLICATION NUMBER: US2005193458
CA INDEXING IS CURRENT THROUGH 6 Sep 2005 (20050906/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 6 Sep 2005 (20050906/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2005

>>> USPAT2 is now available. USPATFULL contains full text of the
>>> original, i.e., the earliest published granted patents or
>>> applications. USPAT2 contains full text of the latest US
>>> publications, starting in 2001, for the inventions covered in
>>> USPATFULL. A USPATFULL record contains not only the original
>>> published document but also a list of any subsequent
>>> publications. The publication number, patent kind code, and
>>> publication date for all the US publications for an invention
>>> are displayed in the PI (Patent Information) field of USPATFULL
>>> records and may be searched in standard search fields, e.g., /PN,
>>> /PK, etc.

>>> USPATFULL and USPAT2 can be accessed and searched together
>>> through the new cluster USPATALL. Type FILE USPATALL to
>>> enter this cluster.
>>>
>>> Use USPATALL when searching terms such as patent assignees,
>>> classifications, or claims, that may potentially change from
>>> the earliest to the latest publication.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Searcher : Shears 571-272-2528